Form 8-K
8-K — Wellgistics Health, Inc.
Accession: 0001493152-26-026452
Filed: 2026-05-29
Period: 2026-05-27
CIK: 0002030763
SIC: 5122 (WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES)
Item: Entry into a Material Definitive Agreement
Item: Unregistered Sales of Equity Securities
Item: Regulation FD Disclosure
Item: Financial Statements and Exhibits
Documents
8-K — form8-k.htm (Primary)
EX-4.1 (ex4-1.htm)
EX-4.2 (ex4-2.htm)
EX-10.1 (ex10-1.htm)
EX-10.2 (ex10-2.htm)
EX-10.3 (ex10-3.htm)
EX-10.4 (ex10-4.htm)
EX-99.2 (ex99-2.htm)
GRAPHIC (ex10-3_001.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: form8-k.htm · Sequence: 1
false
0002030763
0002030763
2026-05-27
2026-05-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 27, 2026
WELLGISTICS
HEALTH, INC.
(Exact
name of registrant as specified in its charter)
Delaware
001-42530
93-3264234
(State
or other jurisdiction
of
incorporation)
(Commission
File
Number)
(IRS
Employer
Identification
No.)
3000
Bayport Drive
Suite
950
Tampa,
FL
33607
(Address
of principal executive offices)
(Zip
Code)
Registrant’s
telephone number, including area code: (844) 203-6092
Not
Applicable
(Former
name or former address, if changed since last report)
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading
Symbol(s)
Name
of each exchange on which registered
Common
Stock, $0.0001 par value per share
WGRX
The
Nasdaq Capital Market LLC
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act of 1933 or Rule 12b-2
under the Securities Exchange Act of 1934.
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01 Entry into a Material Definitive Agreement.
Securities
Purchase Agreement
On
May 27, 2026, Wellgistics Health, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase
Agreement”) with certain accredited investors (collectively, the “Purchasers”), pursuant to which the Company agreed
to issue and sell to the Purchasers convertible promissory notes in the aggregate principal amount of $21,132,812.50 (the “Notes”)
and warrants to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) (the
“PIPE Warrants”). The Notes are being issued for an aggregate cash purchase price of $16,906,250, reflecting a 20% original
issue discount, before deducting placement agent fees and offering expenses. The closing of the offering occurred on May 27, 2026 (the
“Closing”).
The
Notes mature on the twelve-month anniversary of their issuance unless earlier converted or repaid in accordance with their terms and
bear interest at a rate of 0% per annum. The Company may not prepay the Notes without the consent of the applicable holder. Unless waived
by holders of a majority in principal amount of the then outstanding Notes, the Company is required to apply the net cash proceeds received
by the Company from any Qualified Financing (as defined in the Notes) to the repayment of the Notes on a pro rata basis, subject to certain
customary and transaction-specific exclusions.
At
any time before the Mandatory Conversion Date (as defined below), the Notes are convertible, in whole or in part, at the option of the
holder, into shares of Common Stock at a conversion price equal to the lesser of (i) $6.00 per share and (ii) 100% of the closing price
of the Common Stock on the trading day immediately preceding the applicable conversion date, subject to an initial floor price of $1.00
per share and adjustment as provided in the Notes.
Upon
the later to occur of (i) the date on which the resale registration statement covering the applicable registrable securities is declared
effective by the Securities and Exchange Commission (the “SEC”), (ii) the date on which the Company has obtained the Required
Stockholder Approval (as defined below), (iii) the effectiveness of any amendment to the Company’s certificate of incorporation
necessary to authorize blank check preferred stock, and (iv) the filing of the certificate of designation for a new series of convertible
preferred stock with the Secretary of State of the State of Delaware (the “Mandatory Conversion Date”), the outstanding balance
of the Notes will automatically convert into shares of the Company’s Series A Convertible Preferred Stock (the “Series A
Preferred Stock”), with each share of Series A Preferred Stock having a stated value of $1,000. Effective as of the Mandatory Conversion
Date, the conversion price will be deemed reset and thereafter will equal the lesser of (x) $50.00 per share and (y) 100% of the closing
price of the Common Stock on the trading day immediately preceding the applicable conversion date, subject to the applicable floor price
and adjustment as provided in the Notes and the certificate of designation.
The
certificate of designation for the Series A Preferred Stock provides that, beginning six months from the date of issuance, the Series
A Preferred Stock will accrue dividends equal to 10% of the stated value over each subsequent twelve-month period, with such dividends
accruing on a monthly basis and being added to the stated value. The Series A Preferred Stock will generally vote together with the Common
Stock as a single class on an as-issued basis of one vote per share, subject to certain separate class consent rights. Upon a liquidation,
dissolution or winding-up of the Company, the holders of Series A Preferred Stock will be entitled to receive, on a pari passu basis
with the holders of Common Stock, for each share of Series A Preferred Stock, an amount equal to the greater of (i) the stated value
of such share and (ii) the amount that a holder of Common Stock would receive if such share of Series A Preferred Stock were fully converted
into Common Stock, disregarding conversion limitations.
The
Purchase Agreement and the related transaction documents contain a beneficial ownership limitation of 9.99% and an exchange cap equal
to 19.99% of the shares of Common Stock or voting power outstanding immediately before execution of the Purchase Agreement, calculated
in accordance with the rules of the applicable trading market, including Nasdaq Listing Rule 5635(d) (the “Exchange Cap”).
Prior to receipt of the Required Stockholder Approval, the Company may not issue, and the holders may not receive, shares of Common Stock
pursuant to the transaction documents to the extent such issuance would exceed the Exchange Cap.
Under
the Purchase Agreement, the Company agreed to use commercially reasonable efforts to obtain, as promptly as reasonably practicable following
the Closing, stockholder approval to the extent required by Nasdaq Listing Rule 5635(d) and other applicable trading market rules for
(i) the issuance of shares of Common Stock pursuant to the transaction documents in excess of the Exchange Cap, including shares issuable
upon conversion of the Notes, conversion of the Series A Preferred Stock and exercise, including mandatory exercise or call, of the Warrants,
and (ii) to the extent required, an amendment to the Company’s certificate of incorporation to authorize blank check preferred
stock (collectively, the “Required Stockholder Approval”). The Purchase Agreement provides that any proxy statement, information
statement or other materials seeking such approval will be filed with the SEC no later than twenty calendar days following the Closing
and that the Company will file the certificate of designation within three business days after receipt of the Required Stockholder Approval.
The
PIPE Warrants are exercisable for shares of Common Stock at an exercise price of $7.50 per share, subject to adjustment as provided therein,
and expire on May 27, 2031. Each PIPE Warrant is exercisable for a number of shares of Common Stock equal to 150% of the initial principal
amount of the Note purchased by the applicable Purchaser divided by the official closing price of the Common Stock on the date of issuance
as reported by Nasdaq, without regard to conversion limitations in the Notes. The PIPE Warrants include a cashless exercise feature and
customary adjustments for stock splits, dividends, combinations, recapitalizations and similar events.
The
PIPE Warrants also include a mandatory exercise or call feature pursuant to which, if the volume weighted average price of the Common
Stock equals or exceeds 150% of the then-applicable exercise price of the applicable PIPE Warrant for at least five consecutive trading
days, and specified equity conditions are satisfied, the Company may require the holder to exercise all or the applicable portion of
such PIPE Warrant, subject to the applicable beneficial ownership limitation, the Exchange Cap, the Required Stockholder Approval and
the rules and regulations of the applicable trading market. The PIPE Warrants further provide that the Company may, in its sole discretion
and without the consent of the holder, reduce the cash exercise price payable upon exercise by up to 80% of the then-applicable exercise
price solely for purposes of inducing a cash exercise, subject to the limitations set forth in the PIPE Warrants.
Assuming the PIPE Warrants are exercised
in full for cash at the initial exercise price of $7.50 per share, without giving effect to any beneficial ownership limitations, the
Exchange Cap, stockholder approval requirements, cashless exercise provisions, any reduced cash exercise price or other adjustments,
the Company would receive gross proceeds of approximately $39.6 million from the exercise of the PIPE Warrants. In addition, assuming
the Placement Agent Warrants are exercised in full for cash at the same initial exercise price, the Company would receive additional
gross proceeds of approximately $3.2 million, resulting in total potential gross proceeds of approximately $42.8 million from the exercise
of the PIPE Warrants and Placement Agent Warrants. There can be no assurance that any Warrants will be exercised for cash, if at all.
From
the date of the Purchase Agreement until the earlier of (i) seven months from the date of the Purchase Agreement and (ii) thirty days
after the effective date of a resale registration statement registering all of the underlying securities for the Notes, the Company and
its subsidiaries may not issue, enter into any agreement to issue, or announce the issuance or proposed issuance of any shares of capital
stock or capital stock equivalents pursuant to a variable rate transaction without the prior written consent of Purchasers holding a
majority in interest of the Notes then outstanding, subject to specified exceptions, including certain equity incentive and inducement
issuances, certain at-the-market offerings, equity lines of credit or committed equity facilities, and issuances under the transaction
documents.
The Company used a portion of the
proceeds from the Offering to repay outstanding obligations owed to Marco Capital, Inc. under that certain Loan and Security Agreement,
dated November 22, 2024, by and between Marco Capital, Inc. and Wellgistics, LLC, which obligations were guaranteed by Wellgistics Health,
Inc. pursuant to a Guaranty Agreement dated November 22, 2024. As of May 5, 2026, the aggregate outstanding amount of such obligations
was approximately $1.77 million.
Registration
Rights Agreement
In
connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement with the Purchasers (the “Registration
Rights Agreement”). Pursuant to the Registration Rights Agreement, the Company agreed to file a resale registration statement covering
the registrable securities within fifteen calendar days after the date of the Registration Rights Agreement and to use commercially reasonable
efforts to have such registration statement declared effective no later than the 45th calendar day after the date of the Registration
Rights Agreement, subject to acceleration if the SEC indicates that the registration statement will not be reviewed or is no longer subject
to review. The Registration Rights Agreement provides for liquidated damages upon certain registration-related failures, including failure
to timely file or obtain effectiveness of the registration statement, in an amount equal to 1.5% of the aggregate subscription amount
paid by the applicable holder for each event date and each monthly anniversary of the event date until the applicable event is cured,
subject to the terms of the Registration Rights Agreement.
Placement
Agency Agreement
On
May 27, 2026, the Company entered into a Placement Agency Agreement with Dawson James Securities, Inc. (the “Placement Agent”),
pursuant to which the Placement Agent acted as the Company’s exclusive placement agent on a best efforts, agency basis in connection
with the offering. As compensation, the Company agreed to pay the Placement Agent a cash fee equal to 3% of the aggregate gross proceeds
received by the Company from the sale of the securities at one or more closings and to issue five-year warrants (the “Placement
Agent Warrants” and, together with the PIPE Warrants, the “Warrants”) to purchase a number of shares of Common Stock
equal to 12% of the aggregate number of shares of Common Stock initially issuable upon conversion of the Notes based on the initial conversion
price, at an exercise price of $6.25 per share. The Placement Agent Warrants are expected to contain terms substantially similar to the
PIPE Warrants, including any mandatory exercise or call provision, cashless exercise provision, registration rights and customary anti-dilution
provisions. The Company also agreed to reimburse the Placement Agent for certain legal and diligence fees and expenses not to exceed
$110,000 and to a twelve-month tail fee with respect to certain investors introduced to the Company by the Placement Agent, subject to
the exceptions set forth in the Placement Agency Agreement.
Lock-Up
Agreements
In
connection with the Offering, certain officers and directors of the Company and stockholders holding a majority of the Company’s
outstanding common stock entered into lock-up agreements with the Placement Agent. Pursuant to the lock-up agreements, the applicable
stockholders agreed, subject to certain customary exceptions, not to offer, pledge, sell, contract to sell, lend or otherwise transfer
or dispose of any shares of the Company’s capital stock or securities convertible into or exercisable or exchangeable for shares
of the Company’s capital stock during the period commencing on the Closing Date and ending on the earliest of (i) ninety (90) days
after the Registration Statement is declared effective under the Securities Act, (ii) one hundred eighty (180) days after the Closing
Date and (iii) such earlier date as the Placement Agent may agree in writing. The lock-up agreements also restrict certain hedging, swap
and similar transactions and provide for stop transfer instructions with respect to the shares subject to the lock-up agreements. The
restrictions are subject to certain customary exceptions, including certain transfers by gift, to trusts or affiliates, by will or intestacy,
in connection with certain equity award or tax withholding transactions, and in connection with certain change-of-control transactions
approved by the Company’s Board of Directors.
The
lock-up press release states that holders of 1,333,930 common shares, representing a majority of the outstanding common shares, entered
into the lock-up arrangement, while the form agreement provides for the lock-up period and transfer restrictions summarized above.
The
foregoing descriptions of the Purchase Agreement, the Notes, the PIPE Warrants, the certificate of designation for the Series A Preferred
Stock, the Registration Rights Agreement, the Placement Agency Agreement and the Lock-Up Agreements do not purport to be complete and
are qualified in their entirety by reference to the full text of such documents, copies or forms of which are filed as exhibits to this
Current Report on Form 8-K and incorporated herein by reference.
Forward-Looking
Statements
This
Current Report on Form 8-K contains forward-looking statements within the meaning of applicable federal securities laws, including statements
regarding the offering, the use of proceeds, the conversion of the Notes, the issuance and filing of the Series A Preferred Stock, the
Company’s ability to obtain stockholder approval, the filing and effectiveness of resale registration statements, and the exercise
of Warrants. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements, including risks described in the Company’s filings with the SEC. The Company
undertakes no obligation to update any forward-looking statements except as required by law.
Item
3.02 Unregistered Sales of Equity Securities.
The
information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02.
The
Notes, the PIPE Warrants, the Placement Agent Warrants, the Series A Preferred Stock issuable upon conversion of the Notes, the shares
of Common Stock issuable upon conversion of the Notes and the Series A Preferred Stock, and the shares of Common Stock issuable upon
exercise of the Warrants were, or will be, offered and sold in transactions exempt from registration under the Securities Act of 1933,
as amended (the “Securities Act”), in reliance on Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated
thereunder. Each Purchaser represented that it is an accredited investor within the meaning of Rule 501(a) of Regulation D and was acquiring
the securities for investment purposes and not with a view to distribution in violation of the Securities Act. The securities issued
and issuable in the offering have not been registered under the Securities Act or applicable state securities laws and may not be offered
or sold in the United States absent registration or an applicable exemption from registration requirements.
Item
7.01 Regulation FD Disclosure.
On
May 27, 2026, the Company issued a press release announcing the financing and debt restructuring transaction described above under Item
1.01. On May 28, 2026, the Company issued a press release announcing that holders of a majority of the Company’s outstanding common
stock entered into a lock-up agreement. Copies of such press releases are furnished herewith as Exhibits 99.1 and 99.2, respectively,
and are incorporated herein by reference.
The
information contained in this Item 7.01, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference into any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such
filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
No.
Description
4.1
Form of Convertible Promissory Note.
4.2
Form of PIPE Warrant.
4.3
Form of Placement Agent Warrant.
10.1
Securities Purchase Agreement, dated May 27, 2026, by and among Wellgistics Health, Inc. and the Purchasers party thereto.
10.2
Registration Rights Agreement, dated May 27, 2026, by and among Wellgistics Health, Inc. and the Purchasers party thereto.
10.3
Placement Agency Agreement, dated May 27, 2026, by and between Wellgistics Health, Inc. and Dawson James Securities, Inc.
10.4
Form of Lock Up Agreement.
99.1
Press
Release issued by Wellgistics Health, Inc. on May 27, 2026.
99.2
Press Release issued by Wellgistics Health, Inc. on May 28, 2026.
104
Cover
Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
May 29, 2026
WELLGISTICS
HEALTH, INC.
By:
/s/
[__]
Name:
Prashant
Patel
Title:
Chief
Executive Officer
EX-4.1
EX-4.1
Filename: ex4-1.htm · Sequence: 2
Exhibit
4.1
NEITHER
THIS NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “ACT”), OR APPLICABLE STATE SECURITIES LAWS AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION
WITH, THE SALE OR DISTRIBUTION THEREOF. SUCH SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, LENT OR OTHERWISE TRANSFERRED
EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION
NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE SECURITIES LAWS, AND IN EACH CASE IN COMPLIANCE WITH THE
TRANSFER RESTRICTIONS SET FORTH HEREIN AND IN THE SECURITIES PURCHASE AGREEMENT.
CONVERTIBLE
PROMISSORY NOTE
$[__]
May
27, 2026
For
value received WELLGISTICS HEALTH, INC., a Delaware corporation (the “Company”), promises to pay to [__________] or its successors
or assigns (“Holder”) the principal sum of US $[__] with simple interest on the outstanding principal amount at the rate
of zero percent (0%) per annum. Interest will commence on the date hereof and will continue on the outstanding principal until paid in
full or otherwise converted pursuant to the terms set forth herein. All principal and interest on the outstanding principal will accrue
and, unless converted earlier as set forth below or repaid in accordance with Section 3, be due and payable on the twelve (12) month
anniversary of the date hereof (the “Maturity Date”). Interest will be computed on the basis of a 365-day year. This Note
is being issued as a series of promissory notes (collectively, the “Notes”, and such other promissory notes, the “Other
Notes”) under that certain Securities Purchase Agreement dated as of the date hereof (the “Securities Purchase Agreement”).
Capitalized terms used and not otherwise defined herein that are defined in the Securities Purchase Agreement shall have the meanings
given such terms in the Securities Purchase Agreement.
1.
Cash Purchase Price. This Convertible Promissory Note (the “Note”) is being purchased for a cash purchase price of $[__],
reflecting a 20% original issue discount.
2.
Definitions.
(a)
“Common Stock” means the Company’s common stock, par value $0.0001 per share.
(b)
“Exchange Cap” means, prior to receipt of the Required Stockholder Approval, 19.99% of the shares of Common Stock or voting
power outstanding immediately prior to the execution of the Securities Purchase Agreement, calculated in accordance with the rules and
regulations of the applicable Trading Market, including Nasdaq Listing Rule 5635(d), and subject to appropriate adjustment for any stock
split, stock dividend, stock combination, recapitalization or similar event occurring after the date of the Securities Purchase Agreement.
(c)
“Note Balance” means at any particular time the then outstanding principal balance and any accrued but unpaid interest on
this Note.
(d)
“Required Stockholder Approval” has the meaning set forth in the Securities Purchase Agreement.
(e)
“Securities Act” means the Securities Act of 1933, as amended.
(f)
“Short Sales” shall include all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act.
(g)
“Trading Day” means a day on which the principal Trading Market is open for trading.
(h)
“Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading
on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or
the New York Stock Exchange (or any successors to any of the foregoing).
3.
Prepayment; Financing Repayment; Application of Payments.
(a)
The Company may not prepay this Note without the consent of the Holder. Upon payment in full of the Note Balance hereunder, this Note
must be surrendered to the Company for cancellation.
(b)
Financing Repayment. Unless waived in writing by the holders of a majority in principal amount of the then outstanding Notes, the Company
shall apply the net cash proceeds received by the Company from any Qualified Financing to the repayment of the Notes on a pro rata basis
based on the outstanding Note Balance of each Note; provided, however, that “Qualified Financing” shall not include (i) any
Exempt Issuance, (ii) any at-the-market offering program, equity line of credit, committed equity facility or other financing permitted
under the Securities Purchase Agreement, (iii) any securities issued pursuant to acquisitions, mergers, strategic transactions, commercial
collaborations, joint ventures or similar arrangements approved by the Board of Directors, (iv) any securities issued in connection with
debt exchanges, liability management transactions, settlements, restructurings, Section 3(a)(9) exchanges, Section 3(a)(10) settlements
or similar transactions approved by the Board of Directors, or (v) securities issued pursuant to any agreement, instrument or obligation
outstanding as of the date hereof and disclosed in the SEC Reports or Disclosure Schedules.
4.
Conversion.
4.1.
Voluntary Conversion into Common Stock. At any time prior to the Mandatory Conversion Date (as defined below), this
Note
shall be convertible, in whole or in part, at the option of the Holder, into shares of Common Stock at the Conversion Price (as defined
herein), subject to the terms and conditions set forth herein.
4.2.
Mandatory Conversion into Preferred Stock.
(a)
Upon the later to occur of (i) the date on which the Registration Statement is declared effective by the Commission, (ii) the date on
which the Company has obtained the Required Stockholder Approval, (iii) the effectiveness of any amendment to the Company’s certificate
of incorporation necessary to authorize blank check preferred stock, and (iv) the filing of the Certificate of Designation with the Secretary
of State of the State of Delaware (the “Mandatory Conversion Date”), the outstanding Note Balance shall automatically, and
without any further action by the Holder or the Company, be converted in full into shares of New Series Convertible Preferred Stock.
Effective as of the Mandatory Conversion Date, the Conversion Price shall be deemed to have been reset and thereafter shall equal the
lesser of (x) $50.00 per share and (y) the Variable Conversion Price (as defined herein), in each case subject to the Floor Price. The
Company shall promptly, and in any event within one (1) Trading Day, notify the Holder in writing upon the occurrence of the Mandatory
Conversion Date.
(b)
The number of shares of New Series Convertible Preferred Stock to be issued upon such conversion shall be equal to (i) the Note Balance
as of the Mandatory Conversion Date divided by (ii) $1,000.00 (the “Stated Value”), with each share of New Series Convertible
Preferred Stock having a Stated Value of $1,000.00. Upon such conversion, this Note shall be deemed converted in full and shall no longer
be outstanding, except for the right of the Holder to receive the shares of New Series Convertible Preferred Stock issuable upon such
conversion.
4.3.
Effect of Conversion.
(a)
Upon any conversion of this Note into Common Stock pursuant to Section 4.1, the Holder shall be entitled to receive the number of shares
of Common Stock equal to (i) the Note Balance being converted divided by (ii) the Conversion Price then in effect.
(b)
Following the Mandatory Conversion Date, the right of the Holder to convert this Note into Common Stock pursuant to Section 4.1 shall
terminate.
(c)
The Company shall deliver the applicable number of shares of Common Stock or New Series Convertible Preferred Stock, as applicable, to
the Holder in accordance with the conversion procedures set forth herein.
4.4.
Conversion Price.
(a)
“Conversion Price” means, as of any Conversion Date, the lesser of (i) $6.00 per share or (ii) the Variable Conversion Price,
subject to adjustment as provided herein, provided, however, that in no event shall the Conversion Price be less than the Floor Price.
(b)
“Floor Price” initially means $1.00 per share.
(c)
“Market Price” means, for any Conversion Date, the closing price of the Common Stock on the Trading Day immediately preceding
such Conversion Date.
(d)
“Variable Conversion Price” means, as of any Conversion Date, 100% of the Market Price.
(e)
The Conversion Price and Floor Price shall be subject to equitable adjustment for stock splits, stock dividends, rights offerings, combinations,
recapitalizations, reclassifications, extraordinary distributions and similar events affecting the Common Stock or any securities into
which the Common Stock may be converted.
4.5.
Conversion Procedures. Conversions hereunder shall be effected by the delivery by the Holder of a written notice of conversion in substantially
the form attached hereto (a “Notice of Conversion”). Upon receipt of any Notice of Conversion, the Company shall promptly
issue and deliver the applicable shares in accordance with the terms hereof. No ink-original, medallion guarantee or additional documentation
shall be required in connection with any conversion hereunder. No fractional shares of Common Stock shall be issued upon any conversion
of this Note. In lieu of any fractional shares, the Company shall round up to the next whole share. Notwithstanding anything to the contrary
herein, the Company shall not be required to issue or deliver any shares of Common Stock or New Series Convertible Preferred Stock to
the extent such issuance or delivery would violate the Exchange Cap, the Required Stockholder Approval provisions, any beneficial ownership
limitation, the rules and regulations of the applicable Trading Market, the Securities Act or applicable state securities laws.
4.6
Floor Price Adjustment.
(a)
Notwithstanding anything to the contrary herein, on the Mandatory Conversion Date, the Floor Price shall automatically, and without any
further action by the Holder or the Company, be adjusted to equal 20% of the closing price of the Common Stock on the Trading Day immediately
preceding the Mandatory Conversion Date, provided the Floor Price shall not increase under any circumstances.
(b)
Notwithstanding anything to the contrary herein, the Floor Price may be adjusted from time to time in accordance with the requirements
set forth in the Securities Purchase Agreement. Without limiting the foregoing, upon approval of the stockholders of the Company obtained
pursuant to the Securities Purchase Agreement to reset the Floor Price, the Floor Price shall automatically be adjusted to an amount
equal to 20% of the closing price of the Common Stock on the Trading Day immediately preceding the date of such stockholder approval,
effective as of such date, and such adjusted amount shall thereafter constitute the “Floor Price” for all purposes under
this Note, provided the Floor Price shall not increase under any circumstances.
4.7.
Exchange Cap. Notwithstanding anything to the contrary contained herein or in any other Transaction Document, prior to receipt of the
Required Stockholder Approval, the Company shall not issue, and the Holder shall not have the right to receive, any shares of Common
Stock upon conversion of this Note to the extent that, after giving effect to such issuance, the aggregate number of shares of Common
Stock issued pursuant to the Transaction Documents would exceed the Exchange Cap. Any purported issuance of shares of Common Stock in
excess of the Exchange Cap prior to receipt of the Required Stockholder Approval shall be null and void ab initio. The limitations set
forth in this Section 4.7 shall apply in addition to, and not in lieu of, any beneficial ownership limitation set forth in the Securities
Purchase Agreement, the Certificate of Designation, this Note or any other Transaction Document.
5.
Events of Default.
5.1.
“Event of Default”, wherever used herein, means any one of the following events (whatever the reason and whether it shall
be voluntary or involuntary or effected by operation of law or pursuant to any judgment, decree or order of any court, or any order,
rule or regulation of any administrative or governmental body):
(i)
any default in the payment of the principal of this Note or any other amount due hereunder, as and when the same shall become due and
payable;
(ii)
the Company shall fail to observe or perform any obligation or shall breach any term or provision of this Note and such failure or breach
shall not have been remedied within five calendar days after the date on which notice of such failure or breach shall have been delivered;
(iii)
the Company or any of its subsidiaries shall commence, or there shall be commenced against the Company or any subsidiary a case under
any applicable bankruptcy or insolvency laws as now or hereafter in effect or any successor thereto, or the Company or any subsidiary
commences any other proceeding under any reorganization, arrangement, adjustment of debt, relief of debtors, dissolution, insolvency
or liquidation or similar law of any jurisdiction whether now or hereafter in effect relating to the Company or any subsidiary, or there
is commenced against the Company or any subsidiary any such bankruptcy, insolvency or other proceeding which remains undismissed for
a period of 60 days; or the Company or any subsidiary is adjudicated insolvent or bankrupt; or any order of relief or other order approving
any such case or proceeding is entered; or the Company or any subsidiary suffers any appointment of any custodian or the like for it
or any substantial part of its property which continues undischarged or unstayed for a period of 60 days; or the Company or any subsidiary
makes a general assignment for the benefit of creditors; or the Company or any subsidiary shall fail to pay, or shall state that it is
unable to pay, or shall be unable to pay, its debts generally as they become due; or the Company or any subsidiary shall call a meeting
of its creditors with a view to arranging a composition, adjustment or restructuring of its debts; or the Company or any subsidiary shall
by any act or failure to act expressly indicate its consent to, approval of or acquiescence in any of the foregoing; or any corporate
or other action is taken by the Company or any subsidiary for the purpose of effecting any of the foregoing;
(iv)
the Company or any subsidiary shall default in any of its respective obligations under any other note or any mortgage, credit agreement
or other facility, indenture agreement, factoring agreement or other instrument under which there may be issued, or by which there may
be or evidenced any indebtedness for borrowed money or money due under any long term leasing or factoring arrangement of the Company
or any subsidiary, whether such indebtedness now exists or shall hereafter be created, and such default shall result in such indebtedness
becoming or being declared due and payable prior to the date on which it would otherwise become due and payable;
(v)
The Company shall (a) be a party to any Change of Control Transaction (as defined below), (b) agree to sell or dispose all or in excess
of 33% of its assets in one or more transactions (whether or not such sale would constitute a Change of Control Transaction), (c) redeem
or repurchase more than a de minimis number of shares of Common Stock or other equity securities of the Company, or (d) make any distribution
or declare or pay any dividends (in cash or other property, other than common stock) to purchase, acquire, redeem, or retire any of the
Company’s capital stock, of any class, whether now or hereafter outstanding. “Change of Control Transaction” means
the occurrence of any of: (i) an acquisition after the date hereof by an individual or legal entity or “group” (as described
in Rule 13d-5(b)(1) promulgated under the Securities Exchange Act of 1934, as amended) of effective control (whether through legal or
beneficial ownership of capital stock of the Company, by contract or otherwise) of in excess of 33% of the voting securities of the Company,
(ii) a replacement at one time or over time of more than one-half of the members of the Company’s board of directors which is not
approved by a majority of those individuals who are members of the board of directors on the date hereof (or by those individuals who
are serving as members of the board of directors on any date whose nomination to the board of directors was approved by a majority of
the members of the board of directors who are members on the date hereof), (iii) the merger of the Company with or into another entity
that is not wholly-owned by the Company, consolidation or sale of 33% or more of the assets of the Company in one or a series of related
transactions, or (iv) the execution by the Company of an agreement to which the Company is a party or by which it is bound, providing
for any of the events set forth above in (i), (ii) or (iii); or any member of the Company’s management shall cease to be a member
of the Company’s senior management or shall cease to perform any of the material functions and duties currently performed by such
person. For purposes hereof, “senior management” refers to the President, the Chief Executive Officer, the Chief Financial
Officer, the Chief Operations Officer and any officer performing the customary function of such officers; or
(vi)
the Company shall be in breach any covenant in the Securities Purchase Agreement, and such breach, if capable of cure, remains uncured
for ten (10) Business Days after written notice thereof from the Holder, or any representation or warranty of the Company in the Securities
Purchase Agreement shall have been untrue or incorrect when made and such inaccuracy would reasonably be expected to have a Material
Adverse Effect; or
(vii)
the suspension from trading or the failure of (viii) the Common Stock to be trading or listed (as applicable)or quoted on Nasdaq for
a period of two (2) consecutive days Nasdaq is open for trading.
5.2.
Remedies Upon Event of Default. If any Event of Default occurs and is continuing beyond any applicable cure period, the Holder may, by
written notice to the Company, declare the full Note Balance immediately due and payable in cash. Commencing after the occurrence and
during the continuance of any Event of Default that results in acceleration of this Note, the outstanding Note Balance shall accrue interest
at the rate of ten percent (10%) per annum, or such lower maximum rate permitted under applicable law. The Holder need not provide and
the Company hereby waives any presentment, demand, protest or other notice of any kind, and the Holder may immediately and without expiration
of any grace period enforce any and all of his rights and remedies hereunder and all other remedies available to it under applicable
law. Any declaration of acceleration may be rescinded and annulled by the Holder at any time prior to payment in full of the Note Balance.
No such rescission or annulment shall affect any subsequent Event of Default or impair any right consequent thereon.
6.
Governing Law. The terms of this Note are governed by and construed in accordance with the laws of the State of Delaware.
7.
Time of Essence. Time is of the essence with respect to all of the Company’s obligations and agreements under this Note.
8.
Successor and Assigns. This Note and all provisions, conditions, promises and covenants hereof are binding in accordance with the terms
hereof upon the Company, its successors and assigns. The obligations of the Company set forth herein will not be assignable by the Company
without Holder’s prior written consent.
8.1.
Transfer. Subject to compliance with the Securities Act, applicable state securities laws and the applicable provisions of the Securities
Purchase Agreement, this Note may be offered for sale, sold, transferred or assigned without the consent of the Company; provided that
any transferee of this Note shall agree in writing to be bound by the terms and conditions of this Note and the applicable provisions
of the Securities Purchase Agreement, including, without limitation, the Exchange Cap, the Required Stockholder Approval provisions and
the no-short-sale and no-hedging covenant set forth herein. Any purported transfer in violation of this Section 8.1 shall be null and
void ab initio.
9.
Collection Expenses. The Company further agrees, subject only to any limitation imposed by applicable law, to pay all reasonable and
documented expenses, including reasonable attorneys’ fees, incurred by the Holder in endeavoring to collect any amounts payable
hereunder which are not paid when due.
10.
Waiver. The Company hereby waives presentment, protest, demand for payment, notice of dishonor, and any and all other notices or demands
in connection with the delivery, acceptance, performance, default, or enforcement of this Note.
11.
Amendment. This Note may be amended with the written consent of the holders of a majority of the outstanding indebtedness under the Notes
and the Company, which consent will be binding upon the Holder hereof.
12.
Entire Agreement. This Note contains the entire understanding of the Company and the Holder with respect to the subject matter hereof
and expressly supersedes any and all prior agreements and understandings among them with respect to such subject matter. All pronouns
contained herein, and any variations thereof, are deemed to refer to the masculine, feminine or neutral, singular or plural, as to the
identity of the parties hereto may require.
13.
No Short Sales. The Holder agrees it shall not maintain a net short position with respect to the Common Stock in excess of the number
of shares of Common Stock then actually issued to such Holder or then issuable to such Holder upon conversion or exercise of securities
held by such Holder.
[Remainder
of page intentionally left blank]
IN
WITNESS WHEREOF, the Company and the Holder have caused this Note to be executed and issued as a sealed instrument as of the date and
year first written above.
WELLGISTICS HEALTH, INC.
By:
Name:
Title:
HOLDER:
By:
Name:
[Signature
Page to Convertible Promissory Note]
EXHIBIT
A
WELLGISTICS
HEALTH, INC.
CONVERSION
NOTICE
Reference
is made to the Convertible Promissory Note (the “Note”) issued to the undersigned by Wellgistics Health, Inc., a Delaware
corporation (the “Company”). In accordance with and pursuant to the Note, the undersigned hereby elects to convert all or
a portion of the outstanding Note Balance (as defined in the Note) of the Note indicated below into shares of Common Stock, $0.0001 par
value per share (the “Common Stock”), of the Company, as of the date specified below. Capitalized terms not defined herein
shall have the meaning as set forth in the Note.
Date
of Conversion: ________________________________________________
Aggregate
Principal to be converted: __________________________________
Aggregate
accrued and unpaid Interest with respect to such portion of the Aggregate Principal to be converted: ______________________
AGGREGATE
CONVERSION AMOUNT TO BE CONVERTED: ____________________________
Please
confirm the following information:
Conversion
Price: ______________________
Number
of shares of Common Stock to be issued: ____________________________
Please
issue the Common Stock into which the Note is being converted to Holder, or for its benefit, as follows:
☐
Check here if requesting delivery as a certificate to the following name and to the following address:
Issue
to: _____________________________________________________________
☐
Check here if requesting delivery by Deposit/Withdrawal at Custodian as follows:
DTC
Participant: ______________________
DTC
Number: __________________________
Account
Number: ______________________
Date:
_____________ __, _____
Name
of Registered Holder: _____________________________________________
By:
________________________________
Name:
Title:
Tax
ID:
Address:
ACKNOWLEDGMENT
The
Company hereby (a) acknowledges this Conversion Notice, (b) certifies, solely to the Company’s knowledge and based on the information
available to the Company as of the date hereof, whether the above indicated number of shares of Common Stock [are][are not] eligible
to be resold by the Holder either (i) pursuant to Rule 144, subject to the Holder’s execution and delivery to the Company of a
customary Rule 144 representation letter and any required legal opinion, or (ii) pursuant to an effective and available registration
statement, and (c) hereby directs _________________ to issue the above indicated number of shares of Common Stock in accordance with
the Transfer Agent Instructions dated _____________, 20__ from the Company and acknowledged and agreed to by ________________________.
WELLGISTICS HEALTH, INC.
By:
Name:
Title:
EX-4.2
EX-4.2
Filename: ex4-2.htm · Sequence: 3
Exhibit
4.2
NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY NOT BE PLEDGED, HYPOTHECATED, LENT OR OTHERWISE TRANSFERRED EXCEPT IN COMPLIANCE WITH THE SECURITIES ACT, APPLICABLE
STATE SECURITIES LAWS, THE TRANSFER RESTRICTIONS SET FORTH HEREIN AND THE APPLICABLE PROVISIONS OF THE SECURITIES PURCHASE AGREEMENT.
Wellgistics
Health, INC.
WARRANT
TO PURCHASE COMMON STOCK
Date
of Issuance: May 27, 2026 (“Issuance Date”)
Wellgistics
Health, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, [_____], the registered holder hereof or its permitted assigns (the “Holder”),
is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect,
upon exercise of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer
or replacement hereof, the “Warrant”), at any time or times on or after the Issuance Date, but not after 11:59 p.m.,
New York time, on the Expiration Date (as defined below), May 27, 2031 (subject to adjustment as provided herein) fully paid and non-assessable
shares of Common Stock (as defined below) (the “Warrant Shares”). Except as otherwise defined herein, capitalized
terms in this Warrant shall have the meanings set forth in Section 16. This Warrant is one of the Warrants to purchase Common Stock (the
“SPA Warrants”) issued to Holder pursuant to that certain Securities Purchase Agreement dated May 27, 2026 by and
among the Company, the Holder and the other investors thereto (the “Securities Purchase Agreement”). Capitalized terms
used and not otherwise defined herein that are defined in the Securities Purchase Agreement shall have the meanings given such terms
in the Securities Purchase Agreement.
1.
EXERCISE OF WARRANT.
(a)
Mechanics of Exercise. Subject to the terms and conditions hereof (including, without limitation, the limitations set forth
in Section 1(g)), this Warrant may be exercised by the Holder on any day on or after the Issuance Date in whole or in part, by delivery
(whether via facsimile or otherwise) of a written notice, in the form attached hereto as Exhibit A (the “Exercise
Notice”), of the Holder’s election to exercise this Warrant. Within one (1) Trading Day following an exercise of this
Warrant as aforesaid, the Holder shall deliver payment to the Company of an amount equal to the Exercise Price in effect on the date
of such exercise multiplied by the number of Warrant Shares as to which this Warrant was so exercised (in respect of such specific exercise,
the “Aggregate Exercise Price”) in cash or via wire transfer of immediately available funds if the Holder did not
notify the Company in such Exercise Notice that such exercise was made pursuant to a Cashless Exercise (as defined in Section 1(e)).
If the Company has delivered a notice pursuant to Section 1(m) and the Holder elects to exercise this Warrant for cash during the period
specified in such notice, then the Aggregate Exercise Price for the Warrant Shares subject to such cash exercise shall be calculated
using the applicable Reduced Cash Exercise Price; provided that the Holder may not elect a Cashless Exercise with respect to any Warrant
Shares exercised at the Reduced Cash Exercise Price. The Holder shall not be required to deliver the original of this Warrant in order
to effect an exercise hereunder. Execution and delivery of an Exercise Notice with respect to less than all of the Warrant Shares shall
have the same effect as cancellation of the original of this Warrant certificate and issuance of a new Warrant certificate evidencing
the right to purchase the remaining number of Warrant Shares. Execution and delivery of an Exercise Notice for all of the then-remaining
Warrant Shares shall have the same effect as cancellation of the original of this Warrant certificate after delivery of the Warrant Shares
in accordance with the terms hereof. On or before the first (1st) Trading Day following the date on which the Company has received an
Exercise Notice, the Company shall transmit by facsimile an acknowledgment of confirmation of receipt of such Exercise Notice, in the
form attached hereto as Exhibit B, to the Holder and the Company’s transfer agent (the “Transfer Agent”).
On or before the first (1st) Trading Day following the date on which the Company has received such Exercise Notice (the “Required
Delivery Date”), the Company shall, upon the request of the Holder, credit such aggregate number of shares of Common Stock
to which the Holder is entitled pursuant to such exercise to the Holder’s or its designee’s balance account with The Depository
Trust Company (“DTC”) through its Deposit/Withdrawal at Custodian system. Upon delivery of an Exercise Notice, the
Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this
Warrant has been exercised, irrespective of the date such Warrant Shares are credited to the Holder’s DTC account. If this Warrant
is submitted in connection with any exercise pursuant to this Section 1(a) and the number of Warrant Shares represented by this Warrant
is greater than the number of Warrant Shares being acquired upon an exercise, then, at the request of the Holder and upon surrender hereof
by the Holder at the principal office of the Company, the Company shall as soon as practicable and in no event later than three (3) Business
Days after any exercise and at its own expense, issue and deliver to the Holder (or its designee) a new Warrant (in accordance with Section
7(d)) representing the right to purchase the number of Warrant Shares purchasable immediately prior to such exercise under this Warrant,
less the number of Warrant Shares with respect to which this Warrant is exercised. No fractional shares of Common Stock are to be issued
upon the exercise of this Warrant, but rather the number of shares of Common Stock to be issued shall be rounded up to the nearest whole
number. The Company shall pay any and all taxes and fees which may be payable with respect to the issuance and delivery of Warrant Shares
upon exercise of this Warrant.
(b)
Warrant Coverage; Maximum Warrant Shares. For purposes of this Warrant, the “Face Value” means the initial principal
amount of the Note purchased by the Holder pursuant to the Securities Purchase Agreement. This Warrant provides for 150% warrant coverage
on the Face Value, such that the maximum number of Warrant Shares purchasable hereunder at any time shall be equal to (i) 150% of the
Face Value, divided by (ii) the official closing price of the Common Stock on the Issuance Date as reported by Nasdaq, in each case without
regard to any limitations on conversion set forth in the Note. For the avoidance of doubt, the number of Warrant Shares purchasable hereunder
shall not increase as a result of any future adjustment, reset, default provision, anti-dilution provision or other change to the Conversion
Price or number of shares issuable under the Note after the Issuance Date, except for adjustments expressly provided in Section 2(a)
of this Warrant for stock splits, stock dividends, combinations, recapitalizations and similar events affecting the Common Stock. Any
fractional Warrant Shares resulting from the foregoing calculation shall be rounded up to the nearest whole share. For the avoidance
of doubt, the Company acknowledges that under certain circumstances each Warrant may be exercisable for more than one share of common
stock.
(c)
Exercise Price. For purposes of this Warrant, “Exercise Price” means $7.50, subject to adjustment as
provided herein.
(d)
Company’s Failure to Timely Deliver Securities. If the Company fails to issue and credit the balance account of Holder
or Holder’s nominee with DTC for such number of Warrant Shares for which this Warrant is exercised by the Holder, then, in addition
to all other remedies available to Holder, at the sole discretion of Holder, the Company shall:
(i)
pay in cash to Holder on each Trading Day after the Required Delivery Date that the issuance and credit of such Warrant Shares
is not timely effected an amount equal to 5% of the product of (A) the number of shares of Common Stock not so credited to Holder or
Holder’s nominee multiplied by (B) the Closing Sale Price of the Common Stock on the Trading Day immediately preceding the Required
Delivery Date; or
(ii)
if on or after the Required Delivery Date, Holder (or any other Person in respect, or on behalf, of Holder) purchases (in an open market
transaction or otherwise) Common Stock (“Replacement Shares”) to deliver in satisfaction of a sale by Holder of all
or any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of
the number of shares of Common Stock, that Holder so anticipated receiving from the Company without any restrictive legend, then, within
five (5) Trading Days after Holder’s request and in Holder’s sole discretion, either (A) pay cash to Holder in an amount
equal to Holder’s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the Replacement
Shares (the “Buy-In Price”), at which point the Company’s obligation to so credit Holder’s balance account
shall terminate and such shares shall be cancelled, or (B) promptly honor its obligation to so credit Holder’s DTC account representing
such number of shares of Common Stock that would have been so delivered if the Company timely complied with its obligations hereunder
and pay cash to Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (1) such number of shares of
Common Stock that the Company was required to deliver to Holder by the Required Delivery Date multiplied by (2) the lowest Closing Sale
Price of the Common Stock on any Trading Day during the period commencing on the date Holder purchased Replacement Shares and ending
on the date of such delivery and payment under this clause (ii).
To
the extent permitted by law, the Company’s obligations to issue and deliver the Common Stock upon exercise of the Warrant in accordance
with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver
or consent with respect to any provision hereof, the recovery of any judgment against any person or any action to enforce the same, or
any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other person of
any obligation to the Company or any violation or alleged violation of law by the Holder or any other person, and irrespective of any
other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of the Common
Stock. Nothing herein shall limit the Holder’s right to pursue any other remedies available to it hereunder, at law or in equity
including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure
to timely deliver the Common Stock issuable upon exercise of this Warrant as required pursuant to the terms hereof. Notwithstanding anything
to the contrary in this Section 1(d), the Company shall not be required to issue or deliver any Warrant Shares to the extent such issuance
or delivery would violate the Maximum Percentage, the Exchange Cap, the Required Stockholder Approval provisions, the rules and regulations
of the applicable Trading Market, the Securities Act or applicable state securities laws.
(e)
Cashless Exercise. Notwithstanding anything contained herein to the contrary (other than Section 1(g) below) at any time
the Holder may in its sole discretion (and without limiting the Holder’s rights and remedies contained herein or in any of the
other Transaction Documents (as defined in the Securities Purchase Agreement)), exercise this Warrant in whole or in part and, in lieu
of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the Aggregate Exercise Price,
elect instead to receive upon such exercise the “Net Number” of shares of Common Stock determined according to the following
formula (a “Cashless Exercise”):
Net
Number = (A x B) / C
For
purposes of the foregoing formulas:
A=
The
total number of shares with respect to which this Warrant is then being exercised.
B=
The
Black Scholes Value (as defined in Section 16 herein).
C=
The
lower of the two Closing Bid Prices of the Common Stock in the two Trading Days prior the time of such exercise (as such Closing
Bid Price is defined in Section 16 herein).
Notwithstanding
anything herein to the contrary, the Company shall not issue to the Holder any Warrant Shares to the extent such shares, after giving
effect to such issuance after exercise, and when added to the number of shares of Common Stock issued and issuable upon (i) exercise
of any other warrants issued pursuant to the Securities Purchase Agreement or (ii) conversion of any Note, in each case if and to the
extent required by the applicable rules of the Eligible Market on which the Common Stock is then traded, would exceed 19.99% of the total
number of shares of Common Stock outstanding as of the date hereof, unless and until the Company obtains approval of its stockholders.
In such event, the Company shall, as promptly as practicable, use best efforts to obtain the approval of the Company’s stockholders
to issue Warrant Shares in excess of such amount in accordance with the requirements of the applicable Eligible Market. Notwithstanding
anything to the contrary herein, the Holder may not elect a Cashless Exercise with respect to any Warrant Shares for which the Company
has made available, and the Holder elects to use, a Reduced Cash Exercise Price pursuant to Section 1(m). For purposes of calculating
the Net Number in any Cashless Exercise, “Exercise Price” and “Black Scholes Value” shall be determined without
giving effect to any Reduced Cash Exercise Price.
(f)
Disputes. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the number
of Warrant Shares to be issued pursuant to the terms hereof (including, without limitation, the Net Number), the Company shall promptly
issue to the Holder the number of Warrant Shares that are not disputed, provided that following such issuance to Holder such dispute
shall be resolved in accordance with Section 13.
(g)
Limitations on Exercises and Exchanges. Notwithstanding anything to the contrary contained in this Warrant, this Warrant
shall not be exercisable or exchangeable by the Holder hereof to the extent (but only to the extent) that the Holder or any of its affiliates
would beneficially own in excess of 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number
of shares of Common Stock outstanding after giving effect to the issuance of Common Stock issuable upon exercise of the Warrants calculated
in accordance with Section 13(d) of the Exchange Act (the “Maximum Percentage”). The Holder, upon written notice to
the Company, may increase or decrease the Maximum Percentage provisions of this Section 1(g), provided that the Maximum Percentage in
no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares
of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 1(g) shall continue to apply. Any
increase in the Maximum Percentage will not be effective until the 61st day after such notice is delivered to the Company. To the extent
the above limitation applies, the determination of whether this Warrant shall be exercisable or exchangeable (vis-à-vis other
convertible, exercisable or exchangeable securities owned by the Holder or any of its affiliates) and of which such securities shall
be exercisable or exchangeable (as among all such securities owned by the Holder) shall, subject to such Maximum Percentage limitation,
be determined on the basis of the first submission to the Company for conversion, exercise or exchange (as the case may be). No prior
inability to exercise or exchange this Warrant pursuant to this paragraph shall have any effect on the applicability of the provisions
of this paragraph with respect to any subsequent determination of exercisability or exchangeability. For the purposes of this paragraph,
beneficial ownership and all determinations and calculations (including, without limitation, with respect to calculations of percentage
ownership) shall be determined in accordance with Section 13(d) of the 1934 Act (as defined in the Securities Purchase Agreement) and
the rules and regulations promulgated thereunder. The provisions of this paragraph shall be implemented in a manner otherwise than in
strict conformity with the terms of this paragraph to correct this paragraph (or any portion hereof) which may be defective or inconsistent
with the intended Maximum Percentage beneficial ownership limitation herein contained or to make changes or supplements necessary or
desirable to properly give effect to such Maximum Percentage limitation. The limitations contained in this paragraph shall apply to a
successor Holder of this Warrant. The holders of Common Stock shall be third party beneficiaries of this paragraph and the Company may
not waive this paragraph without the consent of holders of a majority of its Common Stock. For any reason at any time, upon the written
or oral request of the Holder, the Company shall within two (2) Business Days confirm orally and in writing to the Holder the number
of shares of Common Stock then outstanding, including by virtue of any prior conversion or exercise or exchange of convertible or exercisable
or exchangeable securities into shares of Common Stock, including, without limitation, pursuant to this Warrant or securities issued
pursuant to the Securities Purchase Agreement.
(h)
Reservation of Shares; Insufficient Authorized Shares. Company shall initially reserve out of its authorized and unissued
shares of Common Stock a number of shares of Common Stock equal to 250% of the maximum number of Warrant Shares issuable to satisfy the
Company’s obligations to issue shares of Common Stock hereunder, and the Company shall at all times keep reserved for issuance
under this Warrant a number of shares of Common Stock equal to 250% of the maximum number of Warrant Shares issuable to satisfy the Company’s
obligation to issue shares of Common Stock hereunder.
(i)
Activity Restrictions. For so long as Holder holds this Warrant or any Warrant Shares, Holder will not: (i) engage or participate
in any actions, plans or proposals which relate to or would result in (a) acquiring additional securities of the Company, alone or together
with any other Person, which would result in beneficially owning or controlling, or being deemed to beneficially own or control, more
than 9.99% of the total outstanding shares of Common Stock or other voting securities of the Company, (b) an extraordinary corporate
transaction, such as a merger, reorganization or liquidation, involving Company, (c) a sale or transfer of a material amount of assets
of the Company, (d) any change in the present board of directors or management of the Company, including any plans or proposals to change
the number or term of directors or to fill any existing vacancies on the board, (e) any material change in the present capitalization
or dividend policy of the Company, (f) any other material change in the Company’s business or corporate structure, including but
not limited to, if the Company is a registered closed-end investment company, any plans or proposals to make any changes in its investment
policy for which a vote is required by Section 13 of the Investment Company Act of 1940, (g) changes in the Company’s charter,
bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Company by any Person,
(h) causing a class of securities of the Company to be delisted from a national securities exchange or to cease to be authorized to be
quoted in an inter-dealer quotation system of a registered national securities association, (i) a class of equity securities of the Company
becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act, or (j) any action, intention, plan or arrangement
similar to any of those enumerated above, or (ii) request the Company or its directors, officers, employees, agents or representatives
to amend or waive any provision of this Section 1(i); provided, however, that notwithstanding anything to the contrary contain in clauses
(i) and (ii) above, Holder may vote any shares of Common Stock owned or controlled by it, solicit any proxies, or seek to advise or influence
any Person with respect to any voting securities of the Company. Holder may only exercise this Warrant for a cash exercise price if the
trading price at the time of exercise is greater than the then applicable Exercise Price.
(j)
Mandatory Exercise.
(i)
If, at any time after the Effectiveness Date, (A) the VWAP of the Common Stock equals or exceeds 150% of the then-applicable Exercise
Price for at least ten (10) consecutive Trading Days; (B) the average daily dollar trading volume of the Common Stock for such ten (10)
Trading Day period equals or exceeds $5,000,000, where the dollar trading volume for any Trading Day is calculated by multiplying (x)
the aggregate number of shares of Common Stock traded on such Trading Day by (y) the VWAP of the Common Stock on such Trading Day; and
(C) the Equity Conditions are satisfied on each such Trading Day and through and including the Mandatory Exercise Date, the Company may
from time to time, deliver written notice to the Holder requiring the Holder to exercise all or the applicable portion of this Warrant
specified in such notice; provided that no such mandatory exercise shall require the Holder to exercise this Warrant to an extent that
would result in the Holder (together with its Affiliates) beneficially owning in excess of the Maximum Percentage (each, a “Mandatory
Exercise Notice”).
(ii)
Each Mandatory Exercise Notice shall specify the portion of this Warrant to be exercised and the Mandatory Exercise Date, which date
shall be no earlier than the fifth (5th) Trading Day and no later than the tenth (10th) Trading Day following delivery of such notice.
Unless a Cashless Exercise is elected, the Holder shall deliver an Exercise Notice and pay the applicable Aggregate Exercise Price on
or prior to the Mandatory Exercise Date.
(iii)
The Company may deliver multiple mandatory exercise notices pursuant to this Section 1(j), provided that each such notice independently
satisfies the conditions set forth herein at the time of delivery.
(iv)
Any mandatory exercise pursuant to this Section 1(j) shall at all times remain subject to the Maximum Percentage, the Exchange Cap, the
Required Stockholder Approval and the rules and regulations of the applicable Trading Market. No mandatory exercise notice shall require
the Holder to exercise this Warrant to the extent such exercise would result in a violation of any such limitation.
(v)
If the Equity Conditions cease to be satisfied at any time after delivery of a mandatory exercise notice and prior to the Mandatory Exercise
Date, then such notice shall be null and void unless waived by the Holder.
(k)
Exchange Cap. Notwithstanding anything to the contrary contained herein or in any other Transaction Document, prior to receipt
of the Required Stockholder Approval, the Company shall not issue, and the Holder shall not have the right to receive, any shares of
Common Stock upon exercise of this Warrant to the extent that, after giving effect to such issuance, the aggregate number of shares of
Common Stock issued pursuant to the Transaction Documents would exceed the Exchange Cap. Any purported issuance of shares of Common Stock
in excess of the Exchange Cap prior to receipt of the Required Stockholder Approval shall be null and void ab initio. The limitations
set forth in this Section 1(k) shall apply in addition to, and not in lieu of, the Maximum Percentage set forth in Section 1(g).
(l)
Short Sales. Each Holder agrees it shall not maintain a net short position with respect to the Common Stock in excess of the number
of shares of Common Stock then actually issued to such Holder or then issuable to such Holder upon conversion or exercise of securities
held by such Holder.
(m)
Company Optional Cash Exercise Price Reduction.
(i)
Notwithstanding anything to the contrary contained herein, the Company may, in its sole discretion and without the consent of the Holder,
reduce the cash exercise price payable upon exercise of this Warrant for all or any portion of the Warrant Shares then issuable hereunder
by up to eighty percent (80%) of the then-applicable Exercise Price solely for purposes of inducing a cash exercise of this Warrant during
a period specified by the Company in a written notice delivered to the Holder (the “Reduced Cash Exercise Price”). Any such
notice shall specify the Reduced Cash Exercise Price, the number of Warrant Shares to which such Reduced Cash Exercise Price applies,
and the period during which such Reduced Cash Exercise Price shall be available.
(ii)
The Reduced Cash Exercise Price shall apply solely to cash exercises of this Warrant actually completed during the period specified by
the Company in the applicable notice. The Holder shall not be entitled to use the Reduced Cash Exercise Price in connection with any
Cashless Exercise, any calculation of Black Scholes Value, any calculation of Black Scholes Value - FT, any adjustment provision, any
Fundamental Transaction provision, any mandatory exercise trigger, or any other calculation or economic right under this Warrant.
(iii)
If the Holder does not exercise this Warrant for cash during the period specified by the Company in the applicable notice, then, following
the expiration of such period, this Warrant shall remain outstanding in accordance with its terms at the Exercise Price otherwise then
in effect without giving effect to the Reduced Cash Exercise Price.
(iv)
For the avoidance of doubt, any Reduced Cash Exercise Price shall be used solely to calculate the Aggregate Exercise Price payable by
the Holder for Warrant Shares purchased for cash during the applicable period and shall not be deemed to amend, reduce or otherwise modify
the Exercise Price for any other purpose under this Warrant.
(v)
Notwithstanding anything to the contrary herein, the Company shall not reduce the cash exercise price by more than 80% of the original
exercise price, below the par value of the Common Stock, or to the extent such reduction or the issuance of Warrant Shares upon exercise
at such Reduced Cash Exercise Price would violate the Securities Act, applicable state securities laws, the Exchange Cap, the Required
Stockholder Approval provisions, the rules and regulations of the applicable Trading Market or any other applicable law.
2.
ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES. The Exercise Price and number of Warrant Shares issuable upon
exercise of this Warrant are subject to adjustment from time to time as set forth in this Section 2.
(a)
Stock Dividends and Splits. Without limiting any provision of Section 4, if the Company, at any time on or after the date
of the Securities Purchase Agreement, (i) pays a stock dividend on one or more classes of its then outstanding shares of Common Stock
or otherwise makes a distribution on any class of capital stock that is payable in Common Stock, (ii) subdivides (by any stock split,
stock dividend, recapitalization or otherwise) one or more classes of its then outstanding shares of Common Stock into a larger number
of shares or (iii) combines (by combination, reverse stock split or otherwise) one or more classes of its then outstanding shares of
Common Stock into a smaller number of shares, then in each such case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock outstanding immediately before such event and of which the denominator shall
be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to clause (i) of this
paragraph shall become effective immediately after the record date for the determination of shareholders entitled to receive such dividend
or distribution, and any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the effective
date of such subdivision or combination. If any event requiring an adjustment under this paragraph occurs during the period that an Exercise
Price is calculated hereunder, then the calculation of such Exercise Price shall be adjusted appropriately to reflect such event.
(b) Reserved.
(c)
Reserved.
(d)
Reserved.
(e)
Other Events. In the event that the Company shall take any action to which the provisions hereof are not strictly applicable,
or, if applicable, would not operate to protect the Holder from dilution or if any event occurs of the type contemplated by the provisions
of this Section 2 but not expressly provided for by such provisions (including, without limitation, the granting of stock appreciation
rights, phantom stock rights or other rights with equity features), then the Company’s board of directors shall in good faith determine
and implement an appropriate adjustment in the Exercise Price and the number of Warrant Shares (if applicable) so as to protect the rights
of the Holder, provided that no such adjustment pursuant to this Section 2(e) will increase the Exercise Price or decrease the number
of Warrant Shares as otherwise determined pursuant to this Section 2, provided further that if the Holder does not accept such adjustments
as appropriately protecting its interests hereunder against such dilution, then the Company’s board of directors and the Holder
shall agree, in good faith, upon an independent investment bank of nationally recognized standing to make such appropriate adjustments,
whose determination shall be final and binding and whose fees and expenses shall be borne by the Company.
(f)
No Adjustment for Reduced Cash Exercise Price. Any Reduced Cash Exercise Price made available by the Company pursuant to Section
1(m) shall not constitute an adjustment to the Exercise Price or the number of Warrant Shares issuable hereunder and shall not trigger
any anti-dilution, reset, adjustment or similar provision of this Warrant or any other Transaction Document.
3.
RIGHTS UPON DISTRIBUTION OF ASSETS. In addition to any adjustments pursuant to Section 2 above, if the Company shall declare
or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of Common Stock, by way of return
of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, indebtedness, property or
options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction,
other than a distribution of Common Stock covered by Section 2(a)) (a “Distribution”), at any time after the issuance
of this Warrant, then, in each such case, provision shall be made so that upon exercise of this Warrant, the Holder shall be entitled
to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number
of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Maximum Percentage) immediately before the date on which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of Common Stock are to be determined for the participation in such Distribution
(provided, however, to the extent that the Holder’s right to participate in any such Distributions would result in the Holder exceeding
the Maximum Percentage, then the Holder shall not be entitled to participate in such Distribution to such extent (or the beneficial ownership
of any such Common Stock as a result of such Distribution to such extent) and such Distribution to such extent shall be held in abeyance
for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Maximum Percentage).
4.
PURCHASE RIGHTS; FUNDAMENTAL TRANSACTIONS.
(a)
Purchase Rights. In addition to any adjustments pursuant to Section 2 above, if at any time the Company grants, issues
or sells any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the
number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof,
including without limitation, the Maximum Percentage) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined
for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder’s right to participate in
any such Purchase Right would result in the Holder exceeding the Maximum Percentage, then the Holder shall not be entitled to participate
in such Purchase Right to such extent (or beneficial ownership of such Common Stock as a result of such Purchase Right to such extent)
and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would
not result in the Holder exceeding the Maximum Percentage).
(b)
Fundamental Transactions. The Company shall not enter into or be party to a Fundamental Transaction unless the Successor
Entity assumes in writing all of the obligations of the Company under this Warrant and the other Transaction Documents related to this
Warrant in accordance with the provisions of this Section 4(b) pursuant to written agreements in form and substance reasonably satisfactory
to the Holder, including agreements confirming the obligations of the Successor Entity as set forth in this paragraph (b) and (c) and
elsewhere in this Warrant and an obligation to deliver to the Holder in exchange for this Warrant a security of the Successor Entity
evidenced by a written instrument substantially similar in form and substance to this Warrant, including, without limitation, which is
exercisable for a corresponding number of shares of capital stock equivalent to the Common Stock acquirable and receivable upon exercise
of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an
exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value
of the Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such adjustments to the number
of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately
prior to the consummation of such Fundamental Transaction). Notwithstanding the foregoing, at the election of the Holder upon exercise
of this Warrant following a Fundamental Transaction, the Successor Entity shall deliver to the Holder, in lieu of the Common Stock (or
other securities, cash, assets or other property (except such items still issuable under Sections 3 and 4(a) above, which shall continue
to be receivable thereafter)) issuable upon the exercise of this Warrant prior to the applicable Fundamental Transaction, such shares
of common stock (or its equivalent) of the Successor Entity (including its Parent Entity), or other securities, cash, assets or other
property, which the Holder would have been entitled to receive upon the happening of the applicable Fundamental Transaction had this
Warrant been exercised immediately prior to the applicable Fundamental Transaction; provided, however, that such amount of reserved shares
of Common Stock shall be limited by the Maximum Percentage of Common Stock as set forth in Section 1(g).
(c)
Black Scholes Value – FT. Notwithstanding the foregoing and the provisions of Section 4(b) above, at the request
of the Holder delivered at any time commencing on the earliest to occur of (i) the public disclosure of any Fundamental Transaction,
(ii) the consummation of any Fundamental Transaction and (iii) the Holder first becoming aware of any Fundamental Transaction through
the date that is ninety (90) days after the public disclosure of the consummation of such Fundamental Transaction, the Company or the
Successor Entity, at the election of the Holder, shall purchase this Warrant from the Holder on the date of the consummation of such
Fundamental Transaction by paying to the Holder cash in an amount equal to the Black Scholes Value – FT. For the avoidance of doubt,
any Black Scholes Value - FT payable pursuant to this Section 4(c) shall be calculated without giving effect to any Reduced Cash Exercise
Price.
(d)
Application. The provisions of this Section 4 shall apply similarly and equally to successive Fundamental Transactions
and shall be applied as if this Warrant (and any such subsequent warrants issued hereunder) were fully exercisable and without regard
to any limitations on the exercise of this Warrant (provided that the Holder shall continue to be entitled to the benefit of the Maximum
Percentage, applied however with respect to shares of capital stock registered under the 1934 Act and thereafter receivable upon exercise
of this Warrant (or any such other warrant)).
5.
NONCIRCUMVENTION. The Company hereby covenants and agrees that the Company will not, by amendment of its certificate of
incorporation, bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue
or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, and will at all times in good faith carry out all the provisions of this Warrant and take all action as may be required to protect
the rights of the Holder. Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any Common
Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, (ii) shall take all such actions as may be
necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable shares of Common Stock
upon the exercise of this Warrant, and (iii) shall, so long as any of the SPA Warrants are outstanding, take all action necessary to
reserve and keep available out of its authorized and unissued shares of Common Stock, solely for the purpose of effecting the exercise
of the SPA Warrants, the maximum number of shares of Common Stock as shall from time to time be necessary to effect the exercise of the
SPA Warrants then outstanding.
6.
WARRANT HOLDER NOT DEEMED A SHAREHOLDER. Except as otherwise specifically provided herein, the Holder, solely in its capacity
as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company
for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in its capacity as the Holder
of this Warrant, any of the rights of a shareholder of the Company or any right to vote, give or withhold consent to any corporate action
(whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice
of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which
it is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed
as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a shareholder
of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. Notwithstanding this Section 6,
the Company shall provide the Holder with copies of the same notices and other information given to the shareholders of the Company generally,
contemporaneously with the giving thereof to the shareholders.
7.
REISSUANCE OF WARRANTS.
(a)
Transfer of Warrant. If this Warrant is to be transferred, the Holder shall surrender this Warrant to the Company, whereupon
the Company will forthwith issue and deliver upon the order of the Holder a new Warrant (in accordance with Section 7(d)), registered
as the Holder may request, representing the right to purchase the number of Warrant Shares being transferred by the Holder and, if less
than the total number of Warrant Shares then underlying this Warrant is being transferred, a new Warrant (in accordance with Section
7(d)) to the Holder representing the right to purchase the number of Warrant Shares not being transferred. If, at the time of the surrender
of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant
to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible
for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company
may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, provide to
the Company an opinion of counsel selected by the Holder and reasonably acceptable to the Company, the form and substance of which opinion
shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred securities
under the Securities Act.
(b)
Lost, Stolen or Mutilated Warrant. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the
loss, theft, destruction or mutilation of this Warrant (as to which a written certification and the indemnification contemplated below
shall suffice as such evidence), and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to
the Company in customary and reasonable form and, in the case of mutilation, upon surrender and cancellation of this Warrant, the Company
shall execute and deliver to the Holder a new Warrant (in accordance with Section 7(d)) representing the right to purchase the Warrant
Shares then underlying this Warrant.
(c)
Exchangeable for Multiple Warrants. This Warrant is exchangeable, upon the surrender hereof by the Holder at the principal
office of the Company, for a new Warrant or Warrants (in accordance with Section 7(d)) representing in the aggregate the right to purchase
the number of Warrant Shares then underlying this Warrant, and each such new Warrant will represent the right to purchase such portion
of such Warrant Shares as is designated by the Holder at the time of such surrender; provided, however, no warrants for fractional share
of Common Stock shall be given.
(d)
Issuance of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant,
such new Warrant (i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the
right to purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued pursuant to Section 7(a)
or Section 7(c), the Warrant Shares designated by the Holder which, when added to the number of shares of Common Stock underlying the
other new Warrants issued in connection with such issuance, does not exceed the number of Warrant Shares then underlying this Warrant),
(iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance Date, and (iv) shall
have the same rights and conditions as this Warrant.
8.
NOTICES. Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall
be given in accordance with Section 10(f) of the Securities Purchase Agreement. The Company shall provide the Holder with prompt written
notice of all actions taken pursuant to this Warrant, including in reasonable detail a description of such action and the reason therefor.
Without limiting the generality of the foregoing, the Company will give written notice to the Holder (i) as soon as practicable upon
each adjustment of the Exercise Price and the number of Warrant Shares, setting forth in reasonable detail, and certifying, the calculation
of such adjustment(s) and (ii) at least fifteen (15) days prior to the date on which the Company closes its books or takes a record (A)
with respect to any dividend or distribution upon the Common Stock, (B) with respect to any grants, issuances or sales of any Options,
Convertible Securities or rights to purchase stock, warrants, securities, indebtedness, or other property pro rata to holders of Common
Stock or (C) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each
case that such information (to the extent it constitutes, or contains, material, non-public information regarding the Company shall be
made known to the public prior to or in conjunction with such notice being provided to the Holder and (iii) at least ten (10) Trading
Days prior to the consummation of any Fundamental Transaction. It is expressly understood and agreed that the time of execution specified
by the Holder in each Exercise Notice shall be definitive and may not be disputed or challenged by the Company.
9.
AMENDMENT AND WAIVER. Except as otherwise provided herein, the provisions of this Warrant (other than Section 1(g)) may
be amended and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only
if the Company has obtained the written consent of the Holder. The Holder shall be entitled, at its option, to the benefit of any amendment
of any other similar warrant issued under the Securities Purchase Agreement. No waiver shall be effective unless it is in writing and
signed by an authorized representative of the waiving party.
10. SEVERABILITY.
If any provision of this Warrant is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent
jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest
extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity
of the remaining provisions of this Warrant so long as this Warrant as so modified continues to express, without material change, the
original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s)
in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization
of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the
prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of
the prohibited, invalid or unenforceable provision(s).
11. GOVERNING
LAW. This Warrant shall be governed by and construed and enforced in accordance with, and all questions concerning the construction,
validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State of New York, without giving
effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would
cause the application of the laws of any jurisdictions other than the State of New York. The Company hereby irrevocably submits to the
exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of
any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably
waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of
any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding
is improper. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.
Nothing contained herein shall be deemed or operate to preclude the Holder from bringing suit or taking other legal action against the
Company in any other jurisdiction to collect on the Company’s obligations to the Holder or to enforce a judgment or other court
ruling in favor of the Holder. THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL
FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS WARRANT OR ANY TRANSACTION CONTEMPLATED HEREBY.
12. CONSTRUCTION;
HEADINGS. This Warrant shall be deemed to be jointly drafted by the Company and the Holder and shall not be construed against any Person
as the drafter hereof. The headings of this Warrant are for convenience of reference and shall not form part of, or affect the interpretation
of, this Warrant. Terms used in this Warrant but defined in the other Transaction Documents shall have the meanings ascribed to such
terms on the Closing Date (as defined in the Securities Purchase Agreement) in such other Transaction Documents unless otherwise consented
to in writing by the Holder.
13. DISPUTE
RESOLUTION. In the case of a dispute as to the determination of the Exercise Price, the Closing Sale Price, the Closing Bid Price,
the Bid Price or fair market value or the arithmetic calculation of the Warrant Shares (as the case may be), the Company or the Holder
(as the case may be) shall submit the disputed determinations or arithmetic calculations (as the case may be) via facsimile (i) within
two (2) Business Days after receipt of the applicable notice giving rise to such dispute to the Company or the Holder (as the case may
be) or (ii) if no notice gave rise to such dispute, at any time after the Holder or the Company (as the case may be) learned of the circumstances
giving rise to such dispute. If the Holder and the Company are unable to agree upon such determination or calculation (as the case may
be) of the Exercise Price, the Closing Sale Price, the Closing Bid Price, the Bid Price or fair market value or the number of Warrant
Shares (as the case may be) within three (3) Business Days of such disputed determination or arithmetic calculation being submitted to
the Company or the Holder (as the case may be), then the Company shall, within two (2) Business Days submit via facsimile (a) the disputed
arithmetic calculation of the Warrant Shares, the disputed determination of the Exercise Price, the Closing Sale Price, the Closing Bid
Price, the Bid Price or fair market value (as the case may be) to an independent, reputable investment bank selected by the Holder, with
the consent of the Company (which may not be unreasonably withheld, conditioned or delayed), or (b) if acceptable to the Holder, the
disputed arithmetic calculation of the Warrant Shares to the Company’s independent, outside accountant. The Company shall cause
at its expense the investment bank or the accountant (as the case may be) to perform the determinations or calculations (as the case
may be) and notify the Company and the Holder of the results no later than ten (10) Business Days from the time it receives such disputed
determinations or calculations (as the case may be). Such investment bank’s or accountant’s determination or calculation
(as the case may be) shall be binding upon all parties absent demonstrable error. The fees and expenses of such investment bank or accountant
shall be borne by the parties in the same proportion as the respective amounts by which the investment bank’s or accountant’s
determination differs from such party’s calculation.
14. REMEDIES,
CHARACTERIZATION, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF. The remedies provided in this Warrant shall be cumulative and
in addition to all other remedies available under this Warrant and the other Transaction Documents, at law or in equity (including a
decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right of the Holder to pursue actual
damages for any failure by the Company to comply with the terms of this Warrant. The Company covenants to the Holder that there shall
be no characterization concerning this instrument other than as expressly provided herein. Amounts set forth or provided for herein with
respect to payments, exercises and the like (and the computation thereof) shall be the amounts to be received by the Holder and shall
not, except as expressly provided herein, be subject to any other obligation of the Company (or the performance thereof). The Company
acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for
any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the holder
of this Warrant shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without the
necessity of showing economic loss and without any bond or other security being required. The Company shall provide all information and
documentation to the Holder that is requested by the Holder to enable the Holder to confirm the Company’s compliance with the terms
and conditions of this Warrant (including, without limitation, compliance with Section 2 hereof). The issuance of shares as contemplated
hereby upon the exercise of this Warrant shall be made without charge to the Holder or such shares for any issuance tax or other costs
in respect thereof, provided that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved
in the issuance and delivery of any certificate in a name other than the Holder or its agent on its behalf.
15. TRANSFER.
Subject to compliance with the Securities Act, applicable state securities laws, Section 7(a) and the applicable provisions of the Securities
Purchase Agreement, this Warrant may be offered for sale, sold, transferred or assigned without the consent of the Company; provided
that any transferee of this Warrant shall agree in writing to be bound by the terms and conditions of this Warrant, including, without
limitation, the Maximum Percentage, the Exchange Cap, the mandatory exercise provisions of Section 1(j), and the no-short-sale and no-hedging
covenant set forth in Section 1(l). Any purported transfer in violation of this Section 15 shall be null and void ab initio.
16. CERTAIN
DEFINITIONS. For purposes of this Warrant, the following terms shall have the following meanings:
(a)
“Bid Price” means, for any security as of the particular time of determination, the bid price of such security
on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg as of such time
of determination, or if the foregoing does not apply, the bid price of such security in the over-the-counter market on the electronic
bulletin board for such security as reported by Bloomberg as of such time of determination, or, if no bid price is reported for such
security by Bloomberg as of such time of determination, the average of the bid prices of all of the market makers for such security as
reported in the “pink sheets” by OTC Markets Group Inc. (formerly Pink Sheets LLC) as of such time of determination. If the
Bid Price cannot be calculated for a security as of the particular time of determination on any of the foregoing bases, the Bid Price
of such security as of such time of determination shall be the fair market value as mutually determined by the Company and the Holder.
If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved in
accordance with the procedures in Section 13. All such determinations shall be appropriately adjusted for any stock dividend, stock split,
stock combination or other similar transaction during such period.
(b)
“Black Scholes Value” means the Black Scholes value of an option for one share of Common Stock at the date
of the applicable Cashless Exercise, as such Black Scholes value is determined, calculated using the Black Scholes Option Pricing Model
obtained from the “OV” function on Bloomberg utilizing (i) an underlying price per share equal to the Exercise Price (ii)
a risk-free interest rate corresponding to the U.S. Treasury rate, (iii) a strike price equal to the Exercise Price in effect at the
time of the applicable Cashless Exercise, without giving effect to any Reduced Cash Exercise Price, (iv) an expected volatility equal
to 175%, and (v) a deemed remaining term of the Warrant of five (5) years (regardless of the actual remaining term of the Warrant).
(c)
“Black Scholes Value – Consideration” means the value of the applicable Option or Convertible Security
(as the case may be) as of the date of issuance thereof calculated using the Black Scholes Option Pricing Model obtained from the “OV”
function on Bloomberg utilizing (i) an underlying price per share equal to the Closing Sale Price of the Common Stock on the Trading
Day immediately preceding the public announcement of the execution of definitive documents with respect to the issuance of such Option
or Convertible Security (as the case may be), (ii) a strike price equal to the Exercise Price in effect on the date of the Holder’s
request pursuant to Section 4(c), without giving effect to any Reduced Cash Exercise Price, and (iii) an expected volatility equal to
the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization
factor) as of the Trading Day immediately following the date of issuance of such Option or Convertible Security (as the case may be).
(d)
“Black Scholes Value – FT” means the value of the unexercised portion of this Warrant remaining on the date
of the Holder’s request pursuant to Section 4(c), which value is calculated using the Black Scholes Option Pricing Model obtained
from the “OV” function on Bloomberg utilizing (i) an underlying price per share equal to the greater of (A) the highest Closing
Sale Price of the Common Stock during the period beginning on the Trading Day immediately preceding the earliest to occur of (1) the
public disclosure of the applicable Fundamental Transaction, (2) the consummation of the applicable Fundamental Transaction and (3) the
date on which the Holder first became aware of the applicable Fundamental Transaction and ending on the Trading Day of the Holder’s
request pursuant to Section 4(c) and (B) the sum of the price per share being offered in cash in the applicable Fundamental Transaction
(if any) plus the value of the non-cash consideration being offered in the applicable Fundamental Transaction (if any), (ii) a strike
price equal to the Exercise Price in effect on the date of the Holder’s request pursuant to Section 4(c), (iii) a risk-free interest
rate corresponding to the U.S. Treasury rate for a period equal to the greater of (A) the remaining term of this Warrant as of the date
of the Holder’s request pursuant to Section 4(c) and (B) the remaining term of this Warrant as of the date of consummation of the
applicable Fundamental Transaction or as of the date of the Holder’s request pursuant to Section 4(c) if such request is prior
to the date of the consummation of the applicable Fundamental Transaction and (iv) an expected volatility equal to the greater of 175%
and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the
Trading Day immediately following the earliest to occur of (A) the public disclosure of the applicable Fundamental Transaction, (B) the
consummation of the applicable Fundamental Transaction and (C) the date on which the Holder first became aware of the applicable Fundamental
Transaction.
(e)
“Bloomberg” means Bloomberg, L.P.
(f)
“Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in New York,
New York are authorized or required by law to remain closed.
(g)
“Closing Bid Price” and “Closing Sale Price” means, for any security as of any date, the
last closing bid price and the last closing trade price, respectively, for such security on the principal securities exchange or trading
market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the average of the bid prices,
or the ask prices, respectively, of all of the market makers for such security as reported in the “pink sheets” by OTC Markets
Group Inc. (formerly Pink Sheets LLC). If the Closing Bid Price or the Closing Sale Price cannot be calculated for a security on a particular
date on any of the foregoing bases, the Closing Bid Price or the Closing Sale Price (as the case may be) of such security on such date
shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree
upon the fair market value of such security, then such dispute shall be resolved in accordance with the procedures in Section 13. All
such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction
during such period.
(h)
“Common Stock” means the common stock, par value $0.0001 per share, of the Company and any other shares of
stock issued or issuable with respect thereto (whether by way of a stock dividend or stock split or in exchange for or upon conversion
of such shares or otherwise in connection with a combination of shares, distribution, recapitalization, merger, consolidation, other
corporate reorganization or other similar event with respect to the Common Stock).
(i)
“Convertible Securities” means any capital stock or other security of the Company that is at any time and under
any circumstances directly or indirectly convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof
to acquire, any capital stock or other security of the Company (including, without limitation, Common Stock).
(j)
“Eligible Market” means a Trading Market.
(k)
“Expiration Date” means the date that is May 27, 2031, or, if such date falls on a day other than a Business
Day or on which trading does not take place on the principal securities exchange or trading market where the Common Stock is listed (a
“Holiday”), the next date that is not a Holiday.
(l)
“Fundamental Transaction” means that (i) the Company shall, directly or indirectly, in one or more related
transactions, (1) consolidate or merge with or into (whether or not the Company is the surviving entity) any other Person unless the
shareholders of the Company immediately prior to such consolidation or merger continue to hold more than 50% of the outstanding shares
of Voting Stock after such consolidation or merger, or (2) sell, lease, license, assign, transfer, convey or otherwise dispose of all
or substantially all of its properties or assets to any other Person, in connection with which the Company is dissolved, or (3) allow
any other Person to make a purchase, tender or exchange offer that is accepted by the holders of more than 50% of the outstanding shares
of Voting Stock of the Company (not including any shares of Voting Stock of the Company held by the Person or Persons making or party
to, or associated or affiliated with the Persons making or party to, such purchase, tender or exchange offer), or (4) consummate a stock
or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off
or scheme of arrangement) with any other Person whereby such other Person acquires more than 50% of the outstanding shares of Voting
Stock of the Company (not including any shares of Voting Stock of the Company held by the other Person or other Persons making or party
to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination),
or (ii) any “person” or “group” (as these terms are used for purposes of Sections 13(d) and 14(d) of the 1934
Act and the rules and regulations promulgated thereunder) is or shall become the “beneficial owner” (as defined in Rule 13d-3
under the 1934 Act), directly or indirectly, of 50% of the aggregate ordinary voting power represented by issued and outstanding Voting
Stock of the Company.
(m)
“Options” means any rights, warrants or options to subscribe for or purchase Common Stock or Convertible Securities.
(n)
“Parent Entity” of a Person means an entity that, directly or indirectly, controls the applicable Person and whose
common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent
Entity, the Person or Parent Entity with the largest public market capitalization as of the date of consummation of the Fundamental Transaction.
(o)
“Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust,
an unincorporated organization, any other entity or a government or any department or agency thereof.
(p)
“Successor Entity” means the Person (or, if so elected by the Holder, the Parent Entity) formed by, resulting from
or surviving any Fundamental Transaction or the Person (or, if so elected by the Holder, the Parent Entity) with which such Fundamental
Transaction shall have been entered into.
(q)
“Trading Day” means a day on which the principal Trading Market for the Common Stock is open for trading.
(r)
“Voting Stock” of a Person means capital stock of such Person of the class or classes pursuant to which the
holders thereof have the general voting power to elect, or the general power to appoint, at least a majority of the board of directors,
managers or trustees of such Person (irrespective of whether or not at the time capital stock of any other class or classes shall have
or might have voting power by reason of the happening of any contingency).
(s)
“VWAP” means, for any security as of any date, the dollar volume-weighted average price for such security on
the principal Trading Market for such security during the period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m.,
New York time, as reported by Bloomberg through its “Volume at Price” function. If VWAP cannot be calculated for such security
on such date on the foregoing basis, the VWAP of such security on such date shall be the fair market value as mutually determined by
the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such
dispute shall be resolved in accordance with the procedures in Section 13. All such determinations shall be appropriately adjusted for
any stock dividend, stock split, stock combination or other similar transaction during such period.
(t)
Reserved.
(u)
“Effectiveness Date” means the first date on which a Registration Statement covering the resale of all Warrant
Shares is declared effective by the Commission and is available for the resale of all Warrant Shares by the Holder.
(v)
“Equity Conditions” means, with respect to any date of determination, that each of the following conditions
is satisfied: (i) a Registration Statement covering the resale of all Warrant Shares issuable upon exercise of this Warrant is effective
and available for the resale of such Warrant Shares, or such Warrant Shares are freely tradable by the Holder pursuant to Rule 144 without
volume or manner-of-sale restrictions and without the requirement for current public information; (ii) the Common Stock is listed or
quoted on a Trading Market and the Company is in compliance in all material respects with the continued listing requirements of such
Trading Market; (iii) the Company has not failed to timely deliver any shares of Common Stock required to be delivered pursuant to any
Transaction Document; (iv) the issuance of the applicable Warrant Shares would not violate the Exchange Cap, the Maximum Percentage or
the rules and regulations of the applicable Trading Market; (v) the Company has a sufficient number of authorized and unreserved shares
of Common Stock available to issue the applicable Warrant Shares; and (vi) no public announcement of a pending, proposed or intended
Fundamental Transaction or similar transaction has occurred and remains pending.
(w)
“Exchange Cap” means, prior to receipt of the Required Stockholder Approval, 19.99% of the shares of Common
Stock or voting power outstanding immediately prior to the execution of the Securities Purchase Agreement, calculated in accordance with
the rules and regulations of the applicable Trading Market, including Nasdaq Listing Rule 5635(d), and subject to appropriate adjustment
for any stock split, stock dividend, stock combination, recapitalization or similar event occurring after the date of the Securities
Purchase Agreement.
(x)
“Mandatory Exercise Date” means the date specified by the Company in a mandatory exercise notice delivered
pursuant to Section 1(j), which date shall be no earlier than the fifth (5th) Trading Day and no later than the tenth (10th) Trading
Day following delivery of such notice.
(y)
“Reduced Cash Exercise Price” shall have the meaning set forth in Section 1(m).
(z)
“Registration Statement” has the meaning set forth in the Registration Rights Agreement.
(aa)
“Required Stockholder Approval” has the meaning set forth in the Securities Purchase Agreement.
(bb)
“Rule 144” means Rule 144 promulgated by the Commission under the Securities Act.
(cc)
“Short Sales” includes all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act.
(dd)
“Trading Market” has the meaning set forth in the Securities Purchase Agreement.
[signature
page follows]
IN
WITNESS WHEREOF, the Company has caused this Warrant to Purchase Common Stock to be duly executed as of the Issuance Date set out above.
WELLGISTICS
HEALTH, INC.
By:
Name:
Title:
EXHIBIT
A
EXERCISE
NOTICE
TO
BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS WARRANT TO PURCHASE COMMON STOCK
WELLGISTICS
HEALTH, INC.
The
undersigned holder hereby exercises the right to purchase ________shares of the Common Stock (“Warrant Shares”) of
Wellgistics Health, Inc., a Delaware corporation (the “Company”), evidenced by Warrant to Purchase Common Stock No.
(the “Warrant”). Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth
in the Warrant.
1.
Form of Exercise Price. The Holder intends that payment of the Exercise Price shall be made as:
______________
a
“Cash Exercise” with respect to ______________
Warrant Shares; and/or
______________
a
“Cashless Exercise” with respect to ______________
Warrant Shares.
In
the event that the Holder has elected a Cashless Exercise with respect to some or all of the Warrant Shares, the Holder represents and
warrants that _________________ shares of Common Stock are to be delivered pursuant to such Cashless Exercise.
2 .
Payment of Exercise Price. In the event that the Holder has elected a Cash Exercise with respect to some or all of the Warrant
Shares, the Holder shall pay the Aggregate Exercise Price in the sum of $______ to the Company in accordance with the terms of the Warrant.
3.
Delivery of Warrant Shares and Net Number of Common Stock. The Company shall deliver to Holder, or its designee or agent
as specified below, _____________ shares of Common Stock in respect of the exercise contemplated hereby. Delivery shall be made to Holder,
or for its benefit, to the following address:
_______________________________
_______________________________
_______________________________
Date: __________________,____
Name
of Registered Holder
By:
Name:
Title:
Account
Number: _______________________ (if electronic book entry transfer) Transaction Code Number:
Transaction
Code Number: _______________________ (if electronic book entry transfer)
EXHIBIT
B
ACKNOWLEDGMENT
The
Company hereby acknowledges this Exercise Notice and hereby directs _________ to issue the above indicated number of shares of Common
Stock in accordance with the Transfer Agent Instructions dated ____________, 20__, from the Company and acknowledged and agreed to by ____________.
WELLGISTICS
HEALTH, INC.
By:
Name:
Title:
EX-10.1
EX-10.1
Filename: ex10-1.htm · Sequence: 4
Exhibit
10.1
SECURITIES
PURCHASE AGREEMENT
This
Securities Purchase Agreement (this “Agreement”) is dated as of May 27, 2026, between Wellgistics Health, Inc.,
a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including
its successors and assigns, a “Purchaser,” collectively the “Purchasers” and together with the
Company, the “Parties”).
WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of
1933, as amended (the “Securities Act”), and Rule 506 promulgated thereunder, the Company desires to issue and
sell to the Purchasers, and the Purchasers desire to purchase from the Company, securities of the Company as more fully described in
this Agreement (the “Offering”).
NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the Company and the Purchasers agree as follows:
ARTICLE I
DEFINITIONS
1.1
Definitions. In addition to the terms defined elsewhere in this Agreement: (a) capitalized terms that are not otherwise
defined herein have the meanings given to such terms in the Notes (as defined herein), and (b) the following terms have the meanings
set forth in this Section 1.1:
“Action”
shall have the meaning ascribed to such term in Section 3.1(j).
“Affiliate”
means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls or is controlled
by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act.
“Board
of Directors” means the board of directors of the Company.
“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day
on which commercial banking institutions in the State of New York are authorized or required by law or other governmental action to close.
“Certificate
of Designation” means the Certificate of Designation relating to the New Series Convertible Preferred Stock to be filed by
the Company with the Secretary of State of the State of Delaware, in the form of Exhibit A attached hereto.
“Closing”
means the Closing of the purchase and sale of the Securities pursuant to Section 2.1(a).
“Closing
Date” means with respect to the closing of the purchase and sale of the Securities pursuant to Section 2.1(a), the Trading
Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions
precedent to the Company’s obligations to deliver the Securities to be issued and sold, in each case, have been satisfied or waived,
but in no event later than the second Trading Day following the date on which the Company gives notice to the Purchasers that all conditions
of such Closing have been met other than payment and delivery of the Closing deliverables required by this Agreement.
“Commission”
means the United States Securities and Exchange Commission.
“Common
Stock” means the shares of common stock of the Company, par value $0.0001 per share, and any other class of securities into
which such securities may hereafter be reclassified or changed.
“Company
Counsel” means Whiteford, Taylor & Presto LLP.
“Conversion
Price” shall have the meaning ascribed to such term in the Notes.
“Environmental
Laws” shall have the meaning ascribed to such term in Section 3.1(m).
“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
“Equity
Conditions” means, with respect to any date of determination, that each of the following conditions is satisfied: (a) a resale
Registration Statement covering the Warrant Shares issuable upon exercise of the applicable Warrants is effective and available for the
resale of all such Warrant Shares, or such Warrant Shares are freely tradable by the holder pursuant to Rule 144 without volume or manner-of-sale
restrictions and without the requirement for current public information; (b) the Common Stock is listed or quoted on a Trading Market
and the Company is in compliance in all material respects with the continued listing requirements of such Trading Market; (c) the Company
has not failed to timely deliver any shares of Common Stock required to be delivered pursuant to any Transaction Document; (d) the issuance
of the applicable Warrant Shares would not violate the Exchange Cap, any beneficial ownership limitation, or the rules and regulations
of the applicable Trading Market; (e) the Company has a sufficient number of authorized and unreserved shares of Common Stock available
to issue the applicable Warrant Shares; and (f) no public announcement of a pending, proposed or intended fundamental transaction, change
of control, merger, consolidation, sale of substantially all assets or similar transaction has occurred and remains pending.
“Exchange
Cap” means, prior to receipt of the Required Stockholder Approval, 19.99% of the shares of Common Stock or voting power outstanding
immediately prior to the execution of this Agreement, calculated in accordance with the rules and regulations of the applicable Trading
Market, including Nasdaq Listing Rule 5635(d), and subject to appropriate adjustment for any stock split, stock dividend, stock combination,
recapitalization or similar event occurring after the date hereof.
“Exempt
Issuance” means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant
to any stock or option plan duly adopted for such purpose by a majority of the non-employee members of the Board of Directors or a majority
of the members of a committee of non-employee directors established for such purpose for services rendered to the Company and the Company’s
stockholders or pursuant to Nasdaq Rule 5635(c)(4), (b) Warrants issued in connection with the Offering and any shares of Common Stock
upon exercise of the Warrants, if applicable, and/or shares of Common Stock upon the exercise or exchange of or conversion of any Securities
issued hereunder, any securities upon exercise of warrants and/or other securities exercisable or exchangeable for or convertible into
shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended since
the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion
price of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities, and (c)
securities issued pursuant to acquisitions, mergers, strategic transactions, commercial collaborations, joint ventures, licensing arrangements
or other similar transactions approved by a majority of the disinterested directors of the Company, provided that such transaction is
not undertaken primarily for capital-raising purposes and the recipient is, itself or through its subsidiaries, an operating company,
an owner of an asset, a strategic partner, a commercial counterparty or an equity holder of any of the foregoing.
“Hazardous
Materials” shall have the meaning ascribed to such term in Section 3.1(m).
“Indebtedness”
means: (a) all obligations for borrowed money; (b) all obligations evidenced by bonds, debentures, notes, or other similar
instruments and all reimbursement or other obligations in respect of letters of credit, bankers acceptances, current swap agreements,
interest rate hedging agreements, interest rate swaps, or other financial products; (c) all obligations or liabilities secured
by a Lien or encumbrance on any asset of the Company irrespective of whether such obligation or liability is assumed; and (d) any
obligation guaranteeing or intended to guarantee (whether directly or indirectly guaranteed, endorsed, co-made, discounted or sold with
recourse) any of the foregoing obligations of any other person.
“Intellectual
Property Rights” shall have the meaning ascribed to such term in Section 3.1(p).
“Legend
Removal Date” shall have the meaning ascribed to such term in Section 4.1(c).
“Lien”
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.
“Material
Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b).
“Material
Permits” shall have the meaning ascribed to such term in Section 3.1(n).
“Mandatory
Exercise Date” means, with respect to any Warrant, the date designated in a mandatory exercise notice delivered by the Company
pursuant to the terms of such Warrant, which date shall be no earlier than the fifth (5th) Trading Day and no later than the tenth (10th)
Trading Day following delivery of such notice, unless otherwise agreed by the Company and the applicable holder.
“Mandatory
Exercise Trigger” means, with respect to any Warrant, that the VWAP of the Common Stock equals or exceeds 150% of the then-applicable
exercise price of such Warrant for at least five (5) consecutive Trading Days, provided that the Equity Conditions are satisfied on each
such Trading Day and through and including the applicable Mandatory Exercise Date.
“New
Series Convertible Preferred Stock” means a series of convertible preferred stock of the Company having the rights, preferences
and privileges set forth in the Certificate of Designation, in the form of Exhibit A hereto.
“Notes”
means the convertible promissory notes issued pursuant to this Agreement in the form of Exhibit B attached hereto as amended,
restated, amended and restated or otherwise modified from time to time.
“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.
“PIPE
Warrants” means the warrants to purchase Common Stock delivered to the Purchasers at Closing in accordance with Section 2.2(a)(iii)
hereof.
“Placement
Agency Agreement” means the placement agency agreement, dated May 27, 2026, between the Company and the Placement Agent.
“Placement
Agent” means Dawson James Securities, Inc.
“Placement
Agent Warrants” means the warrants to purchase Common Stock delivered to the Placement Agent at Closing in accordance with
Section 2.2(a)(iv) hereof.
“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.
“Purchaser
Party” shall have the meaning ascribed to such term in Section 4.5.
“Reduced
Cash Exercise Price” means, with respect to any Warrant, a reduced cash exercise price made available by the Company pursuant
to the terms of such Warrant solely for purposes of inducing a cash exercise of such Warrant, which reduced price shall not be used for
purposes of calculating any Black Scholes Value, Black Scholes Value - FT, cashless exercise amount, mandatory exercise trigger, anti-dilution
adjustment or other economic right under such Warrant.
“Registration
Rights Agreement” means the Registration Rights Agreement, to be dated as of the date hereof, among the Company, the Purchasers
and the investors in the Equity Transaction, in the form of Exhibit C attached hereto.
“Registration
Statement” means a registration statement meeting the requirements set forth in the Registration Rights Agreement and covering
the resale of the Underlying Securities, as provided for in the Registration Rights Agreement.
“Required
Approvals” shall have the meaning ascribed to such term in Section 3.1(e).
“Required
Minimum” means, as of any date, the maximum aggregate number of shares of Common Stock then issued or potentially issuable
in the future pursuant to the Transaction Documents, including any Underlying Securities issuable upon conversion in full of the Notes,
ignoring any conversion limits set forth therein.
“Required
Stockholder Approval” shall have the meaning ascribed to such term in Section 4.9.
“Rule 144”
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.
“SEC
Reports” means the reports, schedules, forms, statements and other documents filed by the Company under the Securities Act
and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof
(or such shorter period as the Company was required by law or regulation to file such material), including the exhibits thereto and documents
incorporated by reference therein.
“Securities”
means the Notes and the Underlying Shares.
“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
“Subscription
Amount” means the aggregate amount to be paid for the Notes purchased hereunder as specified below in Section 2.1(b),
in United States dollars and in immediately available funds.
“Trading
Day” means a day on which the principal Trading Market is open for trading.
“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York
Stock Exchange (or any successors to any of the foregoing).
“Transactions”
mean the transactions contemplated by the Transaction Documents.
“Transaction
Documents” means this Agreement, the Notes, the Registration Rights Agreement, the Warrants and all exhibits and schedules
thereto and hereto.
“Transfer”
means the (a) sale of, offer to sell, contract or agreement to sell, hypothecate, pledge, grant of any option to purchase or otherwise
dispose of or agreement to dispose of, directly or indirectly, or establishment or increase of a put equivalent position or liquidation
with respect to or decrease of a call equivalent position within the meaning of Section 16 of the Exchange Act, and the rules and
regulations of the Commission promulgated thereunder with respect to, any security, (b) entry into any swap or other arrangement
that transfers to another, in whole or in part, any of the economic consequences of ownership of any security, whether any such transaction
is to be settled by delivery of such securities, in cash or otherwise, or (c) public announcement of any intention to effect any
transaction specified in clause (a) or (b).
“Transfer
Agent” means the transfer agent of the Company and any successor thereto.
“Underlying
Common Shares” means the Common Stock issuable pursuant to the terms of the Notes, without respect to any limitation or restriction
on the conversion of the Notes.
“Underlying
Preferred Shares” means any shares of New Series Convertible Preferred Stock issuable pursuant to the terms of the Notes in
lieu of the Underlying Common Shares, in each case without regard to any limitation or restriction on conversion.
“Underlying
Shares” means collectively, the Underlying Common Shares and Underlying Preferred Shares.
“Underlying
Securities” means collectively, the Underlying Common Shares and the Common Stock issuable upon the conversion of the Underlying
Preferred Shares.
“Variable
Rate Transaction” means any transaction entered into by the Company, including any (i) equity line, an at-the-market
or similar agreement for an at-the-market offering, or similar agreement, (ii) issuance, or agreement to issue, any capital stock,
floating or variable priced equity linked instruments or any other Indebtedness or equity security, in any case with price reset rights
including protection against lower priced issuances or adjustments in the event of such issuances (not including adjustments for stock
splits, distributions, dividends, recapitalizations and the like).
“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time); provided, however, that if the Common Stock is then listed or quoted on
more than one Trading Market, then the Trading Market for purposes of any calculations to be made pursuant to the terms of the Notes
and the Warrants shall be the principal Trading Market for the Common Stock as determined by the Company in good faith based on trading
volume and listing status), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for
such date (or the nearest preceding date) on OTCQB or OTCQX, as applicable, (c) if the Common Stock is not then listed or quoted for
trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the “Pink Sheets” published by OTC Markets
Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share
of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent
appraiser selected in good faith by the Company and reasonably acceptable to the Purchasers of a majority in interest of the Securities
then outstanding, the reasonable fees and expenses of which shall be paid by the Company.
“Warrants”
means collectively, the Placement Agent Warrants and the PIPE Warrants.
“Warrant
Shares” means the shares of Common Stock issuable upon exercise of the Warrants.
ARTICLE II
PURCHASE
AND SALE
2.1
Closing.
(a) Closing.
The Closing shall take place remotely via the exchange of documents and signatures on the date hereof or at such other time and place
as the Company and the Purchasers mutually agree upon orally or in writing (the closing for which is designated as the “Closing”).
(b) Sale
of Notes. At the Closing, subject to the terms and conditions set forth herein, the Company agrees to sell, and the Purchasers agree
to purchase, the Notes for the aggregate amount of $21,132,812.50.
(c) Closing
Procedures. At the Closing, the Purchasers shall, upon delivery of the Notes by the Company, deliver to the Company via wire transfer
the Subscription Amount in immediately available funds in accordance with the wire instructions for the Company’s account as set
forth on Exhibit D (the “Wire Instructions”), and the Company and the Purchasers shall deliver the other
items set forth in Section 2.2 that are deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth
in Sections 2.2 and 2.3, the Closing shall occur by electronic exchange of documents and wiring of the Subscription Amounts by the Purchasers
in accordance with the Wire Instructions.
(d) Beneficial
Ownership Limitation. Notwithstanding any other provisions hereof, any purported delivery of Common Stock to the Purchasers hereunder
shall be void and have no effect to the extent (but only to the extent) that, after such delivery, the amount of shares of Common Stock
owned by the Purchasers would exceed the Beneficial Ownership Limitation (as defined below). If any delivery owed to the Purchasers hereunder
is not made, in whole or in part, as a result of this provision, the Company’s obligation to make such delivery shall not be extinguished
and the Company shall make such delivery as promptly as practicable after, but in no event later than one Trading Day after, the Purchasers
give notice to the Company that, after such delivery, the Common Stock owned by the Purchasers would not exceed the Beneficial Ownership
Limitation. The “Beneficial Ownership Limitation” shall be 9.99% of the number of the Common Stock outstanding. Beneficial
ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder.
2.2
Deliveries.
(a) On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to the Purchasers the following:
(i) this
Agreement, duly executed by the Company;
(ii)
each Note, registered in the name of each Purchaser;
(iii)
a PIPE Warrant, registered in the name of each Purchaser, to purchase a number of shares of Common Stock equal (i) One Hundred Fifty
Percent (150%) of the initial principal amount of the Note divided by (ii) the official closing price of the Common Stock on the date
hereof as reported by Nasdaq, at an exercise price of $7.50 per share, which exercise price shall equal 125% of the closing price of
the Common Stock on the date of execution of this Agreement, and which PIPE Warrant shall include a mandatory exercise or call provision
pursuant to which, if the Mandatory Exercise Trigger occurs, the Company may require the holder thereof to exercise all or the applicable
portion of such PIPE Warrant in accordance with the terms thereof;
(iv)
a Placement Agent Warrant, registered in the name of the Placement Agent, to purchase a number of shares of Common Stock equal to 12%
of the aggregate number of shares of Common Stock initially issuable upon conversion of the Notes based on the initial Conversion Price,
without giving effect to any future adjustments, resets, anti-dilution provisions, default provisions or other increases in the number
of shares issuable under the Notes or any Warrants, and excluding any shares of Common Stock issuable upon exercise of the PIPE Warrants,
at an exercise price of $6.25 per share, which exercise price shall equal 125% of the closing price of the Common Stock on the date of
execution of this Agreement, and which Placement Agent Warrant shall include a mandatory exercise or call provision pursuant to which,
if the Mandatory Exercise Trigger occurs, the Company may require the holder thereof to exercise all or the applicable portion of such
Placement Agent Warrant in accordance with the terms thereof;
(v) the
Registration Rights Agreement, duly executed by the Company;
(vi)
the duly executed Lock-Up Agreements;
(vii)
a customary legal opinion of Company Counsel, addressed to the Placement Agent and the Purchasers, in form and substance reasonably satisfactory
to the Placement Agent and the Purchasers, limited to customary matters for a private placement of this type, including the Company’s
existence and good standing, corporate power and authorization, due execution and delivery of the Transaction Documents, enforceability,
valid issuance of the Securities, no registration requirement under the Securities Act based upon the Purchasers’ representations
and the manner of offering, and Investment Company Act matters;
(viii)
a customary officers’ certificate, duly executed and delivered by the Company’s executive officers, in form and substance
consistent with the requirements set forth in Section 8.B.i. of the Placement Agency Agreement;
(ix)
a Secretary’s Certificate, duly executed and delivered by the Company’s Secretary (or other authorized officer), certifying
(A) that the Company’s certificate of incorporation and bylaws (or comparable charter documents) are true, complete and correct
copies, have not been amended or modified except as disclosed, and are in full force and effect; (B) resolutions duly adopted by the
Company’s board of directors authorizing the execution, delivery and performance of the Company’s obligations under the Transaction
Documents and all other instruments, agreements, certificates and other documents provided for or contemplated by the said Transaction
Documents; (C) the incumbency and authority of the officers of the Company executing the Transaction Documents; and (D) such other customary
certifications as the Placement Agent or Purchasers may reasonably request; and
(x)
written consent or written consents, duly executed by holders of capital stock of the Company holding sufficient voting power to approve,
for purposes of Nasdaq Listing Rule 5635(d), the issuance of shares of Common Stock pursuant to the Transaction Documents in excess of
the Exchange Cap, including, without limitation, shares of Common Stock issuable upon conversion of the Notes, upon conversion of the
New Series Convertible Preferred Stock and upon exercise, including mandatory exercise or call, of the Warrants, in each case in accordance
with their respective terms.
(b) On
or prior to the Closing Date, the Purchasers shall deliver or cause to be delivered to the Company the following:
(i) this
Agreement duly executed by the Purchasers;
(ii) the
Purchaser’s Subscription Amount by wire transfer in accordance with the Wire Instructions; and
(iii) the
Registration Rights Agreement duly executed by the Purchasers.
(c)
Mandatory Exercise Feature of Warrants. Each Warrant shall provide that, upon the occurrence of the Mandatory Exercise Trigger, the Company
shall have the right, but not the obligation, to deliver written notice to the holder of such Warrant requiring such holder to exercise
all or the applicable portion of such Warrant specified in such notice, subject to satisfaction of the Equity Conditions through and
including the applicable Mandatory Exercise Date. Any mandatory exercise shall be subject to the beneficial ownership limitations contained
in the applicable Warrant, the Exchange Cap, the Required Stockholder Approval, and the rules and regulations of the applicable Trading
Market. Each Warrant shall also provide that the Company may, in its sole discretion and without the consent of the holder thereof, reduce
the cash exercise price payable upon exercise of such Warrant by up to eighty percent (80%) of the then-applicable exercise price solely
for purposes of inducing a cash exercise of such Warrant; provided that any such reduced cash exercise price shall apply only to cash
exercises actually completed during the period specified by the Company and shall not be used for purposes of calculating any Black Scholes
Value, Black Scholes Value - FT, cashless exercise amount, mandatory exercise trigger, anti-dilution adjustment or other economic right
under such Warrant.
2.3
Closing Conditions.
(a) The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met or waived in writing
by the Company:
(i) the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) when made and on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as
of a specific date therein, in which case they shall be accurate as of such date);
(ii) all
obligations, covenants and agreements of the Purchasers required to be performed at or prior to the Closing Date shall have been performed
in all material respects; and
(iii) the
delivery by the Purchasers of the items set forth in Section 2.2(b) of this Agreement.
(b) The
obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met or waived in
writing by the Purchasers:
(i) the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of
a specific date therein, in which case they shall be accurate as of such date);
(ii) all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed
in all material respects;
(iii) the
delivery by the Company of the items set forth in Section 2.2(a) of this Agreement; and
(iv)
the Company shall have submitted to The Nasdaq Stock Market LLC (the “Nasdaq”) any listing of additional shares notification,
application or other notice required by the applicable rules of the Trading Market in connection with the issuance of the Securities
and the shares of Common Stock issuable pursuant to the Transaction Documents, and Nasdaq shall not have objected to the consummation
of the transactions contemplated hereby prior to Closing; and
(v) there
shall have been no Material Adverse Effect with respect to the Company since the date hereof.
ARTICLE III
REPRESENTATIONS
AND WARRANTIES
3.1
Representations and Warranties of the Company. Except as set forth in the SEC Reports and in the Disclosure Schedules, which Disclosure
Schedules shall be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure
contained in the corresponding section of the Disclosure Schedules, the Company hereby, individually and severally and not jointly with
the other party, make the following representations and warranties to the Purchasers as of the Closing:
(a) Subsidiaries.
The Company owns, directly or indirectly, all of the capital stock or other equity interests of its subsidiaries free and clear of any
Liens, and all of the issued and outstanding shares of capital stock of each subsidiary are validly issued and are fully paid, non-assessable
and free of pre-emptive and similar rights to subscribe for or purchase securities.
(b) Organization
and Qualification. Each of the Company and its subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization (if a good standing concept exists for such
form of entity in such jurisdiction), with the requisite power and authority to own and use its properties and assets and to carry on
its business as currently conducted. Neither the Company nor any of its subsidiaries is in violation nor default of any of the provisions
of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company
and its subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction
in which the nature of the business conducted or property they owned make such qualification necessary, except where the failure to be
so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material adverse
effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of
operations, assets, business, prospects or condition (financial or otherwise) of the Company and its subsidiaries, taken as a whole,
or (iii) a material adverse effect on either of the Company’s ability to perform in any material respect on a timely basis
their respective obligations under any Transaction Document (any of (i), (ii) or (iii), a “Material Adverse Effect”)
and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail
such power and authority or qualification.
(c) Authorization;
Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents, as applicable, and otherwise to carry out their respective obligations
hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents, as applicable, by
the Company and the consummation of the transactions contemplated hereby and thereby have been duly authorized by all necessary action
on the part of the Company, and no further action is required by the Company, the Board of Directors or the Company’s shareholders
in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document
to which the Company is a party, as applicable, has been (or upon delivery will have been) duly executed by the Company and, when delivered
in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against
the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as
limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar
as indemnification and contribution provisions may be limited by applicable law.
(d) No
Conflicts. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which
they are a party, as applicable, the issuance and sale of the Securities and the consummation by the Company of the transactions contemplated
hereby and thereby do not and will not: (i) conflict with or violate any provision of the Company’s or any of their respective
subsidiary’s certificate or articles of incorporation, bylaws or other organizational or charter documents, (ii) conflict
with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation
of any Lien upon any of the properties or assets of the Company or any of its subsidiaries, or give to others any rights of termination,
amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other
instrument (evidencing a Company or subsidiary debt or otherwise) or other understanding to which the Company or any of its subsidiaries
is a party or by which any property or asset of the Company or any of its subsidiaries is bound or affected, or (iii) subject to
the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other
restriction of any court or governmental authority to which the Company or any of its subsidiaries is subject (including federal, state,
and provincial securities laws and regulations), or by which any property or asset of the Company or any of its subsidiaries is bound
or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in
a Material Adverse Effect.
(e)
Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any
notice to, or make any filing or registration with, any court or other federal, state, local, provincial or other governmental authority,
self-regulatory organization, Trading Market or other Person in connection with the execution, delivery and performance by the Company
of the Transaction Documents, other than, as applicable: (i) the filings required pursuant to Section 4.7 of this Agreement, (ii) the
filing with the Commission pursuant to the Registration Rights Agreement, (iii) the filing of Form D with the Commission and such filings
as are required to be made under applicable state securities laws, (iv) any listing of additional shares notification, application or
other notice required by the applicable Trading Market, (v) the Required Stockholder Approval, (vi) the filing and effectiveness of any
amendment to the Company’s certificate of incorporation required to authorize blank check preferred stock, and (vii) the filing
of the Certificate of Designation with the Secretary of State of the State of Delaware after receipt of the Required Stockholder Approval
and the effectiveness of any required amendment to the Company’s certificate of incorporation (collectively, the “Required
Approvals”).
(f)
Issuance of the Securities. The Securities will be duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company
other than restrictions on transfer provided for in the Transaction Documents. The Underlying Shares, when issued in accordance with
the terms of the Transaction Documents, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by
the Company other than restrictions on transfer provided for in the Transaction Documents. Subject to the Exchange Cap, the Required
Stockholder Approval, the filing and effectiveness of any required amendment to the Company’s certificate of incorporation, the
filing of the Certificate of Designation, and the rules and regulations of the applicable Trading Market, the Company has reserved, or,
in the case of the Underlying Common Shares, will reserve promptly following receipt of the Required Stockholder Approval and the effectiveness
of such required corporate actions, from its duly authorized capital stock a number of shares of Common Stock sufficient to satisfy its
obligations to issue the Underlying Common Shares and Warrant Shares pursuant to the Transaction Documents.
(g) Capitalization.
No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions
contemplated by the Transaction Documents. Other than options and other equity awards granted to officers, employees and directors of
the Company and as contemplated by the Equity Financing, there are no outstanding options, warrants, scrip rights to subscribe to, calls
or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable
for, or giving any Person any right to subscribe for or acquire any Common Stock or the capital stock of any subsidiary of the Company,
or contracts, commitments, understandings or arrangements by which the Company or any of its subsidiaries is or may become bound to issue
additional Common Stock or Common Stock equivalents or capital stock of any subsidiary. The issuance and sale of the Securities will
not obligate the Company or any of its subsidiaries to issue any Common Stock or other securities to any Person (other than the Purchasers)
and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under
any of such securities. There are no outstanding securities or instruments of the Company or any of its subsidiaries that contain any
redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any
of its subsidiaries is or may become bound to redeem a security of the Company or such subsidiary. The Company does not have any stock
appreciation rights or “phantom stock” plans or agreements or any similar plan or agreement. All of the outstanding shares
of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with
all federal, state, and provincial securities laws, and none of such outstanding shares was issued in violation of any preemptive rights
or similar rights to subscribe for or purchase securities. Except for the Required Approvals, no further approval or authorization of
any stockholder, the Board of Directors of the Company, Nasdaq or any other Person is required for the issuance and sale of the Securities
or the consummation of the transactions contemplated by the Transaction Documents. There are no shareholders agreements, voting agreements
or other similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of
the Company, between or among any of the Company’s shareholders.
(h)
Indebtedness. Except as set forth on Schedule 3.1(h), the Company does not have any Indebtedness out-standing. Schedule 3.1(h)
sets forth a true, correct and complete list of all Indebtedness of the Company as of the date hereof, including, for each item of Indebtedness,
(i) the obligor, (ii) the holder or counterparty, (iii) the principal amount outstanding, (iv) the maturity date, (v) the interest rate
(or method of determining the interest rate), and (vi) any security therefor or guarantees in respect thereof.
(i) Material
Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included within
the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof, (i) there has been
no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the
Company has not incurred any liabilities (contingent or otherwise) other than (A) liabilities and obligations incurred in the ordinary
course of business consistent with past practice, (B) liabilities not required to be reflected in their respective financial statements
pursuant to GAAP or disclosed in filings made with the Commission, and (C) liabilities that are executory obligations arising under
contracts to which the Company is a party, (iii) the Company has not altered its method of accounting, (iv) the Company has
not declared or made any dividend or distribution of cash or other property to their respective shareholders or purchased, redeemed or
made any agreements to purchase or redeem any shares of their capital stock and (v) the Company has not issued any equity securities
to any officer, director or Affiliate, except pursuant to existing Company stock option plans.
(j) Litigation.
There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company threatened
against or affecting the Company, any subsidiary or any of their respective properties before or by any court, arbitrator, governmental
or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an “Action”)
which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities
or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither
the Company nor any of its subsidiaries, nor any director or officer thereof, is or has been the subject of any Action involving a claim
of violation of or liability under federal, state, or provincial securities laws or a claim of breach of fiduciary duty.
(k) Labor
Relations. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company,
which could reasonably be expected to result in a Material Adverse Effect. None of the Company’s or any of its subsidiaries’
employees are a member of a union that relates to such employee’s relationship with the Company or such subsidiary, and neither
the Company nor any of its subsidiaries are a party to a collective bargaining agreement, and the Company and its subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any of
its subsidiaries, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure
or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in
favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its subsidiaries
to any liability with respect to any of the foregoing matters. The Company and its subsidiaries are in compliance with all federal, state,
provincial, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment
and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect.
(l) Compliance.
Neither the Company nor any of its subsidiaries: (i) is in default under or in violation of (and no event has occurred that has
not been waived that, with notice or lapse of time or both, would result in a default by the Company or any of their subsidiaries under),
nor have the Company or any of its subsidiaries received notice of a claim that it is in default under or that it is in violation of,
any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties
is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any
court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation
of any governmental authority, including without limitation all foreign, federal, state, provincial, and local laws relating to taxes,
environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each
case as could not have or reasonably be expected to result in a Material Adverse Effect.
(m) Environmental
Laws. The Company and each of its subsidiaries (i) are in compliance with all federal, state, provincial, local and foreign
laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land
surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants,
contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”) into the environment,
or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous
Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice
letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (“Environmental Laws”);
(ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their
respective businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where
in each clause (i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate,
a Material Adverse Effect.
(n) Regulatory
Permits. The Company and each of its subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state, provincial, local or foreign regulatory authorities necessary to conduct their respective businesses, except where the
failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (“Material Permits”),
and neither the Company nor any of its subsidiaries has received any notice of proceedings relating to the revocation or modification
of any Material Permit.
(o) Security
Interests; Priority. Except as set forth on Schedule 3.1(i), none of the assets or properties of the Company is subject to Liens.
Schedule 3.1(i) sets forth a true, correct and complete description of all Liens on the assets or properties of the Company, including,
for each such Lien, (i) the obligation, (ii) the collateral subject thereto, (iii) the identity of the party, and (iv) the relative priority
of such Lien. The Indebtedness and other obligations by the Liens described on Schedule 3.1(i) constitute the only obligations of the
Company that are by any assets or properties of the Company, and, except as set forth on Schedule 3.1(i), no such Liens secure obligations
that are senior to, pari passu with, or entitled to priority over the obligations under the Notes.
(p) Intellectual
Property. The Company and its subsidiaries have, or have rights to use, all intellectual property rights and similar rights necessary
or required for use in connection with their respective businesses which the failure to so have could have a Material Adverse Effect
(collectively, the “Intellectual Property Rights”). None of, and neither the Company nor any of its subsidiaries has
received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or
is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement. Neither the Company nor
any of its subsidiaries has received a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights
violate or infringe upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse
Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement
by another Person of any of the Intellectual Property Rights. The Company and its subsidiaries have taken reasonable security measures
to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.
(q) Insurance.
The Company and its subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in
such amounts as are prudent and customary in the businesses in which the Company and its subsidiaries are engaged, including, but not
limited to, directors and officers insurance coverage. Neither the Company nor any or its subsidiaries has any reason to believe that
it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar
insurers as may be necessary to continue its business without a significant increase in cost.
(r) Transactions
with Affiliates and Employees. None of the officers or directors of the Company or any of its subsidiaries and, to the knowledge
of the Company, none of the employees of the Company or any of its subsidiaries is presently a party to any transaction with the Company
or any of its subsidiaries (other than for services as employees, officers and directors), including any contract, agreement or other
arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from providing
for the borrowing of money from or lending of money to, or otherwise requiring payments to or from any officer, director or such employee
or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is
an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment of
salary, consulting, or placement fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company
and (iii) other employee benefits, including stock option agreements under any stock option plan of the Company.
(s) Certain
Fees. Except for compensation payable to the Placement Agent, there are no brokerage or finder’s fees or commissions that are
or will be payable by the Company or any of its subsidiaries to any broker, financial advisor or consultant, finder, placement agent,
investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall
have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated
in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.
(t) Private
Placement. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.3, no registration
under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers as contemplated hereby.
(u) Investment
Company. The Company are not, and are not an Affiliate of, and immediately after receipt of payment for the Securities, will not
be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended. The
Company shall conduct their business in a manner so that they will not become an “investment company” subject to registration
under the Investment Company Act of 1940, as amended.
(v) Registration
Rights. Other than pursuant to the Registration Rights Agreement, no Person has any right to cause the Company or any of its subsidiaries
to effect the registration under the Securities Act of any securities of the Company or any of its subsidiaries.
(w) Disclosure.
All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its subsidiaries, their respective
businesses and the transactions contemplated hereby are true and correct and do not contain any untrue statement of a material fact or
omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which
they were made, not misleading. The Company acknowledges and agrees that the Purchasers do not make and has not made any representations
or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.3 hereof.
(x) No
Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.3,
neither the Company, nor any of its Affiliates, nor any Person acting on their behalf has, directly or indirectly, made any offers or
sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of (i) the Securities Act which would require the registration
of any such securities under the Securities Act, or (ii) any applicable shareholder approval provisions of any Trading Market on
which any of the securities of the Company are listed or designated.
(y) Solvency.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company
of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company’s assets exceed the
amount that will be required to be paid on or in respect of the Company’s existing debts and other liabilities (including known
contingent liabilities) as they mature, (ii) the Company’s assets do not constitute unreasonably small capital to carry on
its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital
requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof,
and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were they to liquidate all
of their assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect
of their liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay
such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company
has no knowledge of any facts or circumstances which lead them to believe that they will file for reorganization or liquidation under
the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. Neither the Company nor any of its subsidiaries
are in default with respect to any indebtedness for borrowed money or money due under any long-term leasing or factoring arrangement.
(z) Tax
Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material
Adverse Effect, the Company and its subsidiaries each (i) has made or filed all federal, state, provincial, and local income and
all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has
paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns,
reports and declarations and (iii) has set aside on their books provision reasonably adequate for the payment of all material taxes
for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any of its subsidiaries know
of no basis for any such claim.
(aa)
No General Solicitation. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Securities
by any form of general solicitation or general advertising. The Company has offered the Securities for sale only to the Purchasers and
certain other “accredited investors” within the meaning of Rule 501 under the Securities Act.
(bb)
Foreign Corrupt Practices. Neither the Company nor any of its subsidiaries, nor to the knowledge of the Company or any of its
subsidiaries, any agent or other person acting on behalf of the Company or any of its subsidiaries, has (i) directly or indirectly,
used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity,
(ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political
parties or campaigns from corporate funds, or (iii) failed to disclose fully any contribution made by the Company or any of its
subsidiaries (or made by any person acting on its behalf of which the Company is aware) which is in violation of law.
3.2
[Reserved].
3.3 Representations
and Warranties of the Purchasers. Each Purchaser hereby represents and warrants as of the applicable Closing to the Company as follows
(unless as of a specific date therein, in which case they shall be accurate as of such date):
(a) Organization;
Authority. Each Purchaser is an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction
of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and authority to
enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder
and thereunder. The execution and delivery of the Transaction Documents and performance by such Purchaser of the transactions contemplated
by the Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company or similar
action, as applicable, on the part of the Purchaser. Each Transaction Document to which it is a party has been duly executed by the Purchaser,
and when delivered by the Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of
the Purchaser, enforceable against it in accordance with its terms, except (i) as limited by general equitable principles and applicable
bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights
generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies
and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.
(b) Own
Account. The Purchaser understands that the Securities are “restricted securities” and have not been registered under
the Securities Act or any applicable state or provincial securities law and is acquiring the Securities as principal for its own account
and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any
applicable state or provincial securities law, has no present intention of distributing any of such Securities in violation of the Securities
Act or any applicable state or provincial securities law and has no direct or indirect arrangement or understandings with any other persons
to distribute or regarding the distribution of such Securities in violation of the Securities Act or any applicable state or provincial
securities law (this representation and warranty not limiting such Purchaser’s right to sell the Securities pursuant to the Registration
Statement or otherwise in compliance with applicable federal, state, and provincial securities laws). Such Purchaser is acquiring the
Securities hereunder in the ordinary course of its business.
(c) Purchaser
Status. At the time the Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which
it converts the Note it will be an “accredited investor” as defined in Rule 501(a) under the Securities Act.
(d) Experience
of Such Purchaser. The Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities,
and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the
Securities and, at the present time, is able to afford a complete loss of such investment.
(e) General
Solicitation. The Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other communication
regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at
any seminar or, to the knowledge of the Purchaser, any other general solicitation or general advertisement.
(f) Access
to Information. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits
and schedules thereto) and the SEC Reports and has been afforded (i) the opportunity to ask such questions as it has deemed necessary
of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities
and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition,
results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the
opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that
is necessary to make an informed investment decision with respect to the investment. The Purchaser acknowledges and agrees that the Company
does not make and has not made any representations or warranties with respect to the transactions contemplated hereby other than those
specifically set forth in Section 3.1 hereof.
ARTICLE IV.
OTHER
AGREEMENTS OF THE PARTIES
4.1
Transfer Restrictions.
(a) The
Securities may only be disposed of in compliance with applicable state, federal, and provincial securities laws. In connection with any
transfer of restricted Securities other than pursuant to an effective registration statement or Rule 144, to the Company or to
an Affiliate of the Purchasers or in connection with a pledge as contemplated in Section 4.1(b), the Company may require the transferor
thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form
and substance of which opinion shall be reasonably satisfactory to the Company to the effect that such transfer does not require registration
of such transferred Securities under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be
bound by the terms of this Agreement and the Registration Rights Agreement and shall have the rights and obligations of the Purchasers
under this Agreement and the Registration Rights Agreement.
(b) The
Purchasers agree to the imprinting, so long as is required by this Section 4.1, of legend(s) on any of the Securities in
the following forms:
“NEITHER
THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE OR CONVERTIBLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933,
AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.”
(c) The
Company shall remove, or cause to be removed, any legend (including the legend set forth in Section 4.1(b) hereof) from certificates
evidencing restricted Securities: (i) while a registration statement (including the Registration Statement) covering the resale
of such security is effective under the Securities Act, (ii) following any sale of such Underlying Common Shares pursuant to Rule 144,
(iii) if such Underlying Common Shares are eligible for sale under Rule 144 or (iv) if such legend is not required
under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the
Commission). The Company shall request its counsel issue a legal opinion to the Transfer Agent or the Purchaser promptly if required
by the Transfer Agent to effect the removal of any legends hereunder, or if requested by the Purchaser, respectively, without charge
to such Purchaser. If all or any portion of a Note is converted at a time when there is an effective registration statement to cover
the resale of the Underlying Common Shares, or if such Underlying Common Shares may be sold under Rule 144 without the requirement
for the Company to be in compliance with the current public information required under Rule 144 as to such Underlying Common Shares
and without volume or manner-of-sale restrictions or if any such legend is not otherwise required under applicable requirements of the
Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission) then such Underlying Common
Shares shall be issued free of all legends. The Company agrees that following such time as any such legend is no longer required under
this Section 4.1(c), it will, no later than the earlier of (i) two (2) Trading Days and (ii) the number of Trading
Days comprising the Standard Settlement Period (as defined below) following the DWAC transfer by the Purchaser to the Company or the
Transfer Agent of the Underlying Common Shares issued with a restrictive legend (such date, the “Legend Removal Date”),
remove any legend from the Underlying Share held electronically by the Purchaser; provided that such Purchaser shall have previously
delivered to the Company all documents required by the Transfer Agent and/or counsel to deliver Underlying Common Shares that are free
of restrictive legends. The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge
the restrictions on transfer set forth in this Section 4. The Underlying Common Shares subject to legend removal hereunder shall
be transmitted by the Transfer Agent to the Purchaser by crediting the account of such Purchaser’s prime broker with the Depository
Trust Company System as directed by the Purchaser. As used herein, “Standard Settlement Period” means the standard
settlement period, expressed in a number of Trading Days, on the Company’s primary Trading Market with respect to the Common Stock
as in effect on the date of delivery of the Underlying Common Shares issued with a restrictive legend.
(d) In
addition to such Purchaser’s other available remedies, the Company shall pay to the Purchaser, in cash, (i) as partial liquidated
damages and not as a penalty, for each $1,000 of Underlying Common Shares (based on the VWAP of the Common Stock on the date such Securities
are submitted to the Transfer Agent) delivered for removal of the restrictive legend(s) and subject to Section 4.1(c), $10
per Trading Day (increasing to $20 per Trading Day five (5) Trading Days after such damages have begun to accrue) for each Trading
Day after the Legend Removal Date until such electronic shares no longer contain any restrictive legend and (ii) if the Company
fails to (a) issue and deliver (or cause to be delivered) to the Purchaser by the Legend Removal Date the Securities that are free
from all restrictive and other legends and (b) if after the Legend Removal Date the Purchaser purchases (in an open market transaction
or otherwise) Common Stock to deliver in satisfaction of a sale by the Purchaser of all or any portion of the number of shares of Common
Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock that the Purchaser
anticipated receiving from the Company without any restrictive legend, then, an amount equal to the excess of the Purchaser’s total
purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the Common Stock so purchased (including
brokerage commissions and other out-of-pocket expenses, if any) (the “Buy-In Price”) over the product of (A) such
number of Underlying Common Shares that the Company was required to deliver to the Purchaser by the Legend Removal Date multiplied by
(B) the lowest closing sale price of the Common Stock on any Trading Day during the period commencing on the date of the delivery
by the Purchaser to the Company of the Underlying Common Shares and ending on the date of such delivery and payment under this clause
(ii).
(e) The
Purchasers agree with the Company that the Purchasers will sell any Securities pursuant to either the registration requirements of the
Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and that if Securities are sold
pursuant to a Registration Statement, they will be sold in compliance with the plan of distribution set forth therein, and acknowledges
that the removal of the restrictive legend(s) from the Securities as set forth in this Section 4.1 is predicated upon the
Company’s reliance upon this understanding.
4.2
Acknowledgment of Dilution. The Company acknowledge that the issuance of the Securities may result in dilution of the outstanding
Common Stock, which dilution may be substantial under certain market conditions. The Company further acknowledges that its obligations
under the Transaction Documents, including, without limitation, its obligation to issue the Underlying Shares pursuant to the Transaction
Documents, are unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of the
effect of any such dilution or any claim the Company may have against the Purchasers and regardless of the dilutive effect that such
issuance may have on the ownership of the other shareholders of the Company.
4.3
Integration. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security
(as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that
would require the registration under the Securities Act of the sale of the Securities or that would be integrated with the offer or sale
of the Securities for purposes of the rules and regulations of any Trading Market such that it would require shareholder approval
prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.
Notwithstanding the foregoing, this Section 4.3 shall not prohibit the Company from entering into or consummating any transaction that
is structured in a manner that, based on the advice of counsel, would not require integration with the offer and sale of the Securities
for purposes of the Securities Act or the applicable rules of the Trading Market, or that includes a separate exchange cap, stockholder
approval condition or other mechanism designed to comply with the applicable rules of the Trading Market.
4.4
Conversion Procedures. The form of Notice of Conversion included in the Notes sets forth the totality of the procedures required
of the Purchasers in order to convert the Notes. Without limiting the preceding sentences, no ink-original Notice of Conversion shall
be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Conversion form be required
in order to convert the Notes. No additional legal opinion, other information or instructions shall be required of the Purchasers
to convert the Notes. The Company shall honor conversions of the Notes and shall deliver Underlying Shares in accordance with the terms,
conditions and time periods set forth in the Transaction Documents.
4.5
Indemnification of the Purchasers. Subject to the provisions of this Section 4.5, the Company will indemnify and hold harmless
the Purchasers and their respective directors, officers, shareholders, members, partners, employees and agents, each Person who controls
any Purchaser within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, and the directors, officers,
shareholders, members, partners, employees and agents of such controlling persons (each, a “Purchaser Party”), from and against
any and all losses, liabilities, obligations, claims, damages, costs and expenses, including reasonable attorneys’ fees and costs
of investigation, that any Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any representation, warranty,
covenant or agreement made by the Company in this Agreement or the other Transaction Documents, or (b) any third-party claim brought
by a stockholder of the Company or regulatory authority. Notwithstanding the foregoing, the Company shall have no obligation to indemnify
any Purchaser Party to the extent any such loss, liability, obligation, claim, damage, cost or expense arises out of or relates to (i)
any breach by such Purchaser Party of any representation, warranty, covenant or agreement under the Transaction Documents, (ii) any information
furnished in writing by or on behalf of such Purchaser Party expressly for use in any Company disclosure, (iii) any trading, hedging,
short sale, securities lending or other market activity by such Purchaser Party or its Affiliates, (iv) any agreements or understandings
between such Purchaser Party and any stockholder or third party, (v) any failure by such Purchaser Party to comply with the terms of
any Warrant, including any valid mandatory exercise or call provision contained therein, or (vi) any conduct by such Purchaser Party
that is finally judicially determined to constitute a violation of securities laws, fraud, gross negligence, bad faith or willful misconduct.
If any action shall be brought against a Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, the
Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with
counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate
counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense
of the Purchaser Party except to the extent that (A) the employment thereof has been specifically authorized by the Company in writing,
(B) the Company has failed after a reasonable period of time to assume such defense and to employ counsel, or (C) in such action there
is, in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and the position
of the Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such
separate counsel. The Company will not be liable to any Purchaser under this Agreement for any settlement by a Purchaser Party effected
without the Company’s prior written consent, which shall not be unreasonably withheld, conditioned or delayed. The indemnification
required by this Section 4.5 shall be made by periodic payments of the amount thereof during the course of the investigation or defense,
as and when bills are received or are incurred, subject to an undertaking by the applicable Purchaser Party to repay such amounts if
it is ultimately determined by a court of competent jurisdiction that such Purchaser Party was not entitled to indemnification hereunder.
The indemnity agreements contained herein shall be in addition to any cause of action or similar right of a Purchaser Party against the
Company or others and any liabilities the Company may be subject to pursuant to law.
4.6
Reservation of Securities. The Company shall maintain a reserve of the Required Minimum from its duly authorized Common Stock
for issuance pursuant to the Transaction Documents in such amount as may then be required to fulfill its obligations in full under the
Transaction Documents.
4.6A
Nasdaq Exchange Cap. Notwithstanding anything to the contrary contained in this Agreement, the Notes, the Warrants, the Certificate
of Designation or any other Transaction Document, prior to receipt of the Required Stockholder Approval, the Company shall not issue,
and the Purchasers shall not have the right to receive, any shares of Common Stock pursuant to the Transaction Documents to the extent
that, after giving effect to such issuance, the aggregate number of shares of Common Stock issued pursuant to the Transaction Documents
would exceed the Exchange Cap. Any purported issuance of shares of Common Stock in excess of the Exchange Cap prior to receipt of the
Required Stockholder Approval shall be null and void ab initio. The limitations set forth in this Section 4.6A shall apply in addition
to, and not in lieu of, any beneficial ownership limitation contained in this Agreement, the Notes, the Warrants or any other Transaction
Document. No mandatory exercise, call or similar provision contained in any Warrant shall require the Company to issue, or any holder
to acquire, shares of Common Stock in violation of this Section 4.6A.
4.7
Disclosure. The Company shall file a Current Report on Form 8-K disclosing the material terms of the transactions contemplated
by this Agreement within the time required by the Exchange Act. Prior to filing such Form 8-K, the Company shall provide the Purchasers
with a reasonable opportunity to review and comment on the portions of such Form 8-K that describe the Purchasers, the Securities, the
mandatory exercise or call feature of the Warrants, and the material terms of the Transaction Documents; provided, however, that the
Company shall retain final authority over the timing, content and filing of all public disclosures. The Company shall not be required
to disclose any material non-public information provided to the Purchasers except to the extent the Company determines, in consultation
with counsel, that such disclosure is required under applicable law or is necessary to make the statements made in such Form 8-K, in
light of the circumstances under which they are made, not misleading.
4.8
Subsequent Equity Sales. From the date hereof until the earlier of (a) seven months from the date hereof and (b) thirty (30) days
after the effective date of a resale Registration Statement registering all of the Underlying Securities for the Notes, the Company and
its subsidiaries shall not issue, enter into any agreement to issue, or announce the issuance or proposed issuance of any shares of capital
stock or capital stock equivalents pursuant to a Variable Rate Transaction without the prior written consent of Purchasers holding a
majority in interest of the Notes then outstanding, which consent shall not be unreasonably withheld, conditioned or delayed. Notwithstanding
the foregoing, this Section 4.8 shall not apply to or prohibit (i) grants or issuances of equity awards or securities pursuant to any
equity incentive plan, employee stock purchase plan, employment agreement, consulting agreement, board compensation arrangement or Nasdaq
Rule 5635(c)(4) inducement grant arrangement, in each case as approved by the Board of Directors or a committee thereof, (ii) any at-the-market
offering program, equity line of credit, committed equity facility or similar financing entered into with the Placement Agent or with
another financial institution or investor introduced or approved by the Placement Agent or (iii) the issuance of shares of Common Stock
upon conversion of the Notes, conversion of the New Series Convertible Preferred Stock or exercise, including mandatory exercise or call,
of the Warrants, in each case in accordance with the Transaction Documents.
4.9
Stockholder Approval. The Company shall use commercially reasonable efforts to obtain, as promptly as reasonably practicable following
the Closing Date, the approval of the Company’s stockholders to the extent required by the applicable rules and regulations of
the Trading Market, including Nasdaq Listing Rule 5635(d), for (i) the issuance of shares of Common Stock pursuant to the Transaction
Documents in excess of the Exchange Cap, including, without limitation, shares of Common Stock issuable upon conversion of the Notes,
upon conversion of the New Series Convertible Preferred Stock and upon exercise, including mandatory exercise or call, of the Warrants,
in each case in accordance with their respective terms, and (ii) to the extent required, an amendment to the Company’s certificate
of incorporation to authorize blank check preferred stock (collectively, the “Required Stockholder Approval”). The Company
may seek the Required Stockholder Approval by means of an information statement on Schedule 14C, a proxy statement on Schedule 14A or
any other method permitted by applicable law and the rules of the Trading Market. Any such proxy or information statement will be filed
with the Commission no later than twenty (20) calendar days following the Closing Date. To the extent required by Nasdaq or applicable
law, the Company shall exclude from the vote on the Required Stockholder Approval any shares of Common Stock held by the Purchasers or
any other Person whose vote is required to be excluded under the rules of the Trading Market. The Company shall not be required to seek
stockholder approval to reset the Floor Price or any similar conversion or exercise price more than once unless such approval is required
by applicable law or the rules of the Trading Market.
4.10
Filing of Certificate of Designation. Within three (3) business days of receipt of the Required Stockholder Approval, the Company
shall file the Certificate of Designation with the Secretary of State of the State of Delaware.
4.11
Dividends and Repurchases. Until the Notes are no longer outstanding, the Company shall not declare or pay any cash dividend or
distribution on its Common Stock or repurchase shares of Common Stock, other than repurchases or forfeitures of equity awards pursuant
to the terms of any equity incentive plan or award agreement, without the prior written consent of Purchasers holding a majority in interest
of the Notes then outstanding. For the avoidance of doubt, this Section 4.11 shall not restrict the Company from making payments on indebtedness,
preferred stock or other obligations outstanding as of the date hereof or incurred in compliance with this Agreement, satisfying tax
withholding obligations, or effecting any reverse stock split.
4.12
Termination.
(a) If,
prior to the Closing, any governmental authority, including the Commission, issues comments with respect to or challenges the enforceability
of the Transactions in a manner that the Company believe, in their sole discretion, could result in material liability to the Company,
the Company shall be permitted to immediately terminate the Transaction without liability; provided, however, that in the event of such
a termination, the Company shall remain responsible for legal fees incurred in connection with the Transaction pursuant to Section 5.1
hereof and will in good-faith allow the Purchasers to review all comments received that informed the decision to the extent permitted
by the governmental authority or applicable law.
(b) If,
prior to the Closing, any governmental authority, including the Commission, issues comments with respect to or challenges the enforceability
of the Transactions in a manner that the Purchasers believe in their sole discretion could result in material liability to the Purchasers,
the Purchasers shall be permitted to immediately terminate the Transactions without liability; provided, that in the event of such termination,
the Company shall remain responsible for legal fees incurred in connection with the Transactions pursuant to Section 5.1 hereof
and will in good-faith allow the Company to review all comments received that informed the decision to the extent permitted by the governmental
authority or applicable law.
ARTICLE V.
MISCELLANEOUS
5.1
Fees and Expenses. Except as expressly set forth in the Transaction Documents or the Placement Agency Agreement, each party shall
pay the fees and expenses of its own advisers, counsel, accountants and other representatives incurred in connection with the negotiation,
preparation, execution, delivery and performance of this Agreement and the other Transaction Documents. The Company shall pay all Transfer
Agent fees, stamp taxes and other taxes and duties levied in connection with the issuance and delivery of the Securities to the Purchasers,
other than income, franchise or similar taxes of the Purchasers.
5.2.
Short Sales. Each Purchaser agrees it shall not maintain a net short position with respect to the Common Stock in excess of the
number of shares of Common Stock then actually issued to such Purchaser or then issuable to such Purchaser upon conversion or exercise
of Securities held by such Purchaser.
5.3
Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding
of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written,
with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.
5.4
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earlier of (a) the date of transmission, if such notice or communication
is delivered via facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages attached
hereto at or prior to 5:30 p.m. (New York City time) on a Business Day, (b) the next Business Day after the date of transmission,
if such notice or communication is delivered via facsimile at the facsimile number or email attachment as set forth on the signature
pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Business Day,
(c) the second (2nd) Business Day following the date of mailing, if sent by U.S. nationally recognized overnight courier
service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications
shall be as set forth on the signature pages attached hereto.
5.5
Amendments; Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument
signed, in the case of an amendment, by the Company and the Purchasers holding 50.1% of the principal amount of the then outstanding
Notes, or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought. No waiver of any default
with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or
a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission
of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any amendment effected in accordance
with this Section 5.5 shall be binding upon the Purchasers and holder of Securities, the Company.
5.6
Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof.
5.7
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of the Purchasers (other than by merger). A Purchaser may assign any or all of its rights under this Agreement to any Person to whom
the Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred
Securities, by the provisions of the Transaction Documents that apply to the Purchaser.
5.8
No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.
5.9
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively
in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of
any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient
venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction
Documents, then, in addition to the obligations of the Company under this Agreement, the prevailing party in such Action or Proceeding
shall be reimbursed by the non-prevailing party for its reasonable attorneys’ fees and other costs and expenses incurred with the
investigation, preparation and prosecution of such Action or Proceeding.
5.10
Survival. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.
5.11
Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature
page were an original thereof.
5.12
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to
be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.
5.13
Replacement of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to
the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also
pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.
5.14
Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages,
each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction
Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that
a remedy at law would be adequate.
5.15
Liquidated Damages. The Company’s obligations to pay any partial liquidated damages or other amounts owing under the Transaction
Documents is a continuing obligation and shall not terminate until all unpaid partial liquidated damages and other amounts have been
paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts are
due and payable shall have been canceled.
5.16
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding
Business Day.
5.17
Construction. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise
the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved
against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition,
each and every reference to share prices and Common Stock in any Transaction Document shall be subject to adjustment for reverse and
forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date
of this Agreement.
5.18
WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY,
THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.
[Signature
Page to Follow]
IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.
WELLGISTICS HEALTH, INC.
By
Name:
Title:
Address for Notice:
[__]
By
Name:
Title:
Address for Notice:
EXHIBIT A
CERTIFICATE
OF DESIGNATION
EXHIBIT B
FORM OF
NOTE
EXHIBIT C
FORM OF
REGISTRATION RIGHTS AGREEMENT
EXHIBIT D
WIRE
TRANSFER INSTRUCTIONS
EX-10.2
EX-10.2
Filename: ex10-2.htm · Sequence: 5
Exhibit
10.2
REGISTRATION
RIGHTS AGREEMENT
This
Registration Rights Agreement (this “Agreement”) is made and entered into as of May 27, 2026, between Wellgistics
Health, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such
purchaser, a “Purchaser” and, collectively, the “Purchasers”).
This
Agreement is made pursuant to the Securities Purchase Agreement, dated on or about the date hereof, between the Company and the Purchasers
(the “Securities Purchase Agreement”).
The
Company and each Purchaser hereby agrees as follows:
ARTICLE
1
Definitions.
Capitalized
terms used and not otherwise defined herein that are defined in the Securities Purchase Agreement shall have the meanings given such
terms in the Securities Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings:
“Advice”
shall have the meaning set forth in Section 6.3.
“Effectiveness
Date” means, with respect to the Initial Registration Statement required to be filed hereunder, the 45th calendar day following
the date hereof and with respect to any additional Registration Statements which may be required pursuant to Section 2.3 or Section
3.3, the 45th calendar day following the date on which an additional Registration Statement is required to be filed hereunder; provided,
however, that in the event the Company is notified by the Commission that one or more of the above Registration Statements will
not be reviewed or is no longer subject to further review and comments, the Effectiveness Date as to such Registration Statement shall
be the third Trading Day following the date on which the Company is so notified if such date precedes the dates otherwise required above,
provided, further, if such Effectiveness Date falls on a day that is not a Trading Day, then the Effectiveness Date shall be the next
succeeding Trading Day.
“Effectiveness
Period” shall have the meaning set forth in Section 2.1.
“Event”
shall have the meaning set forth in Section 2.4.
“Event
Date” shall have the meaning set forth in Section 2.4.
“Filing
Date” means, with respect to the Initial Registration Statement required hereunder, the 15th calendar day following
the date hereof and, with respect to any additional Registration Statements which may be required pursuant to Section 2.3 or Section
3.3, the earliest practical date on which the Company is permitted by SEC Guidance to file such additional Registration Statement
related to the Registrable Securities.
“Holder”
or “Holders” means the holder or holders, as the case may be, from time to time of Registrable Securities.
“Indemnified
Party” shall have the meaning set forth in Section 5.3.
“Indemnifying
Party” shall have the meaning set forth in Section 5.3.
“Initial
Registration Statement” means the initial Registration Statement filed pursuant to this Agreement.
“Losses”
shall have the meaning set forth in Section 5.1.
“Maximum
Amount” means the maximum number of shares of Common Stock issuable upon the conversion the Note (or any securities into which
the Note is convertible), assuming the Note converts at the then applicable Floor Price (as defined in the Note).
“Plan
of Distribution” shall have the meaning set forth in Section 2.1.
“Prospectus”
means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the
Commission pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the
offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to
the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference
in such Prospectus.
“Registrable
Securities” means, as of any date of determination, (a) the Maximum Amount of shares of Common Stock issuable pursuant to the
terms of the Notes, (b) a number of shares equal to 250% of all Warrant Shares then issued and issuable upon exercise of the Warrants
(assuming on such date the Warrants are exercised in full without regard to any exercise limitations therein), (c) any additional of
the shares of Common Stock issued and issuable in connection with any anti-dilution provisions in the Warrants (without giving effect
to any limitations on exercise set forth in the Warrants), and (d) any securities issued or then issuable upon any stock split, dividend
or other distribution, recapitalization or similar event with respect to the foregoing; provided, however, that any such Registrable
Securities shall cease to be Registrable Securities (and the Company shall not be required to maintain the effectiveness of any, or file
another, Registration Statement hereunder with respect thereto) for so long as (a) a Registration Statement with respect to the sale
of such Registrable Securities is declared effective by the Commission under the Securities Act and such Registrable Securities have
been disposed of by the Holder in accordance with such effective Registration Statement, (b) such Registrable Securities have been previously
sold in accordance with Rule 144, or (c) such securities become eligible for resale without volume or manner-of-sale restrictions and
without current public information pursuant to Rule 144 as set forth in a written opinion letter to such effect, addressed, delivered
and acceptable to the Transfer Agent and the affected Holders (assuming that such securities and any securities issuable upon, exercise,
conversion or exchange of which, or as a dividend upon which, such securities were issued or are issuable, were at no time held by any
Affiliate of the Company,), as reasonably determined by the Company, upon the advice of counsel to the Company; provided, further,
that, for the avoidance of doubt, the number of Registrable Securities may increase from time to time in accordance with the terms of
the Notes, including as a result of any adjustments, accruals or other provisions affecting the number of shares issuable thereunder.
“Registration
Statement” means any registration statement required to be filed hereunder pursuant to Section 2.1 and any additional
registration statements contemplated by Section 2.3 or Section 3.3, including (in each case) the Prospectus, amendments
and supplements to any such registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto,
and all material incorporated by reference or deemed to be incorporated by reference in any such registration statement.
“Rule
415” means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.
“Rule
424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.
“Selling
Stockholder Questionnaire” shall have the meaning set forth in Section 3.1.
“SEC
Guidance” means (i) any publicly-available written or oral guidance of the Commission staff, or any comments, requirements
or requests of the Commission staff and (ii) the Securities Act.
ARTICLE
2
Shelf
Registration.
2.1
On or prior to each Filing Date, the Company shall prepare and file with the Commission a Registration Statement covering the resale
of all of the Registrable Securities that are not then registered on an effective Registration Statement for an offering to be made
on a continuous basis pursuant to Rule 415. Each Registration Statement filed hereunder shall be on Form S-3 (except if the Company
is not then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on
another appropriate form in accordance herewith, subject to the provisions of Section 2.5) and shall contain (unless
otherwise directed by at least 85% in interest of the Holders) substantially the “Plan of Distribution” attached
hereto as Annex A and substantially the “Selling Stockholder” section attached hereto as Annex B; provided, however,
that no Holder shall be required to be named as an “underwriter” without such Holder’s express prior written
consent. Subject to the terms of this Agreement, the Company shall use its commercially reasonable efforts to cause a Registration
Statement filed under this Agreement (including, without limitation, under Section 3.3) to be declared effective under the
Securities Act as promptly as possible after the filing thereof, but in any event no later than the applicable Effectiveness Date,
and shall use its commercially reasonable efforts to keep such Registration Statement continuously effective under the Securities
Act until the date that all Registrable Securities covered by such Registration Statement (i) have been sold, thereunder or pursuant
to Rule 144, or (ii) may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for
the Company to be in compliance with the current public information requirement under Rule 144, as determined by the counsel to the
Company pursuant to a written opinion letter to such effect, addressed and acceptable to the Transfer Agent and the affected Holders
(the “Effectiveness Period”). The Company shall telephonically request effectiveness of a Registration Statement
as of 5:00 p.m. (New York City time) on a Trading Day. The Company shall immediately notify the Holders via facsimile or by e-mail
of the effectiveness of a Registration Statement on the same Trading Day that the Company telephonically confirms effectiveness with
the Commission, which shall be the date requested for effectiveness of such Registration Statement. The Company shall, by 9:30 a.m.
(New York City time) on the Trading Day after the effective date of such Registration Statement, file a final Prospectus with the
Commission as required by Rule 424. Failure to so notify the Holder within one (1) Trading Day of such notification of effectiveness
or failure to file a final Prospectus as foresaid shall be deemed an Event under Section 2.4.
2.2
Notwithstanding the registration obligations set forth in Section 2.1, if the Commission informs the Company that all of the
Registrable Securities cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a
single registration statement, the Company agrees to promptly inform each of the Holders thereof and use its commercially reasonable
efforts to file amendments to the Initial Registration Statement as required by the Commission, covering the maximum number of
Registrable Securities permitted to be registered by the Commission, on Form S-3 or such other form available to register for resale
the Registrable Securities as a secondary offering, subject to the provisions of Section 2.5; with respect to filing on Form
S-3 or other appropriate form, and subject to the provisions of Section 2.4 with respect to the payment of liquidated
damages; provided, however, that prior to filing such amendment, the Company shall be obligated to use diligent
efforts to advocate with the Commission for the registration of all of the Registrable Securities in accordance with the SEC
Guidance, including without limitation, Corporation Finance Interpretation 612.09.
2.3
Notwithstanding any other provision of this Agreement and subject to the payment of liquidated damages pursuant to Section
2.4, if the Commission or any SEC Guidance sets forth a limitation on the number of Registrable Securities permitted to be
registered on a particular Registration Statement as a secondary offering (and notwithstanding that the Company used diligent
efforts to advocate with the Commission for the registration of all or a greater portion of Registrable Securities), unless
otherwise directed in writing by a Holder as to its Registrable Securities, the number of Registrable Securities to be registered on
such Registration Statement will be reduced as follows
(a)
First, the Company shall reduce or eliminate any securities to be included other than Registrable Securities; and
(b)
the Company shall reduce Registrable Securities represented by Warrant Shares (applied, in the case that some Warrant Shares may be
registered, to the Holders on a pro rata basis based on the total number of unregistered Warrant Shares held by such
Holders).
In
the event of a cutback hereunder, the Company shall give the Holder at least five (5) Trading Days prior written notice along with the
calculations as to such Holder’s allotment. In the event the Company amends the Initial Registration Statement in accordance with
the foregoing, the Company will use its commercially reasonable efforts to file with the Commission, as promptly as allowed by the Commission
or SEC Guidance provided to the Company or to registrants of securities in general, one or more registration statements on Form S-3 or
such other form available to register for resale those Registrable Securities that were not registered for resale on the Initial Registration
Statement, as amended.
2.4
If: (i) the Initial Registration Statement is not filed on or prior to its Filing Date (if the Company files the Initial
Registration Statement without affording the Holders the opportunity to review and comment on the same as required by Section 3.1 herein
or the Company subsequently withdraws the filing of the Registration Statement, the Company shall be deemed to have not satisfied
this clause (i)), or (ii) the Company fails to file with the Commission a request for acceleration of a Registration Statement in
accordance with Rule 461 promulgated by the Commission pursuant to the Securities Act, within five (5) Trading Days of the date that
the Company is notified (orally or in writing, whichever is earlier) by the Commission that such Registration Statement will not be
“reviewed” or will not be subject to further review, or (iii) prior to the effective date of a Registration Statement,
the Company fails to file a pre-effective amendment and otherwise respond in writing to comments made by the Commission in respect
of such Registration Statement within ten (10) calendar days after the receipt of comments by or notice from the Commission that
such amendment is required in order for such Registration Statement to be declared effective, or (iv) a Registration Statement
registering for resale all of the Registrable Securities is not declared effective by the Commission by the Effectiveness Date of
the Initial Registration Statement (provided that, if the Registration Statement does not allow for the resale of Registrable
Securities at prevailing market prices (i.e., only allows for fixed price sales), the Company shall have been deemed to have not
satisfied this clause), or (v) after the effective date of a Registration Statement, such Registration Statement ceases for any
reason to remain continuously effective as to all Registrable Securities included in such Registration Statement, or the Holders are
otherwise not permitted to utilize the Prospectus therein to resell such Registrable Securities, for more than five consecutive
calendar days or more than an aggregate of fifteen (15) calendar days (which need not be consecutive calendar days) during any
12-month period (any such failure or breach being referred to as an “Event”, and for purposes of clauses (i) and
(iv), the date on which such Event occurs, and for purpose of clause (ii) the date on which such five (5) Trading Day period is
exceeded, and for purpose of clause (iii) the date which such ten (10) calendar day period is exceeded, and for purpose of clause
(v) the date on which such ten (10) or fifteen (15) calendar day period, as applicable, is exceeded being referred to as
“Event Date”), then, in addition to any other rights the Holders may have hereunder or under applicable law, on
each such Event Date and on each monthly anniversary of each such Event Date (if the applicable Event shall not have been cured by
such date) until the applicable Event is cured, the Company shall pay to each Holder an amount in cash, as partial liquidated
damages and not as a penalty, equal to the product of 1.5% multiplied by the aggregate Subscription Amount paid by such Holder
pursuant to the Securities Purchase Agreement, If the Company fails to pay any partial liquidated damages pursuant to this Section
in full within seven days after the date payable, the Company will pay interest thereon at a rate of 18% per annum (or such lesser
maximum amount that is permitted to be paid by applicable law) to the Holder, accruing daily from the date such partial liquidated
damages are due until such amounts, plus all such interest thereon, are paid in full. The partial liquidated damages pursuant to the
terms hereof shall apply on a daily pro rata basis for any portion of a month prior to the cure of an Event.
2.5
If Form S-3 is not available for the registration of the resale of Registrable Securities hereunder, the Company shall (i) register
the resale of the Registrable Securities on another appropriate form and (ii) undertake to register the Registrable Securities on
Form S-3 as soon as such form is available, provided that the Company shall maintain the effectiveness of the Registration Statement
then in effect until such time as a Registration Statement on Form S-3 covering the Registrable Securities has been declared
effective by the Commission.
2.6
Notwithstanding anything to the contrary contained herein, in no event shall the Company be permitted to name any Holder or
affiliate of a Holder as any Underwriter without the prior written consent of such Holder.
ARTICLE
3
Registration
Procedures.
In
connection with the Company’s registration obligations hereunder, the Company shall:
3.1
Not less than five (5) Trading Days prior to the filing of each Registration Statement and not less than one (1) Trading Day prior
to the filing of any related Prospectus or any amendment or supplement thereto (including any document that would be incorporated or
deemed to be incorporated therein by reference), the Company shall (i) furnish to each Holder copies of all such documents proposed
to be filed, which documents (other than those incorporated or deemed to be incorporated by reference) will be subject to the review
of such Holders, and (ii) cause its officers and directors, counsel and independent registered public accountants to respond to such
inquiries as shall be necessary, in the reasonable opinion of respective counsel to each Holder, to conduct a reasonable
investigation within the meaning of the Securities Act. The Company shall not file a Registration Statement or any such Prospectus
or any amendments or supplements thereto to which the Holders of a majority of the Registrable Securities shall reasonably object in
good faith, provided that, the Company is notified of such objection in writing no later than five (5) Trading Days after the
Holders have been so furnished copies of a Registration Statement or one (1) Trading Day after the Holders have been so furnished
copies of any related Prospectus or amendments or supplements thereto. Each Holder agrees to furnish to the Company a completed
questionnaire in the form attached to this Agreement as Annex B (a “Selling Stockholder Questionnaire”) on
a date that is not less than two (2) Trading Days prior to the Filing Date or by the end of the fourth (4th) Trading Day
following the date on which such Holder receives draft materials in accordance with this Section.
3.2
(i) Prepare and file with the Commission such amendments, including post-effective amendments, to a Registration Statement and the
Prospectus used in connection therewith as may be necessary to keep a Registration Statement continuously effective as to the
applicable Registrable Securities for the Effectiveness Period and prepare and file with the Commission such additional Registration
Statements in order to register for resale under the Securities Act all of the Registrable Securities, (ii) cause the related
Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and, as so
supplemented or amended, to be filed pursuant to Rule 424, (iii) respond as promptly as reasonably possible to any comments received
from the Commission with respect to a Registration Statement or any amendment thereto and provide as promptly as reasonably possible
to the Holders true and complete copies of all correspondence from and to the Commission relating to a Registration Statement
(provided that, the Company shall excise any information contained therein which would constitute material non-public information
regarding the Company or any of its Subsidiaries), and (iv) comply in all material respects with the applicable provisions of the
Securities Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by a Registration
Statement during the applicable period in accordance (subject to the terms of this Agreement) with the intended methods of
disposition by the Holders thereof set forth in such Registration Statement as so amended or in such Prospectus as so
supplemented.
3.3
If during the Effectiveness Period, the number of Registrable Securities at any time exceeds 100% of the number of shares of Common
Stock then registered in a Registration Statement, then the Company shall file as soon as reasonably practicable, but in any case
prior to the applicable Filing Date, an additional Registration Statement covering the resale by the Holders of not less than the
number of such Registrable Securities.
3.4
Notify the Holders of Registrable Securities to be sold (which notice shall, pursuant to clauses (iii) through (vi) hereof, be
accompanied by an instruction to suspend the use of the Prospectus until the requisite changes have been made) as promptly as
reasonably possible (and, in the case of (i)(A) below, not less than three (3) Trading Days prior to such filing) and (if requested
by any such Person) confirm such notice in writing no later than one (1) Trading Day following the day (i)(A) when a Prospectus or
any Prospectus supplement or post-effective amendment to a Registration Statement is proposed to be filed, (B) when the Commission
notifies the Company whether there will be a “review” of such Registration Statement and whenever the Commission
comments in writing on such Registration Statement, and (C) with respect to a Registration Statement or any post-effective
amendment, when the same has become effective, (ii) of any request by the Commission or any other federal or state governmental
authority for amendments or supplements to a Registration Statement or Prospectus or for additional information, (iii) of the
issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of a
Registration Statement covering any or all of the Registrable Securities or the initiation of any Proceedings for that purpose, (iv)
of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from
qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding
for such purpose, (v) of the occurrence of any event or passage of time that makes the financial statements included in a
Registration Statement ineligible for inclusion therein or any statement made in a Registration Statement or Prospectus or any
document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires any
revisions to a Registration Statement, Prospectus or other documents so that, in the case of a Registration Statement or the
Prospectus, as the case may be, it will not contain any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made,
not misleading, and (vi) of the occurrence or existence of any pending corporate development with respect to the Company that the
Company believes may be material and that, in the determination of the Company, makes it not in the best interest of the Company to
allow continued availability of a Registration Statement or Prospectus; provided, however, that in no event shall any such notice
contain any information which would constitute material, non-public information regarding the Company or any of its Subsidiaries,
and the Company agrees that the Holders shall not have any duty of confidentiality to the Company or any of its Subsidiaries and
shall not have any duty to the Company or any of its Subsidiaries not to trade on the basis of such information.
3.5
Use its commercially reasonable efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping or
suspending the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from
qualification) of any of the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment.
3.6
Furnish to each Holder, without charge, at least one conformed copy of each such Registration Statement and each amendment thereto,
including financial statements and schedules, all documents incorporated or deemed to be incorporated therein by reference to the
extent requested by such Person, and all exhibits to the extent requested by such Person (including those previously furnished or
incorporated by reference) promptly after the filing of such documents with the Commission, provided that any such item which is
available on the EDGAR system (or successor thereto) need not be furnished in physical form.
3.7
Subject to the terms of this Agreement, the Company hereby consents to the use of such Prospectus and each amendment or supplement
thereto by each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such
Prospectus and any amendment or supplement thereto, except after the giving of any notice pursuant to Section 3.4.
3.8
Prior to any resale of Registrable Securities by a Holder, use its commercially reasonable efforts to register or qualify or
cooperate with the selling Holders in connection with the registration or qualification (or exemption from the Registration or
qualification) of such Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of such
jurisdictions within the United States as any Holder reasonably requests in writing, to keep each registration or qualification (or
exemption therefrom) effective during the Effectiveness Period and to do any and all other acts or things reasonably necessary to
enable the disposition in such jurisdictions of the Registrable Securities covered by each Registration Statement, provided that the
Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified, subject the
Company to any material tax in any such jurisdiction where it is not then so subject or file a general consent to service of process
in any such jurisdiction.
3.9
If requested by a Holder, cooperate with such Holder to facilitate the timely preparation and delivery of certificates representing
Registrable Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates shall be free, to
the extent permitted by the Securities Purchase Agreement, of all restrictive legends, and to enable such Registrable Securities to
be in such denominations and registered in such names as any such Holder may request.
3.10
Upon the occurrence of any event contemplated by Section 3.4, as promptly as reasonably possible under the circumstances
taking into account the Company’s good faith assessment of any adverse consequences to the Company and its stockholders of the
premature disclosure of such event, prepare a supplement or amendment, including a post-effective amendment, to a Registration
Statement or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference,
and file any other required document so that, as thereafter delivered, neither a Registration Statement nor such Prospectus will
contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make
the statements therein, in light of the circumstances under which they were made, not misleading. If the Company notifies the
Holders in accordance with clauses (iii) through (vi) of Section 3.4 above to suspend the use of any Prospectus until the
requisite changes to such Prospectus have been made, then the Holders shall suspend use of such Prospectus. The Company will use its
commercially reasonable efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. The Company
shall be entitled to exercise its right under this Section 3.10 to suspend the availability of a Registration Statement and
Prospectus, subject to the payment of partial liquidated damages otherwise required pursuant to Section 2.4, for a period not
to exceed 60 calendar days (which need not be consecutive days) in any 12-month period.
3.11
Otherwise use commercially reasonable efforts to comply with all applicable rules and regulations of the Commission under the
Securities Act and the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final Prospectus,
including any supplement or amendment thereof, with the Commission pursuant to Rule 424 under the Securities Act, promptly inform
the Holders in writing if, at any time during the Effectiveness Period, the Company does not satisfy the conditions specified in
Rule 172 and, as a result thereof, the Holders are required to deliver a Prospectus in connection with any disposition of
Registrable Securities and take such other actions as may be reasonably necessary to facilitate the registration of the Registrable
Securities hereunder.
3.12
The Company shall use its commercially reasonable efforts to obtain or maintain, as applicable, eligibility for use of Form S-3 (or
any successor form thereto) for the registration of the resale of Registrable Securities.
3.13
The Company may require each selling Holder to furnish to the Company a certified statement as to the number of shares of Common
Stock beneficially owned by such Holder and, if required by the Commission, the natural persons thereof that have voting and
dispositive control over the shares. During any periods that the Company is unable to meet its obligations hereunder with respect to
the registration of the Registrable Securities solely because any Holder fails to furnish such information within three Trading Days
of the Company’s request, any liquidated damages that are accruing at such time as to such Holder only shall be tolled and any
Event that may otherwise occur solely because of such delay shall be suspended as to such Holder only, until such information is
delivered to the Company.
ARTICLE
4
Registration
Expenses.
All
fees and expenses incident to the performance of or compliance with, this Agreement by the Company shall be borne by the Company whether
or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to in the foregoing sentence
shall include, without limitation, (i) all registration and filing fees (including, without limitation, fees and expenses of the Company’s
counsel and independent registered public accountants) (A) with respect to filings made with the Commission, (B) with respect to filings
required to be made with any Trading Market on which the Common Stock is then listed for trading, and (C) in compliance with applicable
state securities or Blue Sky laws reasonably agreed to by the Company in writing (including, without limitation, fees and disbursements
of counsel for the Company in connection with Blue Sky qualifications or exemptions of the Registrable Securities), (ii) printing expenses
(including, without limitation, expenses of printing certificates for Registrable Securities), (iii) messenger, telephone and delivery
expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability insurance, if the Company so desires such
insurance, and (vi) fees and expenses of all other Persons retained by the Company in connection with the consummation of the transactions
contemplated by this Agreement. In addition, the Company shall be responsible for all of its internal expenses incurred in connection
with the consummation of the transactions contemplated by this Agreement (including, without limitation, all salaries and expenses of
its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred
in connection with the listing of the Registrable Securities on any securities exchange as required hereunder. In no event shall the
Company be responsible for any broker or similar commissions of any Holder or, except to the extent provided for in the Transaction Documents,
any legal fees or other costs of the Holders.
ARTICLE
5
Indemnification.
5.1 Indemnification
by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless each Holder,
the officers, directors, members, partners, agents, brokers (including brokers who offer and sell Registrable Securities as
principal as a result of a pledge or any failure to perform under a margin call of Common Stock), investment advisors and employees
(and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or
any other title) of each of them, each Person who controls any such Holder (within the meaning of Section 15 of the Securities Act
or Section 20 of the Exchange Act) and the officers, directors, members, stockholders, partners, agents and employees (and any other
Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other
title) of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all losses,
claims, damages, liabilities, costs (including, without limitation, reasonable attorneys’ fees) and expenses (collectively,
“Losses”), as incurred, arising out of or relating to (1) any untrue or alleged untrue statement of a material
fact contained in a Registration Statement, any Prospectus or any form of prospectus or in any amendment or supplement thereto or in
any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be
stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the
circumstances under which they were made) not misleading or (2) any violation or alleged violation by the Company of the Securities
Act, the Exchange Act or any state securities law, or any rule or regulation thereunder, in connection with the performance of its
obligations under this Agreement, except to the extent, but only to the extent, that (i) such untrue statements or omissions are
based solely upon information regarding such Holder furnished in writing to the Company by such Holder expressly for use therein, or
to the extent that such information relates to such Holder or such Holder’s proposed method of distribution of Registrable
Securities and was reviewed and expressly approved in writing by such Holder expressly for use in a Registration Statement, such
Prospectus or in any amendment or supplement thereto (it being understood that the Holder has approved Annex A hereto for
this purpose) or (ii) in the case of an occurrence of an event of the type specified in Section 3.4(iii)-(vi), the use by
such Holder of an outdated, defective or otherwise unavailable Prospectus after the Company has notified such Holder in writing that
the Prospectus is outdated, defective or otherwise unavailable for use by such Holder and prior to the receipt by such Holder of the
Advice contemplated in Section 6.3. The Company shall notify the Holders promptly of the institution, threat or assertion of
any Proceeding arising from or in connection with the transactions contemplated by this Agreement of which the Company is aware.
Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such indemnified person
and shall survive the transfer of any Registrable Securities by any of the Holders in accordance with Section 6.6.
5.2 Indemnification
by Holders. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its directors, officers,
agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of
the Exchange Act), and the directors, officers, agents or employees of such controlling Persons, to the fullest extent permitted by
applicable law, from and against all Losses, as incurred, to the extent arising out of or based solely upon: any untrue or alleged
untrue statement of a material fact contained in any Registration Statement, any Prospectus, or in any amendment or supplement
thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact
required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in
light of the circumstances under which they were made) not misleading (i) to the extent, but only to the extent, that such untrue
statement or omission is contained in any information so furnished in writing by such Holder to the Company expressly for inclusion
in such Registration Statement or such Prospectus or (ii) to the extent, but only to the extent, that such information relates to
such Holder’s information provided in the Selling Stockholder Questionnaire or the proposed method of distribution of
Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly for use in a Registration
Statement (it being understood that the Holder has approved Annex A hereto for this purpose), such Prospectus or in any
amendment or supplement thereto. In no event shall the liability of a selling Holder be greater in amount than the dollar amount of
the proceeds (net of all expenses paid by such Holder in connection with any claim relating to this Article 5 and the amount
of any damages such Holder has otherwise been required to pay by reason of such untrue statement or omission) received by such
Holder upon the sale of the Registrable Securities included in the Registration Statement giving rise to such indemnification
obligation.
5.3 Conduct
of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any Person entitled to indemnity
hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom indemnity
is sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall have the right to assume the
defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees
and expenses incurred in connection with defense thereof, provided that the failure of any Indemnified Party to give such notice
shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the
extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or
further review) that such failure shall have materially and adversely prejudiced the Indemnifying Party.
An
Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but
the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party
has agreed in writing to pay such fees and expenses, (2) the Indemnifying Party shall have failed promptly to assume the defense of such
Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or (3) the named parties to
any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and counsel to
the Indemnified Party shall reasonably believe that a material conflict of interest is likely to exist if the same counsel were to represent
such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing
that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to
assume the defense thereof and the reasonable fees and expenses of no more than one separate counsel shall be at the expense of the Indemnifying
Party). The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which
consent shall not be unreasonably withheld or delayed. No Indemnifying Party shall, without the prior written consent of the Indemnified
Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes
an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding.
Subject
to the terms of this Agreement, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to
the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section)
shall be paid to the Indemnified Party, as incurred, within ten Trading Days of written notice thereof to the Indemnifying Party, provided
that the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses applicable to such
actions for which such Indemnified Party is finally determined by a court of competent jurisdiction (which determination is not subject
to appeal or further review) not to be entitled to indemnification hereunder.
5.4 Contribution.
If the indemnification under Section 5.1 or 5.2 is unavailable to an Indemnified Party or insufficient to hold an
Indemnified Party harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable by such
Indemnified Party, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified
Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable
considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other
things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged
omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or
Indemnified Party, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent
such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include,
subject to the limitations set forth in this Agreement, any reasonable attorneys’ or other fees or expenses incurred by such
party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the
indemnification provided for in this Section was available to such party in accordance with its terms.
The
parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5.4 were determined by pro
rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the
immediately preceding paragraph. In no event shall the contribution obligation of a Holder of Registrable Securities be greater in amount
than the dollar amount of the proceeds (net of all expenses paid by such Holder in connection with any claim relating to this Article
5 and the amount of any damages such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement
or omission or alleged omission) received by it upon the sale of the Registrable Securities giving rise to such contribution obligation.
The
indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties may have
to the Indemnified Parties.
ARTICLE
6
Miscellaneous.
6.1 Remedies.
In the event of a breach by the Company or by a Holder of any of their respective obligations under this Agreement, each Holder or
the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement,
including recovery of damages, shall be entitled to specific performance of its rights under this Agreement. Each of the Company and
each Holder agrees that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it
of any of the provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance in
respect of such breach, it shall not assert or shall waive the defense that a remedy at law would be adequate.
6.2 No
Piggyback on Registrations; Prohibition on Filing Other Registration Statements. Except for the shares of Common Stock issuable
upon exercise of the warrants issued to the Placement Agent in the transactions contemplated in the Securities Purchase Agreement,
neither the Company nor any of its security holders (other than the Holders in such capacity pursuant hereto) may include securities
of the Company in any Registration Statements other than the Registrable Securities. The Company shall not file any other
registration statements until all Registrable Securities are registered pursuant to a Registration Statement that is declared
effective by the Commission, provided that this Section 6.2 shall not prohibit the Company from filing amendments to
registration statements filed prior to the date of this Agreement so long as no new securities are registered on any such existing
registration statements.
6.3 Discontinued
Disposition. By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of a notice from the Company of
the occurrence of any event of the kind described in Section 3.4(iii) through 3.4 such Holder will forthwith
discontinue disposition of such Registrable Securities under a Registration Statement until it is advised in writing (the
“Advice”) by the Company that the use of the applicable Prospectus (as it may have been supplemented or amended)
may be resumed. The Company will use its commercially reasonable efforts to ensure that the use of the Prospectus may be resumed as
promptly as is practicable. The Company agrees and acknowledges that any periods during which the Holder is required to discontinue
the disposition of the Registrable Securities hereunder shall be subject to the provisions of Section 2.4.
6.4 Amendments
and Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or
supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing
and signed by the Company and the Holders of 50.1% or more of the then outstanding Registrable Securities (for purposes of
clarification, this includes any Registrable Securities issuable upon exercise or conversion of any Security), provided that, if any
amendment, modification or waiver disproportionately and adversely impacts a Holder (or group of Holders), the consent of such
disproportionately impacted Holder (or group of Holders) shall be required. If a Registration Statement does not register all of the
Registrable Securities pursuant to a waiver or amendment done in compliance with the previous sentence, then the number of
Registrable Securities to be registered for each Holder shall be reduced pro rata among all Holders and each Holder shall have the
right to designate which of its Registrable Securities shall be omitted from such Registration Statement. Notwithstanding the
foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights
of a Holder or some Holders and that does not directly or indirectly affect the rights of other Holders may be given only by such
Holder or Holders of all of the Registrable Securities to which such waiver or consent relates; provided, however,
that the provisions of this sentence may not be amended, modified, or supplemented except in accordance with the provisions of the
first sentence of this Section 6.4. No consideration shall be offered or paid to any Person to amend or consent to a waiver
or modification of any provision of this Agreement unless the same consideration also is offered to all of the parties to this
Agreement.
6.5 Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be delivered as set
forth in the Securities Purchase Agreement.
6.6 Successors
and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of
the parties and shall inure to the benefit of each Holder. The Company may not assign (except by merger) its rights or obligations
hereunder without the prior written consent of all of the Holders of the then outstanding Registrable Securities. Each Holder may
assign their respective rights hereunder in the manner and to the Persons as permitted under the Securities Purchase
Agreement.
6.7 No
Inconsistent Agreements. Neither the Company nor any of its Subsidiaries has entered, as of the date hereof, nor shall the
Company or any of its Subsidiaries, on or after the date of this Agreement, enter into any agreement with respect to its securities,
that would have the effect of impairing the rights granted to the Holders in this Agreement or otherwise conflicts with the
provisions hereof. The Company has not previously entered into any agreement granting any registration rights with respect to any of
its securities to any Person that have not been satisfied in full.
6.8 Execution
and Counterparts. This Agreement may be executed in two or more counterparts, all of which when taken together shall be
considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to
the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is
delivered by facsimile transmission or by e- mail delivery of a “.pdf” format data file, such signature shall create a
valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect
as if such facsimile or “.pdf” signature page were an original thereof.
6.9 Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be determined
in accordance with the provisions of the Securities Purchase Agreement.
6.10 Cumulative
Remedies. The remedies provided herein are cumulative and not exclusive of any other remedies provided by law.
6.11 Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid,
illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in
full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they
would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter
declared invalid, illegal, void or unenforceable.
6.12 Headings.
The headings in this Agreement are for convenience only, do not constitute a part of the Agreement and shall not be deemed to limit
or affect any of the provisions hereof.
6.13 Independent
Nature of Holders’ Obligations and Rights. The obligations of each Holder hereunder are several and not joint with the
obligations of any other Holder hereunder, and no Holder shall be responsible in any way for the performance of the obligations of
any other Holder hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and no action
taken by any Holder pursuant hereto or thereto, shall be deemed to constitute the Holders as a partnership, an association, a joint
venture or any other kind of group or entity, or create a presumption that the Holders are in any way acting in concert or as a
group or entity with respect to such obligations or the transactions contemplated by this Agreement or any other matters, and the
Company acknowledges that the Holders are not acting in concert or as a group, and the Company shall not assert any such claim, with
respect to such obligations or transactions. Each Holder shall be entitled to protect and enforce its rights, including without
limitation the rights arising out of this Agreement, and it shall not be necessary for any other Holder to be joined as an
additional party in any proceeding for such purpose. The use of a single agreement with respect to the obligations of the Company
contained was solely in the control of the Company, not the action or decision of any Holder, and was done solely for the
convenience of the Company and not because it was required or requested to do so by any Holder. It is expressly understood and
agreed that each provision contained in this Agreement is between the Company and a Holder, solely, and not between the Company and
the Holders collectively and not between and among Holders.
********************
(Signature
Pages Follow)
IN
WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.
WELLGISTICS HEALTH, INC.
By:
Name:
Title:
[SIGNATURE
PAGE OF HOLDERS FOLLOWS]
[SIGNATURE
PAGE OF HOLDERS]
Name
of Holder:
Signature
of Authorized Signatory of Holder:
Name
of Authorized Signatory:
Title
of Authorized Signatory:
[SIGNATURE
PAGES CONTINUE]
ANNEX
A
Plan
of Distribution
Each
Selling Stockholder (the “Selling Stockholders”) of the securities and any of their pledgees, assignees and successors-in-interest
may, from time to time, sell any or all of their securities covered hereby on the principal Trading Market or any other stock exchange,
market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices.
A Selling Stockholder may use any one or more of the following methods when selling securities:
● ordinary
brokerage transactions and transactions in which the broker-dealer solicits purchasers;
● block
trades in which the broker-dealer will attempt to sell the securities as agent but may position
and resell a portion of the block as principal to facilitate the transaction;
● purchases
by a broker-dealer as principal and resale by the broker-dealer for its account;
● an
exchange distribution in accordance with the rules of the applicable exchange;
● privately
negotiated transactions;
● settlement
of short sales;
● transactions
through broker-dealers that agree with the Selling Stockholders to sell a specified number
of such securities at a stipulated price per security;
● transactions
involving the writing or settlement of options or other hedging transactions, whether through
an options exchange or otherwise;
● a
combination of any such methods of sale; or
● any
other method permitted pursuant to applicable law.
The
Selling Stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act of 1933,
as amended (the “Securities Act”), if available, rather than under this prospectus.
Broker-dealers
engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser)
in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in
excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or
markdown in compliance with FINRA Rule 2121.
In
connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they
assume. The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan
or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option
or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the
delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
The
Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be “underwriters”
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding,
directly or indirectly, with any person to distribute the securities.
The
Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company
has agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under
the Securities Act.
We
agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholders
without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for
the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar
effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule
of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable
state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered
or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is
complied with.
Under
applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously
engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M,
prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the
Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the
common stock by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders
and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including
by compliance with Rule 172 under the Securities Act).
ANNEX
B
SELLING
Stockholders
The
common stock being offered by the Selling Stockholders are those previously issued to the Selling Stockholders, and those issuable to
the Selling Stockholders upon exercise of the warrants. For additional information regarding the issuances of those shares of common
stock and warrants, see “Private Placement of Shares of Common Stock and Warrants” above. We are registering the shares of
common stock in order to permit the Selling Stockholders to offer the shares for resale from time to time. Other than as described below
or elsewhere in this prospectus, the Selling Stockholders have not had any material relationship with us within the past three years.
The
table below lists the Selling Stockholders and other information regarding the beneficial ownership of the shares of common stock by
each of the Selling Stockholders. The second column lists the number of shares of common stock beneficially owned by each Selling Stockholder,
based on its ownership of the shares of common stock and warrants, as of [__], 2026, assuming exercise of the warrants held by the Selling
Stockholder on that date, without regard to any limitations on exercise.
The
third column lists the shares of common stock being offered by this prospectus by the Selling Stockholders.
In
accordance with the terms of a registration rights agreement with the Selling Stockholders, this prospectus generally covers the resale
of the sum of (i) the number of shares of common stock issued to the Selling Stockholders in the “Private Placement of Shares of
Common Stock and Warrants” described above and (ii) the maximum number of shares of common stock issuable upon exercise of the
related warrants, determined as if the outstanding warrants were exercised in full as of the trading day immediately preceding the date
this registration statement was initially filed with the SEC, each as of the trading day immediately preceding the applicable date of
determination and all subject to adjustment as provided in the registration right agreement, without regard to any limitations on the
exercise of the warrants. The fourth column assumes the sale of all of the shares offered by the Selling Stockholders pursuant to this
prospectus.
Under
the terms of the warrants, a Selling Stockholder may not exercise any such warrants to the extent such exercise would cause such Selling
Stockholder, together with its affiliates and attribution parties, to beneficially own a number of shares of common stock which would
exceed 9.99% of our then outstanding common stock following such exercise, excluding for purposes of such determination shares of common
stock issuable upon exercise of such warrants which have not been exercised. The number of shares in the second and fourth columns do
not reflect this limitation. The Selling Stockholders may sell all, some or none of their shares in this offering. See “Plan of
Distribution.”
The
Selling Stockholders may sell all, some or none of their shares in this offering. See “Plan of Distribution.”
Name
of Selling Stockholder
Number
of shares of
Common Stock
Owned Prior to
Offering
Maximum
Number of
shares of Common
Stock to be Sold
Pursuant to this
Prospectus
Number
of shares of
Common Stock
Owned After Offering
Selling
Stockholder Notice and Questionnaire
The
undersigned beneficial owner of common stock (the “Registrable Securities”) of Wellgistics Health, Inc., a Delaware
corporation (the “Company”), understands that the Company has filed or intends to file with the Securities and Exchange
Commission (the “Commission”) a registration statement (the “Registration Statement”) for the registration
and resale under Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”), of the Registrable Securities,
in accordance with the terms of the Registration Rights Agreement (the “Registration Rights Agreement”) to which this
document is annexed. A copy of the Registration Rights Agreement is available from the Company upon request at the address set forth
below. All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement.
Certain
legal consequences arise from being named as a selling stockholder in the Registration Statement and the related prospectus. Accordingly,
holders and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences
of being named or not being named as a selling stockholder in the Registration Statement and the related prospectus.
NOTICE
The
undersigned beneficial owner (the “Selling Stockholder”) of Registrable Securities hereby elects to include the Registrable
Securities owned by it in the Registration Statement.
INVESTOR
QUESTIONNAIRE
The
undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:
1.
Name.
(a)
Full
Legal Name of Investor
(b)
Full
Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities are held:
(c)
Full
Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power to vote
or dispose of the securities covered by this Questionnaire):
2.
Address
for Notices to Investor:
Telephone:
Email:
Contact
Person:
3.
Broker-Dealer
Status:
(a)
Are
you a broker-dealer?
Yes
☐ No ☐
(b)
If
“yes” to Section 3(a), did you receive your Registrable Securities as compensation for investment banking services to
the Company?
Yes
☐ No ☐
Note:
If “no” to Section 3(b), the Commission’s staff has indicated that you should be identified as an underwriter in the
Registration Statement.
(c)
Are
you an affiliate of a broker-dealer?
Yes
☐ No ☐
(d)
If
you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities in the ordinary course of business,
and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or
indirectly, with any person to distribute the Registrable Securities?
Yes
☐ No ☐
Note:
If “no” to Section 3(d), the Commission’s staff has indicated that you should be identified as an underwriter in the
Registration Statement.
4.
Beneficial
Ownership of Securities of the Company Owned by the Investor.
Except
as set forth below in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company other than
the securities issuable pursuant to the Securities Purchase Agreement.
(a)
Type
and Amount of other securities beneficially owned by the Selling Stockholder:
5.
Relationships
with the Company:
Except
as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5%
of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship with
the Company (or its predecessors or affiliates) during the past three years.
State
any exceptions here:
The
undersigned agrees to promptly notify the Company of any material inaccuracies or changes in the information provided herein that may
occur subsequent to the date hereof at any time while the Registration Statement remains effective; provided, that the undersigned shall
not be required to notify the Company of any changes to the number of securities held or owned by the undersigned or its affiliates.
By
signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items I through 5 and
the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto.
The undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment
of the Registration Statement and the related prospectus and any amendments or supplements thereto.
IN
WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either
in person or by its duly authorized agent.
Date:
Investor:
By:
Name:
Title:
PLEASE
EMAIL A .PDF COPY OF THE COMPLETED AND EXECUTED QUESTIONNAIRE TO:
EX-10.3
EX-10.3
Filename: ex10-3.htm · Sequence: 6
Exhibit
10.3
PLACEMENT
AGENCY AGREEMENT
Dawson
James Securities, Inc.
101 North Federal Highway
Boca Raton, Florida 33432
May
27, 2026
Ladies
and Gentlemen:
This
letter (this “Agreement”) constitutes the agreement between Wellgistics Health, Inc., a Delaware corporation (the
“Company”) and Dawson James Securities, Inc. (“Dawson” or the “Placement Agent”)
pursuant to which Dawson shall serve as the exclusive placement agent, on a best efforts, agency basis, in connection with the proposed
private placement offering (the “Offering”) by the Company of its equity or equity-linked securities (the “Securities”),
as more fully described in this Agreement and the Securities Purchase Agreement (as defined below). The Offering will be conducted pursuant
to Rule 506 of Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”), and limited
to “accredited investors” as that term is defined under Rule 501 of Regulation D. Nothing in this Agreement may be construed
to suggest that Dawson would have the power or authority to bind the Company or an obligation for the Company to issue any Securities
or complete the Offering. The Company expressly acknowledges and agrees that Dawson’s obligations hereunder are on a reasonable
“best efforts” basis only and that the execution of this Agreement does not constitute a commitment by Dawson to purchase
the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Dawson placing
the Securities.
1.
Appointment of Dawson James Securities, Inc. as Exclusive Placement Agent.
On
the basis of the representations, warranties, covenants and agreements of the Company herein contained, and subject to all the terms
and conditions of this Agreement, the Company hereby appoints the Placement Agent as its exclusive financial advisor and lead or managing
placement agent and/or book runner and investment banker in connection with the Offering and any financing during the Exclusive Term,
and Dawson agrees to act in such capacity. Pursuant to this appointment, the Placement Agent will solicit offers for the purchase of,
or attempt to place, all or part of the Securities of the Company in the proposed Offering. Until the final Closing or earlier termination
of this Agreement or expiration of the Exclusive Term pursuant to Section 5 hereof, the Company shall not, without the prior written
consent of the Placement Agent, solicit, negotiate with, accept offers from or enter into any agreement with any other broker-dealer,
placement agent, underwriter, financial advisor, investment banking firm or other source of financing in connection with an offering
of the Company’s debt or equity securities or any other financing by the Company. The Company acknowledges that the Placement Agent
will act as an agent of the Company and use its reasonable “best efforts” to solicit offers to purchase the Securities from
the Company. The Placement Agent shall use commercially reasonable efforts to assist the Company in obtaining performance by each Purchaser
whose offer to purchase Securities has been solicited by the Placement Agent, but the Placement Agent shall not, except as otherwise
provided in this Agreement, be obligated to disclose the identity of any potential purchaser or have any liability to the Company in
the event any such purchase is not consummated for any reason. Under no circumstances will the Placement Agent be obligated to underwrite
or purchase any Securities for its own account and, in soliciting purchases of the Securities, the Placement Agent shall act solely as
an agent of the Company. The Placement Agent’s services provided pursuant to this Agreement shall be on an “agency”
basis and not on a “principal” basis.
The
Placement Agent will solicit offers for the purchase of the Securities in the Offering at such times and in such amounts as the Placement
Agent deems advisable and will communicate to the Company, orally or in writing, each reasonable offer to purchase Securities received
by the Placement Agent as an agent of the Company. The Company shall have the sole right to accept offers to purchase Securities and
may reject any such offer, in whole or in part. The Placement Agent may retain other brokers or dealers to act as sub-agents on its behalf
in connection with the Offering and may pay any sub-agent a solicitation fee with respect to any Securities placed by it. The Company
and Placement Agent shall negotiate the timing and terms of the Offering and acknowledge that the Offering and the provision of Placement
Agent services related to the Offering are subject to market conditions and the receipt of all required related clearances and approvals.
2.
Fees and Expenses; Tail;
In
connection with the Placement Agent services described above, the Company shall pay to Dawson the following compensation:
A.
Placement
Agent’s Fee. As compensation for services rendered: (i) the Company shall pay to the Placement Agent in cash by wire transfer
in immediately available funds to an account or accounts designated by the Placement Agent an amount (the “Placement Fee”)
equal to 3% of the aggregate gross proceeds received by the Company from the sale of the Securities at one or more Closings; and
(ii) the Company shall issue to the Placement Agent or its designees, at the Closing of the Offering, five-year warrants (the “Placement
Agent Warrants”) to purchase such number of shares of Common Stock as is equal to 12% of the aggregate number of Securities
sold in the Offering, calculated in the manner set forth in the Securities Purchase Agreement and the applicable warrant documentation.
The Placement Agent Warrants shall be exercisable, in whole or in part, at any time and from time to time during the five-year period
commencing six months from the Closing of the Offering, at an exercise price equal to 125% of the price per Security issued in the
Offering or, if the Securities consist of convertible securities, 125% of the applicable initial conversion price or other price
set forth in the Securities Purchase Agreement. The Placement Agent Warrants shall be the same warrants issued to the investors in
the Offering, including any mandatory exercise or call provision applicable to the investor warrants, and shall include a cashless
exercise provision, registration rights, including one demand registration right and unlimited piggyback registration rights, and
customary anti-dilution provisions for stock dividends, stock splits, combinations, recapitalizations and similar events.
B.
Offering Expenses. The Company agrees to pay all costs, fees and expenses incurred by the Company in connection with the performance
of its obligations hereunder and in connection with the transactions contemplated hereby, including, without limitation: (a) all actual
fees, expenses and disbursements relating to the Securities under the “blue sky” securities laws of such states and other
jurisdictions as the Placement Agent may reasonably designate; (b) the costs of preparing, printing and delivering certificates representing
the Securities; (c) fees and expenses of the transfer agent for the Securities; (d) the fees and expenses of the Company’s accountants;
(e) the fees and expenses of the Company’s legal counsel and other agents and representatives; (f) the legal and diligence fees
and expenses of the Placement Agent not to exceed $110,000. The Placement Agent may deduct from the net proceeds of the Offering payable
to the Company on the Closing Date, the expenses set forth herein to be paid by the Company to the Placement Agent, provided, however,
that in the event that the Offering is terminated, the Company agrees to reimburse the Placement Agent pursuant to Section 5 hereof.
C.
Tail Financing. The Placement Agent shall be entitled to all fees set forth in this Section 2 with respect to any public or private offering
or other financing or capital-raising transaction of any kind (a “Tail Financing”) to the extent that such financing or capital
is provided to the Company by investors whom the Placement Agent had introduced to the Company during the term of this Agreement, if
such Tail Financing is consummated at any time during the 12-month period following the expiration or termination of this Agreement or
the completion of the Offering (the “Tail Period”). Within three Business Days following termination or expiration of this
Agreement, the Placement Agent shall provide a written list of investors to the Company for review, which the Company may reasonably
reject in good faith as to specific investors. In no event shall such list include persons that are existing stockholders of the Company
unless they invested into the Company through the Placement Agent in the Offering. Notwithstanding the foregoing, Tail Financings shall
not include bona fide strategic transactions, commercial collaborations, acquisitions, mergers, restructuring transactions, affiliate
financings, debt exchanges, liability management transactions, Section 3(a)(9) exchanges, Section 3(a)(10) settlements or other transactions
not primarily undertaken for capital-raising purposes.
2
3.
Description of the Offering.
The
Securities to be offered directly to various investors (each, an “Investor” or “Purchaser” and, collectively,
the “Investors” or the “Purchasers”) in the Offering shall be convertible promissory notes in the aggregate principal
amount of $21,132812.50 (the “Notes”), which are being purchased for $16,906,250, and which are convertible into either (i)
shares of Common Stock of the Company, $0.0001 par value, (the “Common Stock”), or (ii) a new series of the Company’s
convertible preferred stock, in each case as further set forth in the Notes. Each Investor will also be issued a Common Stock purchase
warrant to purchase a number of shares of Common Stock equal to the number of shares of Common Stock initially issuable upon conversion
of 150% of the initial principal amount of the Note purchased by such Purchaser, based on the initial Conversion Price, at an exercise
price equal to 125% of the closing price of the Common Stock on the date the Securities Purchase Agreement is executed (the “PIPE
Warrants,” and together with the Notes, the “Securities”). The PIPE Warrants and the Placement Agent Warrants
shall include any mandatory exercise or call provision set forth in the Securities Purchase Agreement and the applicable warrant documentation,
subject to any beneficial ownership limitation, exchange cap, required stockholder approval and the rules and regulations of the applicable
trading market. If the Company shall default in its obligations to deliver Securities to a Purchaser whose offer it has accepted, the
Company shall indemnify and hold the Placement Agent harmless against any loss, claim, damage or expense arising from or as a result
of such default by the Company under this Agreement. The PIPE Warrants and the Placement Agent Warrants shall also provide that the Company
may, in its sole discretion and without the consent of the holder thereof, reduce the cash exercise price payable upon exercise of such
warrants by up to eighty percent (80%) of the then-applicable exercise price solely for purposes of inducing a cash exercise, provided
that any such reduced cash exercise price shall not be used for purposes of calculating any Black Scholes Value, Black Scholes Value
- FT, cashless exercise amount, mandatory exercise trigger, anti-dilution adjustment or other economic right under such warrants.
4.
Delivery and Payment; Closing.
Investors
purchasing Securities shall by check or wire transfer pay for such Securities by transmitting payment to the order of “Wellgistics
Health, Inc.” The Securities shall be registered in such name or names and in such authorized denominations as the Placement Agent
may request in writing prior to the Closing Date. The Closing shall occur electronically through the exchange of signatures at such time
as agreed upon by the Placement Agent and the Company. All actions taken at a Closing shall be deemed to have occurred simultaneously.
5.
Term and Termination of Agreement.
The
term of this Agreement will commence upon the execution of this Agreement and will terminate at the earlier of the final Closing of the
Offering or 11:59 p.m. (New York Time) on June 20, 2026 (the “Exclusive Term”). Notwithstanding anything to the contrary
contained herein, any provision in this Agreement concerning or relating to confidentiality, indemnification, contribution, advancement,
the Company’s representations and warranties and the Company’s obligations to pay fees and reimburse expenses will survive
any expiration or termination of this Agreement. If any condition specified in Section 8 is not satisfied when and as required to be
satisfied, this Agreement may be terminated by the Placement Agent by notice to the Company at any time on or prior to a Closing Date,
which termination shall be without liability on the part of any party to any other party, except that those portions of this Agreement
specified in Section 19 shall at all times be effective and shall survive such termination. Notwithstanding anything to the contrary
in this Agreement, in the event that this Agreement shall not be carried out for any reason whatsoever, within the time specified herein
or any extensions thereof pursuant to the terms herein, the Company shall be obligated to pay to the Placement Agent their actual and
accountable out-of-pocket expenses related to the transactions contemplated herein then due and payable and upon demand the Company shall
pay the full amount thereof to the Placement Agent; provided, that the legal and diligence fees and expenses of the Placement Agent shall
not exceed $110,000; and provided, however, that such expense cap in no way limits or impairs the indemnification and contribution provisions
of this Agreement.
3
6.
Permitted Acts.
Nothing
in this Agreement shall be construed to limit the ability of the Placement Agent, its officers, directors, employees, agents, associated
persons and any individual or entity “controlling,” controlled by,” or “under common control” with the
Placement Agent (as those terms are defined in Rule 405 under the Securities Act) to conduct its business including without limitation
the ability to pursue, investigate, analyze, invest in, or engage in investment banking, financial advisory or any other business relationship
with any individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.
7.
Representations, Warranties and Covenants of the Company.
As
of the date and time of the execution of this Agreement and each Closing Date, the Company represents, warrants and covenants to the
Placement Agent that:
A.
SEC Reports; Financial Statements, etc. The Company has complied in all material respects with requirements to file all reports,
schedules, forms, statements and other documents required to be filed by it under the Securities Act and the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), including pursuant to Section 13(a) or 15(d) thereof, for the 24 months
preceding the date hereof (or such shorter period as the Company was required by law to file such material) (the foregoing materials,
including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the “SEC
Reports”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior
to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements
of the Securities Act and the Exchange Act and the rules and regulations of the Commission promulgated thereunder, and none of the SEC
Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein
or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The
financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements
and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have
been prepared in accordance with United States generally accepted accounting principles (“GAAP”) applied on a consistent
basis during the periods involved, except as may be otherwise specified in such financial statements or the notes thereto and except
that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial
position of the Company and its consolidated subsidiaries as of and for the dates thereof and the results of operations and cash flows
for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments. The financial
statements, including the notes thereto and supporting schedules, included in the SEC Reports fairly present in all material respects
the financial position and the results of operations of the Company at the dates and for the periods to which they apply; and such financial
statements have been prepared in conformity with GAAP, consistently applied throughout the periods involved (provided that unaudited
interim financial statements are subject to year-end audit adjustments that are not expected to be material in the aggregate and do not
contain all footnotes required by GAAP). The pro forma and pro forma as adjusted financial information and the related notes, if any,
included in the SEC Reports have been properly compiled and prepared in accordance with the applicable requirements of the Securities
Act and the rules and regulations thereto (the “Securities Act Regulations”) and present fairly in all material respects
the information shown therein, and the assumptions used in the preparation thereof are reasonable and the adjustments used therein are
appropriate to give effect to the transactions and circumstances referred to therein. All disclosures contained in the SEC Reports regarding
“non-GAAP financial measures” (as such term is defined by the rules and regulations of the Commission), if any, comply with
Regulation G of the Exchange Act to the extent applicable. Except as disclosed in the SEC Reports, (a) the Company has not incurred any
material liabilities or obligations, direct or contingent, or entered into any material transactions other than in the ordinary course
of business, (b) the Company has not declared or paid any dividends or made any distribution of any kind with respect to its capital
stock, (c) there has not been any change in the capital stock of the Company, or, other than in the ordinary course of business, any
grants under any stock compensation plan, and (d) there has not been any change in the Company’s long-term or short-term debt that,
singularly or in the aggregate, would involve a material adverse change or a prospective material adverse change, in or affecting the
condition (financial or otherwise), results of operations, business, assets or prospects of the Company (a “Material Adverse
Change”).
4
B.
Independent Accountants. To the knowledge of the Company, Suri & Co. (the “Auditors”), whose reports are
filed with the Commission, is an independent registered public accounting firm as required by the Securities Act and the Securities Act
Regulations and the Public Company Accounting Oversight Board.
C.
Authorized Capital, etc. The Company’s duly authorized, issued and outstanding capitalization is as disclosed in the SEC
Reports. As of the Closing, except as set forth in the SEC Reports, as of each Closing Date, there will be no stock options, warrants,
or other rights to purchase or otherwise acquire any authorized, but unissued shares of Common Stock of the Company or any security convertible
or exercisable into shares of Common Stock of the Company, or any contracts or commitments to issue or sell shares of Common Stock or
any such options, warrants, rights or convertible securities.
D.
Valid Issuance of Securities, etc.
i.
Outstanding
Securities. All issued and outstanding securities of the Company issued prior to the transactions contemplated by this Agreement
have been duly authorized and validly issued and are fully paid and non-assessable; the holders thereof have no rights of rescission
with respect thereto, and are not subject to personal liability by reason of being such holders; and none of such securities were
issued in violation of the preemptive rights of any holders of any security of the Company or similar contractual rights granted
by the Company. The authorized shares of Common Stock, Company preferred stock and other outstanding securities conform in all material
respects to all statements relating thereto contained in the SEC Reports. The offers and sales of the outstanding shares of Common
Stock were at all relevant times either registered under the Securities Act and the applicable state securities or “blue sky”
laws or, based in part on the representations and warranties of the purchasers of such shares, exempt from such registration requirements
ii.
Securities
Sold Pursuant to this Agreement. The Securities have been duly authorized for issuance and sale and, when issued and paid for,
will be validly issued; the Common Stock underlying the Notes and Placement Agent Warrants has been duly authorized for issuance
and sale and, when issued and paid for, will be validly issued, fully paid and non-assessable; the holders of the Securities are
not and will not be subject to personal liability by reason of being such holders; the Securities are not and will not be subject
to the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the Company; and
all corporate action required to be taken for the authorization, issuance and sale of the Securities has been duly and validly taken.
E.
Registration Rights of Third Parties. Except as set forth in the SEC Reports, no holders of any securities of the Company or any
rights exercisable for or convertible or exchangeable into securities of the Company have the right to require the Company to register
any such securities of the Company under the Securities Act or to include any such securities in a registration statement to be filed
by the Company.
F.
Validity and Binding Effect of Agreements. This Agreement and the Securities Purchase Agreement to be entered into with each Investor
has been duly and validly authorized by the Company, and, when executed and delivered, will constitute, the valid and binding agreements
of the Company, enforceable against the Company in accordance with their respective terms, except: (i) as such enforceability may be
limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights generally; (ii) as enforceability
of any indemnification or contribution provision may be limited under the federal and state securities laws; and (iii) that the remedy
of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion
of the court before which any proceeding therefor may be brought.
5
G.
No Conflicts, etc. The execution, delivery and performance by the Company of this Agreement, the consummation by the Company of
the transactions herein contemplated and the compliance by the Company with the terms hereof do not and will not, with or without the
giving of notice or the lapse of time or both: (i) result in a material breach of, or conflict with any of the terms and provisions of,
or constitute a material default under, or result in the creation, modification, termination or imposition of any lien, charge or encumbrance
upon any property or assets of the Company pursuant to the terms of any agreement or instrument to which the Company is a party; (ii)
result in any violation of the provisions of the Company’s Certificate of Incorporation (as the same may be amended or restated
from time to time, the “Charter”) or the by-laws of the Company; or (iii) violate any existing applicable law, rule,
regulation, judgment, order or decree of any governmental agency or court, domestic or foreign, having jurisdiction over the Company
or any of its assets or businesses (each, a “Governmental Entity”) as of the date hereof.
H.
No Defaults; Violations. Except as set forth in the SEC Reports, no material default exists in the due performance and observance
of any term, covenant or condition of any material license, contract, indenture, mortgage, deed of trust, note, loan or credit agreement,
or any other agreement or instrument evidencing an obligation for borrowed money, or any other material agreement or instrument to which
the Company is a party or by which the Company may be bound or to which any of the properties or assets of the Company is subject. The
Company is not (i) in violation of any term or provision of its Charter or by-laws, or (ii) in violation of any franchise, license, permit,
applicable law, rule, regulation, judgment or decree of any Governmental Entity applicable to the Company.
I.
Corporate Power; Licenses; Consents.
i.
Conduct
of Business. The Company and its subsidiaries each has all requisite corporate power and authority, and has all necessary authorizations,
approvals, orders, licenses, certificates and permits of and from all governmental regulatory officials and bodies that it needs
as of the date hereof to conduct its business as currently operated.
ii.
Transactions
Contemplated Herein. The Company has all corporate power and authority to enter into this Agreement and to carry out the provisions
and conditions hereof, and all consents, authorizations, approvals and orders required in connection therewith have been obtained.
No consent, authorization or order of, and no filing with, any court, government agency or other body is required for the valid issuance,
sale and delivery of the Securities and the consummation of the transactions and agreements contemplated by this Agreement, except
with respect to applicable federal and state securities laws.
J.
Litigation; Governmental Proceedings. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or
governmental proceeding pending or, to the Company’s knowledge, threatened against, or involving the Company which has not been
disclosed in the SEC Reports except any which, singularly or in the aggregate, would not have or reasonably be expected to result in
a Material Adverse Change.
K.
Good Standing. The Company has been duly organized and is validly existing as a corporation and is in good standing under the
laws of the State of Delaware as of the date hereof, and is duly qualified to do business and is in good standing in each other jurisdiction
in which its ownership or lease of property or the conduct of business requires such qualification, except where the failure to qualify,
singularly or in the aggregate, would not have or reasonably be expected to result in a Material Adverse Change.
L.
Insurance. The Company carries or is entitled to the benefits of insurance, with, to the Company’s knowledge, reputable
insurers, and in such amounts and covering such risks which the Company believes are reasonably adequate, and all such insurance is in
full force and effect. The Company has no reason to believe that it will not be able (i) to renew its existing insurance coverage as
and when such policies expire or (ii) to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct
its business as now conducted and at a cost that would not result in a Material Adverse Change.
6
M.
Foreign Corrupt Practices Act. Neither the Company nor, to the Company’s knowledge, any director, officer, agent, employee
or affiliate of the Company or any other person acting on behalf of the Company, has, directly or indirectly, given or agreed to give
any money, gift or similar benefit (other than legal price concessions to customers in the ordinary course of business) to any customer,
supplier, employee or agent of a customer or supplier, or official or employee of any governmental agency or instrumentality of any government
(domestic or foreign) or any political party or candidate for office (domestic or foreign) or other person who was, is, or may be in
a position to help or hinder the business of the Company (or assist it in connection with any actual or proposed transaction) that (i)
might subject the Company to any damage or penalty in any civil, criminal or governmental litigation or proceeding, (ii) if not given
in the past, might have had a Material Adverse Change or (iii) if not continued in the future, might adversely affect the assets, business,
operations or prospects of the Company. The Company has taken reasonable steps to ensure that its accounting controls and procedures
are sufficient to cause the Company to comply in all material respects with the Foreign Corrupt Practices Act of 1977, as amended.
N.
Compliance with OFAC. Neither of the Company nor, to the Company’s knowledge, any director, officer, agent, employee or
affiliate of the Company or any other person acting on behalf of the Company, is currently subject to any U.S. sanctions administered
by the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”), and the Company will not,
directly or indirectly, use the proceeds of the Offering hereunder, or lend, contribute or otherwise make available such proceeds to
any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person currently
subject to any U.S. sanctions administered by OFAC.
O.
Money Laundering Laws. The operations of the Company are and have been conducted at all times in compliance with applicable financial
recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering
statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines,
issued, administered or enforced by any Governmental Entity (collectively, the “Money Laundering Laws”); and no action,
suit or proceeding by or before any Governmental Entity involving the Company with respect to the Money Laundering Laws is pending or,
to the knowledge of the Company, threatened.
P.
Officers’ Certificate. Any certificate signed by any duly authorized officer of the Company and delivered to Dawson or to
Placement Agent Counsel shall be deemed a representation and warranty by the Company to the Placement Agents as to the matters covered
thereby.
Q.
Subsidiaries. Except as disclosed in the SEC Reports, the Company has no direct or indirect subsidiaries.
R.
Related Party Transactions. There are no business relationships or related party transactions involving the Company or any other
person required to be described in the SEC Reports that have not been described as required.
S.
Board of Directors. The qualifications of the persons serving as members of the Company’s board of director and the overall
composition of the Company’s board of directors comply with the Exchange Act, the rules and regulations thereunder (the “Exchange
Act Regulations”), the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder (the “Sarbanes-Oxley Act”)
applicable to the Company.
T.
Sarbanes-Oxley Compliance.
i.
Disclosure
Controls. The Company has developed and currently maintains disclosure controls and procedures that will comply with Rule 13a-15
or 15d-15 under the Exchange Act Regulations applicable to it, and such controls and procedures are effective to ensure that all
material information concerning the Company will be made known on a timely basis to the individuals responsible for the preparation
of the Company’s Exchange Act filings and other public disclosure documents.
ii.
Compliance
The Company is in material compliance with the provisions of the Sarbanes-Oxley Act applicable to it, and has implemented or will
implement such programs and taken reasonable steps to ensure the Company’s future compliance (not later than the relevant statutory
and regulatory deadlines therefor) with all of the material provisions of the Sarbanes-Oxley Act.
7
U.
Accounting Controls. The Company maintains systems of “internal control over financial reporting” (as defined
under Rules 13a-15 and 15d-15 under the Exchange Act Regulations) that comply with the requirements of the Exchange Act and have been
designed by, or under the supervision of, its principal executive and principal financial officers, or persons performing similar functions,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance
that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded
as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access
to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability
for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.
The Company is not aware of any material weaknesses in its internal controls. The Company’s Auditors and the Audit Committee of
the Board of Directors of the Company have been advised of: (i) all significant deficiencies and material weaknesses, if any, in the
design or operation of internal controls over financial reporting which are known to the Company’s management and that have adversely
affected or are reasonably likely to adversely affect the Company’ ability to record, process, summarize and report financial information;
and (ii) any fraud, if any, known to the Company’s management, whether or not material, that involves management or other employees
who have a significant role in the Company’s internal controls over financial reporting.
V.
No Investment Company Status. The Company is not and, after giving effect to the Offering and the application of the proceeds
thereof as described in the SEC Reports, will not be, required to register as an “investment company,” as defined in the
Investment Company Act of 1940, as amended.
W.
No Labor Disputes. Except as set forth in the SEC Reports, no labor dispute with the employees of the Company exists or, to the
knowledge of the Company, is imminent.
X.
Intellectual Property Rights. The Company and its subsidiaries own or possess or can acquire on reasonable terms adequate rights
to use all patents, patent rights, licenses, inventions, copyrights, know-how (including trade secrets and other unpatented and/or unpatentable
proprietary or confidential information, systems or procedures), trademarks, service marks, trade names and other intellectual property
(collectively, “Intellectual Property”) necessary to carry on the business of the Company and its subsidiaries (the
“Company Intellectual Property”). Neither the Company nor any subsidiary has received any written notice of any infringement
of, or conflict with any asserted rights of others with respect to any Intellectual Property which would render any Intellectual Property
invalid or inadequate to protect the interest of the Company or any of its subsidiaries. The Company and its subsidiaries have taken
commercially reasonable steps in accordance with normal industry practice to maintain the confidentiality of its trade secrets and other
confidential information, and to secure interests in the Company Intellectual Property developed by their employees, consultants, agents
and contractors in the course of their service to the Company and its subsidiaries. No government funding, facilities or resources of
a university, college, other educational institution or research center or funding from third parties was used in the development of
any Company Intellectual Property that is owned or purported to be owned by the Company or any of its subsidiaries, and no governmental
agency or body, university, college, other educational institution or research center has any claim or right in or to any Company Intellectual
Property that is owned or purported to be owned by the Company or any of its subsidiaries.
Y.
Taxes. The Company and its subsidiaries each has filed all returns (as hereinafter defined) required to be filed with taxing authorities
prior to the date hereof or has duly obtained extensions of time for the filing thereof. The Company and its subsidiaries each has paid
all taxes (as hereinafter defined) shown as due on such returns that were filed and has paid all taxes imposed on or assessed against
the Company and its subsidiaries. The provisions for taxes payable, if any, shown on the financial statements filed with or as part of
the SEC Reports are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including the dates
of such consolidated financial statements. No issues have been raised (and are currently pending) by any taxing authority in connection
with any of the returns or taxes asserted as due from the Company, and no waivers of statutes of limitation with respect to the returns
or collection of taxes have been given by or requested from the Company. The term “taxes” mean all federal, state, local,
foreign and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service,
service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties
or other taxes, fees, assessments or charges of any kind whatever, together with any interest and any penalties, additions to tax or
additional amounts with respect thereto. The term “returns” means all returns, declarations, reports, statements and other
documents required to be filed in respect to taxes.
8
Z.
Employee Benefit Laws. The operations of the Company and its subsidiaries are and have been conducted at all times in material
compliance with the Employee Retirement Income Security Act of 1974, as amended, the rules and regulations thereunder and any related
or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Employee
Benefit Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator
involving the Company or its subsidiaries with respect to the Employee Benefit Laws is pending or, to the knowledge of the Company, threatened.
AA.
Compliance with Laws. The Company and its subsidiaries each: (A) is and at all times has been in compliance with all statutes,
rules, or regulations applicable to its business (“Applicable Laws”), except as would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Change; (B) has not received any correspondence from any Governmental Entity
alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits
and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”); (C) possesses all material
Authorizations and such Authorizations are valid and in full force and effect and the Company is not in material violation of any term
of any such Authorizations, in each case except as would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Change; (D) has not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration
or other action from any Governmental Entity or third party alleging that any product operation or activity is in violation of any Applicable
Laws or Authorizations and has no knowledge that any such Governmental Entity or third party is considering any such claim, litigation,
arbitration, action, suit, investigation or proceeding; (E) has not received written notice that any Governmental Entity has taken, is
taking or intends to take action to limit, suspend, modify or revoke any Authorizations; and (F) has filed, obtained, maintained or submitted
all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required
by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments were complete and correct on the date filed (or were corrected or supplemented by a subsequent submission).
BB.
Industry Data. The statistical and market-related data included in the SEC Reports are based on or derived from sources that the
Company reasonably and in good faith believes are reliable and accurate or represent the Company’s good faith estimates that are
made on the basis of data derived from such sources.
CC.
Margin Securities. The Company owns no “margin securities” as that term is defined in Regulation U of the Board of
Governors of the Federal Reserve System (the “Federal Reserve Board”), and none of the proceeds of Offering will be
used, directly or indirectly, for the purpose of purchasing or carrying any margin security, for the purpose of reducing or retiring
any indebtedness which was originally incurred to purchase or carry any margin security or for any other purpose which might cause any
of the shares of Common Stock to be considered a “purpose credit” within the meanings of Regulation T, U or X of the Federal
Reserve Board.
DD.
Listing. The Company shall use its commercially reasonable efforts to maintain the listing of the shares of Common Stock (including
the Common Stock underlying the Notes and Placement Agent Warrants) issued to the Investors and the Placement Agent on such national
securities exchange for at least five years from the date of this Agreement.
EE.
[RESERVED].
9
FF.
Internal Controls. Except set forth in the SEC Reports, the Company shall use its commercially best effort to cure the identified
material weaknesses and maintain a system of internal accounting controls sufficient to provide reasonable assurances that: (i) transactions
are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary in
order to permit preparation of financial statements in accordance with GAAP and to maintain accountability for assets; (iii) access to
assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability
for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.
GG.
No Fiduciary Duties. The Company acknowledges and agrees that the Placement Agent’s responsibility to the Company is solely
contractual in nature and that neither the Placement Agent nor its affiliates or any selling agent shall be deemed to be acting in a
fiduciary capacity, or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with the Offering and
the other transactions contemplated by this Agreement.
HH.
Blue Sky Qualifications. The Company shall use its best efforts, in cooperation with the Placement Agent, if necessary, to qualify
the Securities for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign)
as the Placement Agent may designate and to maintain such qualifications in effect so long as required to complete the distribution of
the Securities; provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify
as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation
in respect of doing business in any jurisdiction in which it is not otherwise so subject.
II.
No General Solicitation. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has engaged
in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale
of the Securities.
JJ.
No Integrated Offering. None of the Company or any of its affiliates, nor any Person acting on their behalf has, directly or indirectly,
made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require registration
of the issuance of any of the Securities under the Securities Act, whether through integration with prior offerings or otherwise, or
cause this offering of the Securities to require approval of stockholders of the Company under any applicable stockholder approval provisions.
None of the Company, its affiliates, nor any person acting on their behalf will take any action or steps that would require registration
of the issuance of any of the Securities under the Securities Act or cause the offering of any of the Securities to be integrated with
other offerings of securities of the Company.
KK.
Reservation of Shares. So long as any of the Notes, PIPE Warrants or Placement Agent Warrants remain outstanding, the Company shall take
all action reasonably necessary to have authorized and reserved for the purpose of issuance a number of shares of Common Stock sufficient
to satisfy its obligations to issue shares of Common Stock upon conversion or exercise of the Notes, PIPE Warrants and Placement Agent
Warrants, in each case as provided in the Securities Purchase Agreement and the applicable transaction documents.
LL.
Regulation D Compliance. None of the Company or the Company’s directors, executive officers or, to the Company’s knowledge,
its affiliates is a “bad actor” as defined in Rule 506(d) of the Securities Act.
8.
Conditions of the Obligations of the Placement Agent.
The
obligations of the Placement Agent hereunder shall be subject to the accuracy of the representations and warranties on the part of the
Company set forth in Section 7 hereof, in each case as of the date hereof and as of each Closing Date as though then made, to the timely
performance by each of the Company of its covenants and other obligations hereunder on and as of such dates, and to each of the following
additional conditions:
10
A.
Form D and Blue Sky. The Company shall file a Form D with respect to the Securities as required under Regulation D and to provide
a copy thereof to Placement Agent promptly after such filing. The Company shall, on or before the Closing Date, take such action as the
Company shall reasonably determine is necessary in order to obtain an exemption for, or to, qualify the Securities for sale to the Investors
at the Closing pursuant to this Agreement under applicable securities or “blue sky” laws of the states of the United States
(or to obtain an exemption from such qualification), and shall provide evidence of any such action so taken to the Placement Agent on
or prior to the Closing Date. Without limiting any other obligation of the Company under this Agreement, the Company shall timely make
all filings and reports relating to the offer and sale of the Securities required under all applicable securities laws (including, without
limitation, all applicable federal securities laws and all applicable “blue sky” laws), and the Company shall comply with
all applicable federal, state, local and foreign laws, statutes, rules, regulations and the like relating to the offering and sale of
the Securities to the Investors.
B.
Officers’ Certificates.
i.
Officers’
Certificate. The Company shall have furnished to the Placement Agent a certificate, dated the Closing Date, of its Chief Executive
Officer, and its Chief Financial Officer stating that (i) to their knowledge after reasonable investigation, as of the Closing Date,
the representations and warranties of the Company in this Agreement are true and correct and the Company has complied with all agreements
and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date, and (ii) there has
not been, subsequent to March 31, 2026, any Material Adverse Change in the financial position or results of operations of the Company,
or any change or development that, singularly or in the aggregate, would involve a Material Adverse Change or a prospective Material
Adverse Change, in or affecting the condition (financial or otherwise), results of operations, business, assets or prospects of the
Company.
ii.
Secretary’s
Certificate. At of the Closing Date the Placement Agent shall have received a certificate of the Company signed by the Secretary
of the Company, dated the Closing Date, certifying: (i) that each of the Charter and Bylaws is true and complete, has not been modified
and is in full force and effect; (ii) that the resolutions of the Company’s Board of Directors relating to the Offering are
in full force and effect and have not been modified; (iii) the good standing of the Company and its subsidiaries; and (iv) as to
the incumbency of the officers of the Company. The documents referred to in such certificate shall be attached to such certificate.
C.
Additional Documents. At the Closing Date, Placement Agent Counsel shall have been furnished with such customary documents, certificates
and opinions as they may reasonably require in order to evidence the accuracy of any of the representations or warranties, or the fulfillment
of any of the conditions, herein contained, consistent with the Engagement Letter, this Agreement, the Securities Purchase Agreement
and the other transaction documents; and all proceedings taken by the Company in connection with the issuance and sale of the Securities
as herein contemplated shall be reasonably satisfactory in form and substance to the Placement Agent and Placement Agent Counsel.
9.
Indemnification and Contribution; Procedures.
A.
Indemnification of the Placement Agent. The Company agrees to indemnify and hold harmless the Placement Agent, its affiliates
and each person controlling such Placement Agent (within the meaning of Section 15 of the Securities Act), and the directors, officers,
agents and employees of the Placement Agent, its affiliates and each such controlling person (the Placement Agent, and each such entity
or person hereafter is referred to as an “Indemnified Person”) from and against any losses, claims, damages, judgments,
assessments, costs and other liabilities (collectively, the “Liabilities”), and shall reimburse each Indemnified Person
for all fees and expenses (including the reasonable fees and expenses of counsel for the Indemnified Persons, except as otherwise expressly
provided in this Agreement) (collectively, the “Expenses”) and agrees to advance payment of such Expenses as they
are incurred by an Indemnified Person in investigating, preparing, pursuing or defending any actions, whether or not any Indemnified
Person is a party thereto, arising out of or based upon any untrue statement or alleged untrue statement of a material fact contained
in (i) any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of
the Offering, including any term sheets or “road show” or investor presentations made to investors by the Company (whether
in person or electronically); or (ii) any application or other document or written communication (in this Section 9, collectively called
“application”) executed by the Company or based upon written information furnished by the Company in any jurisdiction in
order to qualify the Securities under the securities laws thereof or to file for an exemption from such requirement or filed with the
Commission, any state securities commission or agency, any national securities exchange; or the omission or alleged omission therefrom
of a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading, unless such statement or omission was made in reliance upon, and in conformity with, information
provided to the Company in writing specifically for use in an application (the “Placement Agent’s Information”).
The Company also agrees to reimburse each Indemnified Person for all Expenses as they are incurred in connection with such Indemnified
Person’s enforcement of his or its rights under this Agreement.
11
B.
Procedure. Upon receipt by an Indemnified Person of actual notice of an action against such Indemnified Person with respect to
which indemnity may reasonably be expected to be sought under this Agreement, such Indemnified Person shall promptly notify the Company
in writing; provided that failure by any Indemnified Person so to notify the Company shall not relieve the Company from any obligation
or liability which the Company may have on account of this Section 9 or otherwise to such Indemnified Person. The Company shall, if requested
by the Placement Agent, assume the defense of any such action (including the employment of counsel designated by the Placement Agent
and reasonably satisfactory to the Company). Any Indemnified Person shall have the right to employ separate counsel in any such action
and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person
unless: (i) the Company has failed promptly to assume the defense and employ separate counsel designated by the Placement Agent for the
benefit of the Placement Agent and the other Indemnified Persons or (ii) such Indemnified Person shall have been advised that in the
opinion of counsel that there is an actual or potential conflict of interest that prevents (or makes it imprudent for) the counsel designated
by the Placement Agent and engaged by the Company for the purpose of representing the Indemnified Person, to represent both such Indemnified
Person and any other person represented or proposed to be represented by such counsel. The Company shall not be liable for any settlement
of any action effected without its written consent (which shall not be unreasonably withheld). In addition, the Company shall not, without
the prior written consent of the Placement Agent, settle, compromise or consent to the entry of any judgment in or otherwise seek to
terminate any pending or threatened action in respect of which advancement, reimbursement, indemnification or contribution may be sought
hereunder (whether or not such Indemnified Person is a party thereto) unless such settlement, compromise, consent or termination (i)
includes an unconditional release of each Indemnified Person, acceptable to such Indemnified Party, from all Liabilities arising out
of such action for which indemnification or contribution may be sought hereunder and (ii) does not include a statement as to or an admission
of fault, culpability or a failure to act, by or on behalf of any Indemnified Person. The advancement, reimbursement, indemnification
and contribution obligations of the Company required hereby shall be made by periodic payments of the amount thereof during the course
of the investigation or defense, as every Liability and Expense is incurred and is due and payable, and in such amounts as fully satisfy
each and every Liability and Expense as it is incurred (and in no event later than 30 days following the date of any invoice therefore).
C.
Indemnification of the Company. The Placement Agent agrees to indemnify and hold harmless the Company, its directors, its executive
officers and persons who control the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act
against any and all Liabilities, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions made
in the Subscription Documents or any amendment or supplement thereto, in reliance upon, and in strict conformity with, the Placement
Agent’s Information. In case any action shall be brought against the Company or any other person so indemnified based on the Subscription
Documents or any amendment or supplement thereto, and in respect of which indemnity may be sought against the Placement Agent, the Placement
Agent shall have the rights and duties given to the Company, and the Company and each other person so indemnified shall have the rights
and duties given to the Placement Agent by the provisions of Section 9.B. The Company agrees promptly to notify the Placement Agent of
the commencement of any litigation or proceedings against the Company or any of its executive officers, directors or any person, if any,
who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, in connection with
the issuance and sale of the Securities or in connection with the Subscription Documents.
12
D.
Contribution. In the event that a court of competent jurisdiction makes a finding that indemnity is unavailable to an Indemnified
Person, the Company shall contribute to the Liabilities and Expenses paid or payable by such Indemnified Person in such proportion as
is appropriate to reflect (i) the relative benefits to the Company, on the one hand, and to the Placement Agent and any other Indemnified
Person, on the other hand, of the matters contemplated by this Agreement or (ii) if the allocation provided by the immediately preceding
clause is not permitted by applicable law, not only such relative benefits but also the relative fault of the Company, on the one hand,
and the Placement Agent and any other Indemnified Person, on the other hand, in connection with the matters as to which such Liabilities
or Expenses relate, as well as any other relevant equitable considerations; provided that in no event shall the Company contribute less
than the amount necessary to ensure that all Indemnified Persons, in the aggregate, are not liable for any Liabilities and Expenses in
excess of the amount of commissions actually received by the Placement Agent pursuant to this Agreement. The relative fault shall be
determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or
alleged omission to state a material fact relates to information supplied by the Company on the one hand or the Placement Agent on the
other and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or
omission. The Company and the Placement Agent agree that it would not be just and equitable if contributions pursuant to this subsection
(D) were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations
referred to above in this subsection (D). For purposes of this paragraph, the relative benefits to the Company, on the one hand, and
to the Placement Agent on the other hand, of the matters contemplated by this Agreement shall be deemed to be in the same proportion
as: (a) the total value received by the Company in the Offering, whether or not such Offering is consummated, bears to (b) the commissions
paid to the Placement Agent under this Agreement. Notwithstanding the above, no person guilty of fraudulent misrepresentation within
the meaning of Section 11(f) of the Securities Act shall be entitled to contribution from a party who was not guilty of fraudulent misrepresentation.
E.
Limitation. The Company also agrees that no Indemnified Person shall have any liability (whether direct or indirect, in contract
or tort or otherwise) to the Company for or in connection with advice or services rendered or to be rendered by any Indemnified Person
pursuant to this Agreement, the transactions contemplated thereby or any Indemnified Person’s actions or inactions in connection
with any such advice, services or transactions, except to the extent that a court of competent jurisdiction has made a finding that Liabilities
(and related Expenses) of the Company have resulted exclusively from such Indemnified Person’s gross negligence or willful misconduct
in connection with any such advice, actions, inactions or services.
F.
Survival. The advancement, reimbursement, indemnity and contribution obligations set forth in this Section 9 shall remain in full
force and effect regardless of any termination of, or the completion of any Indemnified Person’s services under or in connection
with, this Agreement.
10.
Limitation of Dawson’s Liability to the Company.
Dawson
and the Company further agree that neither Dawson nor any of its affiliates or any of their respective officers, directors, controlling
persons (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act), employees or agents shall have any
liability to the Company, its security holders or creditors, or any person asserting claims on behalf of or in the right of the Company
(whether direct or indirect, in contract or tort, for an act of negligence or otherwise) for any losses, fees, damages, liabilities,
costs, expenses or equitable relief arising out of or relating to this Agreement or the Services rendered hereunder, except for losses,
fees, damages, liabilities, costs or expenses that arise out of or are based on any action of or failure to act by Dawson and that are
finally judicially determined to have resulted solely from the gross negligence or willful misconduct of Dawson.
13
11.
Limitation of Engagement to the Company.
The
Company acknowledges that Dawson has been retained only by the Company, that Dawson is providing services hereunder as an independent
contractor (and not in any fiduciary or agency capacity) and that the Company’s engagement of Dawson is not deemed to be on behalf
of, and is not intended to confer rights upon, any shareholder, owner or partner of the Company or any other person not a party hereto
as against Dawson or any of its affiliates, or any of its or their respective officers, directors, controlling persons (within the meaning
of Section 15 of the Securities Act or Section 20 of the Exchange Act), employees or agents. Unless otherwise expressly agreed in writing
by Dawson, no one other than the Company is authorized to rely upon any statement or conduct of Dawson in connection with this Agreement.
The Company acknowledges that any recommendation or advice, written or oral, given by Dawson to the Company in connection with Dawson’s
engagement is intended solely for the benefit and use of the Company’s management and directors in considering a possible Offering,
and any such recommendation or advice is not on behalf of, and shall not confer any rights or remedies upon, any other person or be used
or relied upon for any other purpose. Dawson shall not have the authority to make any commitment binding on the Company. The Company,
in its sole discretion, shall have the right to reject any investor introduced to it by Dawson. The Company agrees that it will perform
and comply with the covenants and other obligations set forth in any purchase agreement and related transaction documents between the
Company and the Investors in the Offering, if any, and that Dawson will be entitled to rely on the representations, warranties, agreements
and covenants of the Company contained in any such purchase agreement and related transaction documents as if such representations, warranties,
agreements and covenants were made directly to Dawson by the Company, provided that no such representations, warranties, agreements and
covenants shall in any way limit or modify the representations, warranties, agreements and covenants set forth in this Agreement.
12.
Amendments and Waivers.
No
supplement, modification or waiver of this Agreement shall be binding unless executed in writing by the party to be bound thereby. The
failure of a party to exercise any right or remedy shall not be deemed or constitute a waiver of such right or remedy in the future.
No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (regardless
of whether similar), nor shall any such waiver be deemed or constitute a continuing waiver unless otherwise expressly provided.
13.
Publicity; Confidentiality.
The
Company agrees that it will not issue press releases or engage in any other publicity concerning the Offering without Dawson’s
prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed, from the date hereof and continuing
for a period of thirty (30) days from the final Closing of the Offering, except as required by applicable law, Nasdaq rules or SEC requirements.
In the event of the consummation or public announcement of the Offering, Dawson shall have the right to disclose its participation in
such Offering, including, without limitation, the placement at its cost of “tombstone” advertisements in financial and other
newspapers and journals. Dawson agrees not to use any confidential information concerning the Company provided to Dawson by the Company
for any purposes other than those contemplated under this Agreement and shall keep strictly confidential all non-public information concerning
the Company provided to Dawson, except to the extent such information: (a) is or becomes publicly available other than through a breach
by Dawson; (b) was known to Dawson prior to disclosure by the Company; (c) becomes known to Dawson from a source other than the Company
without breach of a confidentiality obligation owed to the Company; (d) is required to be disclosed by applicable law, regulation, legal
process or self-regulatory organization; or (e) is independently developed by Dawson without use of the Company’s confidential
information.
14.
Headings.
The
headings of the various sections of this Agreement have been inserted for convenience of reference only and will not be deemed to be
part of this Agreement.
15.
Counterparts.
This
Agreement may be executed in one or more counterparts and, if executed in more than one counterpart, the executed counterparts shall
each be deemed to be an original and all such counterparts shall together constitute one and the same instrument.
14
16.
Severability.
In
case any provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity, legality and
enforceability of the remaining provisions contained herein will not in any way be affected or impaired thereby.
17.
Use of Information.
During
the Engagement Period or until the final Closing, the Company shall cooperate with Dawson and furnish, or cause to be furnished, to Dawson
any and all information and data concerning the Company and the Offering that Dawson reasonably deems appropriate in connection with
its services hereunder (the “Information”). The Company will provide Dawson reasonable access during normal business hours
from and after the date of execution of this Agreement until the date of the Closing to all of the Company’s assets, properties,
books, contracts, commitments and records and to the Company’s officers, directors, employees, appraisers, independent accountants,
legal counsel and other consultants and advisors, in each case as reasonably requested by Dawson in connection with the Offering. The
Company understands, acknowledges and agrees that Dawson will use and rely entirely upon the Information as well as publicly available
information regarding the Company and other potential parties to an Offering and that Dawson does not assume responsibility for independent
verification of the accuracy or completeness of any information, whether publicly available or otherwise furnished to it, concerning
the Company or otherwise relevant to an Offering, including, without limitation, any financial information, forecasts or projections
considered by Dawson in connection with the provision of its services.
18.
Absence of Fiduciary Relationship.
The
Company acknowledges and agrees that: (a) the Placement Agent has been retained solely to act as Placement Agent in connection with the
sale of the Securities and that no fiduciary, advisory or agency relationship between the Company and the Placement Agent has been created
in respect of any of the transactions contemplated by this Agreement, irrespective of whether the Placement Agent has advised or is advising
the Company on other matters; (b) the price and other terms of the Securities set forth in this Agreement were established by the Company
following discussions and arms-length negotiations with the Placement Agent and the Company is capable of evaluating and understanding
and understands and accepts the terms, risks and conditions of the transactions contemplated by this Agreement; (c) it has been advised
that the Placement Agent and its affiliates are engaged in a broad range of transactions that may involve interests that differ from
those of the Company and that the Placement Agent has no obligation to disclose such interest and transactions to the Company by virtue
of any fiduciary, advisory or agency relationship; and (d) it has been advised that the Placement Agent is acting, in respect of the
transactions contemplated by this Agreement, solely for the benefit of the Placement Agent, and not on behalf of the Company.
19.
Survival Of Indemnities, Representations, Warranties, Etc.
The
respective indemnities, covenants, agreements, representations, warranties and other statements of the Company and Placement Agent, as
set forth in this Agreement or made by them respectively, pursuant to this Agreement, shall remain in full force and effect, regardless
of any investigation made by or on behalf of the Placement Agents, the Company, the Purchasers or any person controlling any of them
and shall survive delivery of and payment for the Securities. Notwithstanding any termination of this Agreement, including without limitation
any termination pursuant to Section 5, the payment, reimbursement, indemnity, contribution and advancement agreements contained in Sections
2, 5, 9, and 10, respectively, and the Company’s covenants, representations, and warranties set forth in this Agreement shall not
terminate and shall remain in full force and effect at all times. The indemnity and contribution provisions contained in Section 9 and
the covenants, warranties and representations of the Company contained in this Agreement shall remain operative and in full force and
effect regardless of (i) any termination of this Agreement, (ii) any investigation made by or on behalf of any Placement Agent, any person
who controls any Placement Agent within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act or any
affiliate of any Placement Agent, or by or on behalf of the Company, its directors or officers or any person who controls the Company
within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act, and (iii) the issuance and delivery
of the Securities. The Company and Placement Agent agree to notify each other of the commencement of any Proceeding against either of
them promptly, and, in the case of the Company, against any of the Company’s officers or directors in connection with the issuance
and sale of the Securities.
15
20.
Governing Law.
This
Agreement shall be governed by and construed in accordance with the laws of the State of New York applicable to agreements made and to
be fully performed therein. Any disputes that arise under this Agreement, even after the termination of this Agreement, will be heard
only in the state or federal courts located in the City of New York, State of New York. The parties hereto expressly agree to submit
themselves to the jurisdiction of the foregoing courts in the City of New York, State of New York. The parties hereto expressly waive
any rights they may have to contest the jurisdiction, venue or authority of any court sitting in the City and State of New York.
21.
Notices.
All
communications hereunder shall be in writing and shall be mailed, hand delivered or faxed and confirmed to the parties hereto as follows:
If
to the Company:
Wellgistics
Health, Inc.
3000 Bayport Drive
Suite 950
Tampa, Florida 33607
Attention: Chief Executive Officer
If
to the Placement Agent:
Dawson
James Securities, Inc.
1 North Federal Highway – 5th Floor
Boca Raton, FL 33432
Attention: Chief Executive Officer
Any
party hereto may change the address for receipt of communications by giving written notice to the others.
22.
Miscellaneous.
This
Agreement shall not be modified or amended except in writing signed by Dawson and the Company. This Agreement shall be binding upon and
inure to the benefit of both Dawson and the Company and their respective assigns, successors, and legal representatives. This Agreement
constitutes the entire agreement of Dawson and the Company, and supersedes any prior agreements, with respect to the subject matter hereof.
If any provision of this Agreement is determined to be invalid or unenforceable in any respect, such determination will not affect such
provision in any other respect, and the remainder of this Agreement shall remain in full force and effect. This Agreement may be executed
in counterparts (including facsimile or .pdf counterparts), each of which shall be deemed an original but all of which together shall
constitute one and the same instrument.
23.
Successors.
This
Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the employees, officers and directors
and controlling persons referred to in Section 9 hereof, and to their respective successors, and personal representative, and, except
as set forth in Section 9 of this Agreement, no other person will have any right or obligation hereunder or be considered a third-party
beneficiary hereunder.
24.
Partial Unenforceability.
The
invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not affect the validity or enforceability
of any other section, paragraph or provision hereof. If any Section, paragraph or provision of this Agreement is for any reason determined
to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to
make it valid and enforceable.
25.
General Provisions.
The
Company acknowledges that in connection with the Offering of the Securities the Placement Agent: (i) has acted at arms-length, are not
agents of, and owe no fiduciary duties to the Company or any other person, (ii) owes the Company only those duties and obligations set
forth in this Agreement and (iii) may have interests that differ from those of the Company. The Company waives to the full extent permitted
by applicable law any claims it may have against the Placement Agent arising from an alleged breach of fiduciary duty in connection with
the Offering.
16
In
acknowledgment that the foregoing correctly sets forth the understanding reached by Dawson and the Company, and intending to be legally
bound, please sign in the space provided below, whereupon this letter shall constitute a binding Agreement as of the date executed.
Very
truly yours,
WELLGISTICS
HEALTH, INC.
By:
Name:
Title:
Agreed
and accepted as of the date first above written.
DAWSON
JAMES SECURITIES, INC.
By:
Name:
Robert
D. Keyser, Jr.
Title:
Chief
Executive Officer
17
EX-10.4
EX-10.4
Filename: ex10-4.htm · Sequence: 7
Exhibit
10.4
Lock-Up
Agreement
May
[__], 2026
Dawson
James Securities, Inc.
101
N. Federal Highway, Suite 600
Boca
Raton, FL 33432
Ladies
and Gentlemen:
The
undersigned understands that Dawson James Securities, Inc. (the “Placement Agent”) has entered into a Placement Agency
Agreement with Wellgistics Health, Inc., a Delaware corporation (the “Company”), which provides that Dawson James
Securities, Inc. (the “Placement Agent”) shall serve as the exclusive placement agent for the Company, on a best efforts
basis, in connection with the proposed private offering and placement (the “Offering”) by the Company of its securities,
as further described in the securities purchase agreement (the “Securities Purchase Agreement”), dated as of May [__],
2026 , by and between the Company and the purchasers identified on the signature pages thereto (each, including its successors and assigns,
a “Purchaser,” and collectively the “Purchasers”). Capitalized terms used and not otherwise defined
herein that are defined in the Securities Purchase Agreement shall have the meanings given such terms in the Securities Purchase Agreement.
To
induce the Placement Agent to continue its efforts in connection with the Offering and to induce the Purchasers to participate in the
Offering, the undersigned hereby agrees that, without the prior written consent of the Placement Agent, during the period commencing
on the Closing Date and ending on the earliest of (i) ninety (90) days after the Registration Statement is declared effective under the
Securities Act, (ii) one hundred eighty (180) days after the Closing Date and (iii) such earlier date as the Placement Agent may agree
in writing (the “Lock-Up Period”), the undersigned will not, and will not knowingly cause any entity controlled by the undersigned
to, directly or indirectly, (1) offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of any shares of
capital stock or any securities convertible into or exercisable or exchangeable for shares of capital stock, whether now owned or hereafter
acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (collectively,
the “Lock-Up Securities”); (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any
of the economic consequences of ownership of the Lock-Up Securities; (3) establish or increase a put equivalent position or liquidate
or decrease a call equivalent position within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, and the rules
and regulations of the Commission promulgated thereunder with respect to any Common Stock owned directly by the undersigned or with respect
to which the undersigned has beneficial ownership within the rules and regulations of the Commission, whether any such transaction described
in clause (1) or (2) above is to be settled by delivery of Lock-Up Securities, in cash or otherwise; (4) file or cause to be filed any
registration statement with the Commission relating to the offering of any shares of Common Stock or any securities convertible into
or exercisable or exchangeable for shares of Common Stock, other than the Registration Statement, or make any demand for or exercise
any right with respect to the registration of any Lock-Up Securities; or (5) publicly disclose the intention to make any offer, sale,
pledge or disposition, or to enter into any transaction, swap, hedge or other arrangement relating to any Lock-Up Securities.
Notwithstanding
the foregoing, the restrictions in this lock-up agreement shall not apply to: (a) transfers as a bona fide gift or charitable contribution;
(b) transfers to any trust or other entity for the direct or indirect benefit of the undersigned or the immediate family of the undersigned;
(c) transfers by will, intestacy or the laws of descent and distribution; (d) transfers to partners, members, stockholders or affiliates
of the undersigned, if the undersigned is an entity; (e) distributions to limited partners, members, stockholders or other equity holders
of the undersigned, if the undersigned is an entity; (f) transfers to the Company in connection with the exercise, vesting, settlement
or tax withholding of any equity award, option, warrant or other convertible or exercisable security, provided that any shares received
upon such exercise, vesting or settlement shall remain subject to this lock-up agreement; (g) transfers pursuant to a bona fide third-party
tender offer, merger, consolidation, business combination or other similar transaction involving a change of control of the Company that
has been approved by the Board of Directors of the Company; or (h) transfers with the prior written consent of the Placement Agent; provided,
in each case, that the transferee agrees in writing to be bound by the terms of this lock-up agreement for the remainder of the Lock-Up
Period to the extent such Lock-Up Period remains in effect.
The
undersigned also agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar
against the transfer of the undersigned’s Lock-Up Securities except in compliance with this lock-up agreement.
Any
release or waiver granted by the Placement Agent hereunder shall only be effective two (2) business days after the publication date of
a press release announcing such release or waiver. The provisions of this paragraph will not apply if (a) the release or waiver is effected
solely to permit a transfer of Lock-Up Securities not for consideration and (b) the transferee has agreed in writing to be bound by the
same terms described in this lock-up agreement to the extent and for the duration that such terms remain in effect at the time of such
transfer.
No
provision in this lock-up agreement shall restrict or prohibit the exercise, exchange or conversion by the undersigned of any securities
exercisable, exchangeable or convertible into Common Stock, including any exercise required pursuant to a mandatory exercise or call
provision contained in any warrant; provided that any shares of Common Stock acquired upon such exercise, exchange or conversion shall
remain subject to this lock-up agreement for the remainder of the Lock-Up Period unless otherwise permitted hereby. In addition, no provision
herein shall restrict or prohibit the entry into, amendment or termination of a Rule 10b5-1 trading plan, provided that no sales of Lock-Up
Securities may be made pursuant to such plan during the Lock-Up Period.
The
undersigned understands that the Company, the Placement Agent and the Purchasers are relying upon this lock-up agreement in proceeding
toward consummation of the Offering. The undersigned further understands that this lock-up agreement is irrevocable and shall be binding
upon the undersigned’s heirs, legal representatives, successors and assigns.
This
lock-up agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns (which do not
include any investors in the offering referenced herein) and is not for the benefit of, nor may any provisions hereof be enforced by,
any other person (including any investors in the offering referenced herein).
The
undersigned understands that if the Securities Purchase Agreement (other than the provisions thereof which survive termination) is terminated
prior to payment for and delivery of the securities to be sold thereunder, then this lock-up agreement shall be void and of no further
force or effect.
Whether
or not the Offering actually occurs depends on a number of factors, including market conditions. Any Offering will only be made pursuant
to the Securities Purchase Agreement, the terms of which are subject to negotiation between the Company, the Placement Agent and the
Purchasers.
[SIGNATURE
PAGE TO FOLLOW]
Very
truly yours,
(Name
- Please Print)
(Signature)
(Name
of Signatory, in the case of entities - Please Print)
(Title
of Signatory, in the case of entities - Please Print)
Address:
EX-99.2
EX-99.2
Filename: ex99-2.htm · Sequence: 8
Exhibit
99.2
Wellgistics
Health Announces Lock-Up Agreement with Holders of a Majority of its Common Stock
● Holders
of 1,333,930 common shares agree to minimum 90-day lock-up agreement
TAMPA,
FL, May 28, 2026— Wellgistics Health, Inc. (“Wellgistics”) (NASDAQ: WGRX), a Health IT leader, integrating pharmacy
dispensing AI platform EinsteinRx™ into patented pharmacy smart contracts platform PharmacyChain™, today announced
that holders of a 1,333,930 common shares, representing a majority of the outstanding common shares of the Company, have entered into
a lock-up agreement that precludes the sale of their shares into the market for at least 90 days.
“This
lock-up agreement, when combined with the recent restructuring of our convertible liabilities and the raising of new funding, underscores
the confidence our shareholders have in management to execute against our recently-disclosed vertically-integrated growth plan outlined
in the Company’s recent shareholder letter,” said Wellgistics Health Interim Co-CEO Gerald Commissiong. “We believe
we will achieve important milestones against our execution plan in the weeks and months ahead. We look forward to updating the market
as we make progress in achieving such milestones.”
About
Wellgistics Health, Inc.
Wellgistics
Health (NASDAQ:WGRX) is a Health IT leader integrating its proprietary pharmacy dispensing optimization artificial intelligence platform
EinsteinRx™ into its blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing
journey. Its integrated platform connects more than 6,500 pharmacies and 200+ manufacturers, offering wholesale distribution, digital
prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility verification, onboarding, adherence
support, prior authorization, and cash-pay fulfillment designed to improve patient access and transparency across the prescription ecosystem.
For
more information, visit www.wellgisticshealth.com.
Forward-Looking
Statements
This
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include, without limitation, statements regarding the Company’s recently disclosed growth plan, anticipated milestones,
expected market updates, the expected benefits of the lock-up agreement, the Company’s shareholder support, management’s
ability to execute its business strategy, the Company’s technology platforms, strategic initiatives, liquidity position, capital
resources and Nasdaq compliance.
Forward-looking
statements are based on current expectations, estimates, projections and assumptions and are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include,
among others, risks related to the Company’s ability to execute its growth plan; achieve anticipated milestones; maintain shareholder,
investor and market support; obtain, maintain or utilize additional financing; successfully integrate, commercialize and scale its business
initiatives and technology platforms; maintain compliance with Nasdaq listing standards; and manage market, regulatory, operational and
competitive risks affecting the healthcare, pharmacy, pharmaceutical distribution, artificial intelligence and technology sectors, as
well as other risks described in the Company’s filings with the Securities and Exchange Commission.
Forward-looking
statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise, except as required by law.
Wellgistics
Media & Investor Contact
Media:
media@wellgisticshealth.com
Investor
Relations: IR@wellgisticshealth.com
GRAPHIC
GRAPHIC
Filename: ex10-3_001.jpg · Sequence: 9
Binary file (14062 bytes)
Download ex10-3_001.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 14
v3.26.1
Cover
May 27, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
May 27, 2026
Entity File Number
001-42530
Entity Registrant Name
WELLGISTICS
HEALTH, INC.
Entity Central Index Key
0002030763
Entity Tax Identification Number
93-3264234
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
3000
Bayport Drive
Entity Address, Address Line Two
Suite
950
Entity Address, City or Town
Tampa
Entity Address, State or Province
FL
Entity Address, Postal Zip Code
33607
City Area Code
(844)
Local Phone Number
203-6092
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common
Stock, $0.0001 par value per share
Trading Symbol
WGRX
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
true
Elected Not To Use the Extended Transition Period
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details
Name:
dei_EntityExTransitionPeriod
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration